chr17:7565097:> Detail (hg19)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr17:7,565,097-7,590,864 |
hg38 | chr17:7,661,779-7,687,546 |
HGVS
Type | Transcript | Protein |
---|---|---|
Summary
MGeND
Clinical significance | |
Variant entry | |
GWAS entry | |
Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
Clinical Significance | |
Review star | [No Data.] |
Show details |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.164 | Carcinoma, Transitional Cell | We also found significant inverse correlation between FGFR3 mutations and TP53 a... | BeFree,CTD_human,GAD,LHGDN | 25537218 | Detail |
0.164 | Carcinoma, Transitional Cell | Taken together, our results provide evidence for RTK/RAS pathway activation and ... | BeFree,CTD_human,GAD,LHGDN | 25795707 | Detail |
0.008 | carcinosarcoma | NA | BeFree,LHGDN | Detail | |
0.003 | Cardiomyopathy, Dilated | NA | BeFree,LHGDN | Detail | |
<0.001 | Xeroderma Pigmentosum, Complementation Group D | Specifically, 2 polymorphisms-an arginine-to-glutamine substitution at codon 399... | BeFree | 23096768 | Detail |
0.120 | hypertrophic cardiomyopathy | NA | CTD_human | Detail | |
0.006 | Cardiovascular Diseases | NA | BeFree,GAD | Detail | |
0.085 | colorectal carcinoma | Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk ... | BeFree | 21971103 | Detail |
0.125 | Carotid Artery Diseases | NA | CTD_human,GAD,LHGDN | Detail | |
0.080 | Cecal Neoplasms | NA | CTD_mouse | Detail | |
0.214 | Neoplastic Cell Transformation | NA | CTD_human,CTD_mouse,GAD | Detail | |
0.005 | Cerebellar Neoplasms | NA | GAD | Detail | |
<0.001 | intracranial aneurysm | NA | BeFree | Detail | |
0.120 | brain ischemia | NA | CTD_human | Detail | |
<0.001 | Transient ischemic attack | NA | BeFree | Detail | |
0.056 | Malignant tumor of cervix | Association of a miR-502-binding site single nucleotide polymorphism in the 3'-u... | BeFree | 25169478 | Detail |
0.056 | Malignant tumor of cervix | Several factors may contribute to cervical cancer (CC) development, including ge... | BeFree | 25181402 | Detail |
0.056 | Malignant tumor of cervix | The p53 target gene WIG-1 (ZMAT3) is located in chromosomal region 3q26, that is... | BeFree | 25379706 | Detail |
0.056 | Malignant tumor of cervix | Berberine alters epigenetic modifications, disrupts microtubule network, and mod... | BeFree | 25448308 | Detail |
0.056 | Malignant tumor of cervix | Thus, the polymorphism of p53 codon 72 in exon 4 does not seem to play a role in... | BeFree | 25502079 | Detail |
0.056 | Malignant tumor of cervix | Overexpression of Nm23H1 but not H2 also inhibited tumorigenesis by human cervic... | BeFree | 25748386 | Detail |
0.056 | Malignant tumor of cervix | The mechanism and inhibitory effect of recombinant human P53 adenovirus injectio... | BeFree | 25855930 | Detail |
0.160 | Malignant neoplasm of lung | Therefore, we hypothesized that the genetic variants in these three genes influe... | BeFree | 16912209 | Detail |
0.001 | Cervix Diseases | NA | BeFree | Detail | |
0.003 | Cervical dysplasia | NA | BeFree,GAD | Detail | |
0.090 | Uterine Cervical Neoplasm | NA | BeFree,GAD,LHGDN | Detail | |
0.003 | cheilitis | NA | BeFree,LHGDN | Detail | |
<0.001 | cholangitis | NA | BeFree | Detail | |
<0.001 | Primary biliary cirrhosis | NA | BeFree | Detail | |
0.005 | cholecystitis | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | cholelithiasis | NA | BeFree | Detail | |
<0.001 | cholesteatoma | NA | BeFree | Detail | |
<0.001 | Chondromatosis, Synovial | NA | BeFree | Detail | |
0.004 | chondrosarcoma | NA | BeFree | Detail | |
0.003 | chordoma | NA | LHGDN | Detail | |
0.160 | colorectal cancer | We have previously reported that the common, functionally different variants Arg... | BeFree | 17224235 | Detail |
0.004 | choriocarcinoma | NA | BeFree,GAD | Detail | |
0.017 | Chromosome Aberrations | NA | GAD | Detail | |
0.005 | Hereditary Nonpolyposis Colorectal Cancer | We have previously reported that the common, functionally different variants Arg... | BeFree | 17224235 | Detail |
0.005 | Chromosome Deletion | NA | GAD | Detail | |
0.005 | Cocarcinogenesis | NA | GAD | Detail | |
0.001 | Cockayne syndrome | NA | BeFree | Detail | |
0.002 | colitis | Here we showed first that in human IBD colonic samples and in murine colitis the... | BeFree | 25347196 | Detail |
0.027 | ulcerative colitis | Moreover, p53 is frequently mutated in the early stages of UC-associated cancer. | BeFree,GAD,LHGDN | 24944468 | Detail |
0.027 | ulcerative colitis | Patients with UC with presence of extraintestinal manifestations, complications,... | BeFree,GAD,LHGDN | 25076849 | Detail |
0.027 | ulcerative colitis | TP53/p53 alterations and Aurora A expression in progressor and non-progressor co... | BeFree,GAD,LHGDN | 25333414 | Detail |
<0.001 | Congenital ocular coloboma (disorder) | NA | BeFree | Detail | |
0.191 | Colonic Neoplasms | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
<0.001 | Colonic Polyps | NA | BeFree | Detail | |
0.085 | colorectal carcinoma | We have previously reported that the common, functionally different variants Arg... | BeFree | 17224235 | Detail |
0.080 | Carcinoma of lung | Therefore, we hypothesized that the genetic variants in these three genes influe... | BeFree | 16912209 | Detail |
0.248 | Colorectal Neoplasms | Inactivation of TP53 pathway by TP53 mutations is observed in nearly half of col... | BeFree,CTD_human,GAD,LHGDN | 25609485 | Detail |
0.248 | Colorectal Neoplasms | Multiplex Ligation-dependent Probe Amplification, TP53 sequencing, real-time pol... | BeFree,CTD_human,GAD,LHGDN | 25964555 | Detail |
0.005 | Hereditary nonpolyposis colorectal neoplasms | NA | GAD,LHGDN | Detail | |
<0.001 | common cold | We validated COLD-ddPCR on multiple mutations in TP53 and in EGFR using serial m... | BeFree | 25772705 | Detail |
0.004 | Condylomata Acuminata | NA | BeFree,GAD | Detail | |
0.002 | Conjunctival Neoplasms | NA | GAD | Detail | |
0.002 | Coronary Arteriosclerosis | NA | BeFree | Detail | |
0.003 | Coronary heart disease | NA | BeFree,GAD | Detail | |
0.160 | colorectal cancer | Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk ... | BeFree | 21971103 | Detail |
0.006 | Crohn Disease | NA | BeFree,GAD,LHGDN | Detail | |
0.261 | Nasopharyngeal carcinoma | The results suggested that the Arg399Gln polymorphism of XRCC1 gene, the 1G/2G p... | BeFree | 25481674 | Detail |
0.124 | adenoid cystic carcinoma | Downregulation of p53 promotes in vitro perineural invasive activity of human sa... | BeFree,CTD_human | 25625376 | Detail |
<0.001 | cystadenocarcinoma | NA | BeFree | Detail | |
0.001 | cystadenoma | NA | BeFree | Detail | |
<0.001 | Cystadenoma, Mucinous | NA | BeFree | Detail | |
<0.001 | cystitis | NA | BeFree | Detail | |
0.002 | Phyllodes Tumor | NA | BeFree | Detail | |
<0.001 | Cyst | NA | BeFree | Detail | |
<0.001 | Cytomegalovirus Infections | NA | BeFree | Detail | |
0.011 | Cessation of life | NA | LHGDN | Detail | |
<0.001 | Presenile dementia | NA | BeFree | Detail | |
0.080 | Dementia, Vascular | NA | RGD | Detail | |
0.120 | Demyelinating Diseases | NA | CTD_human | Detail | |
0.001 | Dentigerous Cyst | NA | BeFree | Detail | |
0.003 | Mental Depression | NA | BeFree,GAD | Detail | |
0.001 | depressive disorder | NA | BeFree | Detail | |
<0.001 | dermatitis | NA | BeFree | Detail | |
0.002 | Dermatomycoses | NA | GAD | Detail | |
<0.001 | dermatomyositis | NA | BeFree | Detail | |
<0.001 | scleroderma | NA | BeFree | Detail | |
0.001 | dermoid cyst | NA | BeFree | Detail | |
0.002 | Diabetes | These results uncover a new mechanism of p53 inactivation providing an interesti... | BeFree | 25260780 | Detail |
<0.001 | diabetes insipidus | NA | BeFree | Detail | |
0.005 | diabetes mellitus | These results uncover a new mechanism of p53 inactivation providing an interesti... | BeFree,GAD | 25260780 | Detail |
0.005 | diabetes mellitus | Reduced LRP6 expression and increase in the interaction of GSK3β with p53 contri... | BeFree,GAD | 25655048 | Detail |
0.280 | Diabetes Mellitus, Experimental | NA | CTD_human,CTD_mouse,RGD | Detail | |
0.008 | Diabetes Mellitus, Insulin-Dependent | NA | BeFree,GAD,LHGDN | Detail | |
0.003 | Diabetes Mellitus, Non-Insulin-Dependent | NA | BeFree,GAD | Detail | |
0.082 | Diabetic Nephropathy | NA | GAD,RGD | Detail | |
<0.001 | Digestive System Disorders | NA | BeFree | Detail | |
0.009 | DNA Damage | NA | GAD | Detail | |
0.005 | Down syndrome | In recent years, miR-1246 has been identified as a transcriptional target of p53... | BeFree,GAD | 25591821 | Detail |
0.005 | Down syndrome | Cell senescence was found to appear prematurely in DS cells as shown by SA-β-Gal... | BeFree,GAD | 25852816 | Detail |
<0.001 | Drug abuse | NA | BeFree | Detail | |
0.008 | duodenal ulcer | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Dwarfism | NA | BeFree | Detail | |
<0.001 | Dyspepsia | NA | BeFree | Detail | |
0.002 | Ehlers-Danlos syndrome | NA | GAD | Detail | |
<0.001 | Embolism, Tumor | NA | BeFree | Detail | |
0.120 | Pathological accumulation of air in tissues | NA | CTD_human | Detail | |
<0.001 | encephalitis | NA | BeFree | Detail | |
<0.001 | Experimental Autoimmune Encephalomyelitis | NA | BeFree | Detail | |
<0.001 | Yolk Sac Tumor | NA | BeFree | Detail | |
0.125 | Endometrial Neoplasms | Further, Cdh1(d/d)Trp53(d/d) tumors in 12-month-old mice were highly aggressive,... | BeFree,CTD_mouse,GAD,LHGDN | 24998851 | Detail |
0.002 | endometrial hyperplasia | NA | BeFree | Detail | |
0.003 | Ependymoma | NA | BeFree | Detail | |
<0.001 | Epithelial cyst | NA | BeFree | Detail | |
0.007 | epidermodysplasia verruciformis | NA | BeFree,GAD | Detail | |
<0.001 | epidermolysis bullosa | NA | BeFree | Detail | |
0.003 | Epilepsy, Temporal Lobe | NA | BeFree,LHGDN | Detail | |
<0.001 | Epithelial hyperplasia | NA | BeFree | Detail | |
<0.001 | Erythroplasia | NA | BeFree | Detail | |
<0.001 | Esophageal Achalasia | NA | BeFree | Detail | |
<0.001 | esophagitis | NA | BeFree | Detail | |
0.002 | Exanthema | pERK expression may have an impact on OS in erlotinib-treated patients with adva... | BeFree | 25164437 | Detail |
0.002 | Exanthema | Polysomy 7, polysomy 18, p16 deletion, and p53 deletion were significantly more ... | BeFree | 25517961 | Detail |
0.002 | Exanthema | More than 50% of human cancers contain a mutation or deletion of the p53 gene, a... | BeFree | 26216949 | Detail |
0.004 | Fanconi anemia | Forty-two deleterious germline mutations were identified in 21 genes of 34 patie... | BeFree | 25927356 | Detail |
0.001 | breast fibrocystic disease | NA | BeFree | Detail | |
0.005 | fibrosarcoma | She presented with a clinical diagnosis of Li-Fraumeni-like syndrome (LFL), show... | BeFree | 25935441 | Detail |
0.003 | Fibrosis | NA | LHGDN | Detail | |
<0.001 | pathologic fistula | NA | BeFree | Detail | |
<0.001 | Foot Diseases | NA | BeFree | Detail | |
<0.001 | Fuchs Endothelial Dystrophy | NA | BeFree | Detail | |
<0.001 | Gall Bladder Diseases | NA | BeFree | Detail | |
0.125 | gallbladder neoplasm | NA | CTD_human,GAD,LHGDN | Detail | |
<0.001 | gastrinoma | NA | BeFree | Detail | |
0.016 | gastritis | However, there is increased apoptosis in gastritis which may occur independent o... | BeFree,GAD,LHGDN | 25422197 | Detail |
0.006 | Gastritis, Atrophic | NA | BeFree,GAD | Detail | |
<0.001 | gastroesophageal reflux disease | NA | BeFree | Detail | |
<0.001 | Gastrointestinal Diseases | NA | BeFree | Detail | |
0.005 | Gastrointestinal Neoplasms | NA | GAD | Detail | |
0.002 | Genital Neoplasms, Female | NA | GAD | Detail | |
0.004 | Giant Cell Tumors | NA | BeFree,LHGDN | Detail | |
0.003 | glaucoma | NA | BeFree,GAD | Detail | |
0.012 | Glaucoma, Open-Angle | NA | BeFree,GAD | Detail | |
0.329 | Glioma | Those tumors that lacked LOH 1p19q showed a high frequency of IDH1 mutations and... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 24444336 | Detail |
0.329 | Glioma | Due to the structural homology between p53 and p73, a subtle balance among p53 f... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 24742294 | Detail |
0.329 | Glioma | A total of 157 diffuse gliomas (World Health Organization grades II-IV) were ass... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25040820 | Detail |
0.329 | Glioma | Furthermore, AND did not induce apoptosis or activate ERK and p53 in primary cul... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25162007 | Detail |
0.329 | Glioma | Finally, p53 mutations correlated with alterations in ETC subunit composition an... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25583481 | Detail |
0.329 | Glioma | In support of the functional interaction between CD24 and p53, in silico analyse... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25600590 | Detail |
0.329 | Glioma | The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25750273 | Detail |
0.329 | Glioma | Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had m... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 26061751 | Detail |
0.003 | IgA glomerulonephritis | NA | BeFree,LHGDN | Detail | |
<0.001 | goiter | NA | BeFree | Detail | |
<0.001 | nodular goiter | NA | BeFree | Detail | |
0.002 | Graft Occlusion, Vascular | NA | GAD | Detail | |
<0.001 | Graft-vs-Host Disease | NA | BeFree | Detail | |
0.001 | granulosa cell tumor | NA | BeFree | Detail | |
0.006 | Graves Disease | NA | BeFree,GAD | Detail | |
<0.001 | Hamartoma | NA | BeFree | Detail | |
0.001 | Hamartoma Syndrome, Multiple | NA | BeFree | Detail | |
0.060 | Head and Neck Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | cardiac arrest | ECCCs had SCA-like features with rare expression of estrogen receptor/progestero... | BeFree | 25473756 | Detail |
0.003 | Cardiomegaly | NA | LHGDN | Detail | |
0.085 | Heart failure | NA | BeFree,CTD_mouse,LHGDN | Detail | |
0.002 | congestive heart failure | NA | BeFree | Detail | |
<0.001 | hemangioma | NA | BeFree | Detail | |
<0.001 | hemangiopericytoma | NA | BeFree | Detail | |
0.204 | Hemangiosarcoma | NA | BeFree,CTD_human,CTD_mouse | Detail | |
0.001 | Hematological Disease | NA | BeFree | Detail | |
<0.001 | hemochromatosis | NA | BeFree | Detail | |
<0.001 | Hemorrhoids | NA | BeFree | Detail | |
0.003 | hepatitis | One such example is hepatitis virus-induced liver cancer whereby p53 is inactiva... | BeFree | 25404244 | Detail |
0.003 | hepatitis A | One such example is hepatitis virus-induced liver cancer whereby p53 is inactiva... | BeFree | 25404244 | Detail |
0.037 | hepatitis B | Chronic infection with hepatitis B virus (HBV) and exposure to aflatoxin B1 (AFB... | BeFree,GAD,LHGDN | 24461059 | Detail |
0.037 | hepatitis B | Finally, in HBV-related HCC, transcriptomic profiles were associated with specif... | BeFree,GAD,LHGDN | 25021421 | Detail |
0.037 | hepatitis B | Hepatitis B Virus Core Promoter A1762T/G1764A (TA)/T1753A/T1768A Mutations Contr... | BeFree,GAD,LHGDN | 25567052 | Detail |
0.037 | hepatitis B | Associations of mutations defined 3 groups of genes related to risk factors and ... | BeFree,GAD,LHGDN | 25822088 | Detail |
0.037 | hepatitis B | Moreover, the HBV-MLL4 integration occurred almost exclusively in CTNNB1 and TP5... | BeFree,GAD,LHGDN | 25901726 | Detail |
0.037 | hepatitis B | Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcin... | BeFree,GAD,LHGDN | 26341700 | Detail |
0.001 | Hepatitis, Chronic | NA | BeFree | Detail | |
0.020 | hepatitis C | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Hepatolenticular Degeneration | NA | BeFree | Detail | |
0.001 | Herpes NOS | Results were correlated with immunoreactivity for USP7 (herpes virus-associated ... | BeFree | 25884169 | Detail |
0.009 | Herpes Simplex Infections | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Von Hippel-Lindau syndrome | NA | BeFree | Detail | |
0.003 | Histiocytosis, Langerhans-Cell | NA | BeFree,LHGDN | Detail | |
0.010 | HIV Infections | Uncommon non-oncogenic HPV genotypes, TP53 and MDM2 genes polymorphisms in HIV-i... | BeFree,GAD | 25181402 | Detail |
0.010 | HIV Infections | Host restriction and associated viral latency have been studied for several deca... | BeFree,GAD | 25653431 | Detail |
0.008 | Hodgkin Disease | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | HTLV-I Infections | NA | BeFree | Detail | |
0.004 | Huntington disease | We assessed cellular manganese handling to test for correlations with the ATM-p5... | BeFree,LHGDN | 25489053 | Detail |
0.004 | Hydatidiform mole | NA | BeFree,GAD | Detail | |
<0.001 | hyperglycemia | NA | BeFree | Detail | |
0.011 | Hyperplasia | NA | LHGDN | Detail | |
0.120 | Hypertensive disease | NA | BeFree,CTD_human | Detail | |
<0.001 | pulmonary hypertension | NA | BeFree | Detail | |
<0.001 | hypoglycemia | NA | BeFree | Detail | |
0.008 | Hypopharyngeal Neoplasms | NA | GAD,LHGDN | Detail | |
<0.001 | Angioimmunoblastic Lymphadenopathy | NA | BeFree | Detail | |
0.002 | Immunologic Deficiency Syndromes | Genetic depletion of Snail1 in MSCs that are deficient in p53 tumor suppressor d... | BeFree | 24947186 | Detail |
0.003 | Immunoproliferative Small Intestinal Disease | NA | BeFree,LHGDN | Detail | |
0.125 | Female infertility | NA | CTD_human,GAD | Detail | |
0.124 | male infertility | NA | BeFree,CTD_human,LHGDN | Detail | |
0.001 | Mammary Ductal Carcinoma | NA | BeFree | Detail | |
0.008 | Inflammation | NA | GAD,LHGDN | Detail | |
0.006 | Inflammatory Bowel Diseases | Here we showed first that in human IBD colonic samples and in murine colitis the... | BeFree,GAD,LHGDN | 25347196 | Detail |
<0.001 | influenza | NA | BeFree | Detail | |
<0.001 | insulinoma | NA | BeFree | Detail | |
0.003 | Intestinal Neoplasms | NA | BeFree,GAD | Detail | |
0.202 | ischemia | Induction of p21 independently of p53 is also observed in transgenic mice overex... | BeFree,CTD_human,RGD | 24515317 | Detail |
<0.001 | Kartagener syndrome | NA | BeFree | Detail | |
0.009 | Keloid | NA | BeFree,GAD,LHGDN | Detail | |
0.008 | keratoacanthoma | NA | BeFree,LHGDN | Detail | |
0.132 | keratosis | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
0.016 | actinic keratosis | NA | BeFree,LHGDN | Detail | |
0.003 | seborrheic keratosis | NA | LHGDN | Detail | |
0.002 | Kidney Diseases | This study aimed to characterize the TP53 mutational spectrum in urothelial canc... | BeFree | 25184754 | Detail |
0.004 | Kidney Failure, Acute | NA | BeFree | Detail | |
<0.001 | Kidney Failure, Chronic | NA | BeFree | Detail | |
0.004 | Kidney Neoplasm | NA | BeFree,GAD | Detail | |
0.120 | Vulvar Lichen Sclerosus | NA | BeFree,CTD_human | Detail | |
0.013 | Laryngeal neoplasm | NA | BeFree,GAD,LHGDN | Detail | |
0.011 | Fibroid Tumor | NA | BeFree,GAD,LHGDN | Detail | |
0.007 | leiomyosarcoma | NA | BeFree | Detail | |
0.057 | leukemia | Li-Fraumeni syndrome is caused by germline TP53 mutations and is clinically char... | BeFree,GAD,LHGDN | 24810334 | Detail |
0.057 | leukemia | Lastly, we validate the effectiveness of ALX as a chemotherapeutic agent in vivo... | BeFree,GAD,LHGDN | 25132271 | Detail |
0.057 | leukemia | Expression of TP53 by CD34-positive cells was associated with shorter OS and leu... | BeFree,GAD,LHGDN | 26123119 | Detail |
0.057 | leukemia | The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Syst... | BeFree,GAD,LHGDN | 26402821 | Detail |
0.347 | chronic lymphocytic leukemia | NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leu... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 24597984 | Detail |
0.347 | chronic lymphocytic leukemia | Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 24943832 | Detail |
0.347 | chronic lymphocytic leukemia | Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic ... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 24962518 | Detail |
0.347 | chronic lymphocytic leukemia | Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chroni... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25287991 | Detail |
0.347 | chronic lymphocytic leukemia | From pioneering studies, we know that certain genetic events are found in the ma... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25345442 | Detail |
0.347 | chronic lymphocytic leukemia | We first performed detailed genetic analyses in a CLL cohort (n=110) containing ... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25371178 | Detail |
0.347 | chronic lymphocytic leukemia | TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different ... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25527155 | Detail |
0.347 | chronic lymphocytic leukemia | TP53 codon 72 single nucleotide polymorphism in chronic lymphocytic leukemia. | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25537220 | Detail |
0.347 | chronic lymphocytic leukemia | B-chronic lymphocytic leukemia (B-CLL) patients harboring p53 mutations are inva... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25544776 | Detail |
0.347 | chronic lymphocytic leukemia | Ibrutinib for previously untreated and relapsed or refractory chronic lymphocyti... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25555420 | Detail |
0.347 | chronic lymphocytic leukemia | The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chr... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25587027 | Detail |
0.347 | chronic lymphocytic leukemia | Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptio... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25605254 | Detail |
0.347 | chronic lymphocytic leukemia | TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocyt... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25646413 | Detail |
0.347 | chronic lymphocytic leukemia | Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been considere... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25651976 | Detail |
0.347 | chronic lymphocytic leukemia | Currently, these types of CLL are treated with approaches that do not target the... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25724841 | Detail |
0.347 | chronic lymphocytic leukemia | In addition to miRNAs, the long non-coding RNAs (lncRNAs) nuclear enriched abund... | BeFree,CTD_human,GAD,LHGDN,ORPHANET | 25971364 | Detail |
0.001 | hairy cell leukemia | NA | BeFree | Detail | |
0.002 | lymphoid leukemia | NA | BeFree | Detail | |
0.015 | Acute lymphocytic leukemia | NA | BeFree | Detail | |
0.005 | Leukemia, Lymphocytic, Acute, L1 | NA | BeFree | Detail | |
<0.001 | acute monocytic leukemia | NA | BeFree | Detail | |
0.157 | Leukemia, Myelocytic, Acute | Strong p53 expression in ≥ 1% of bone marrow progenitor cells, observed in 35% (... | BeFree,CTD_mouse,GAD,LHGDN | 24682512 | Detail |
0.157 | Leukemia, Myelocytic, Acute | The regimen was active against patient-derived acute myelogenous leukemia (AML) ... | BeFree,CTD_mouse,GAD,LHGDN | 25283841 | Detail |
0.157 | Leukemia, Myelocytic, Acute | Results confirm high frequencies of RAS and other activated signaling mutations ... | BeFree,CTD_mouse,GAD,LHGDN | 25331116 | Detail |
0.157 | Leukemia, Myelocytic, Acute | MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian ... | BeFree,CTD_mouse,GAD,LHGDN | 25361931 | Detail |
0.157 | Leukemia, Myelocytic, Acute | Role of TP53 mutations in the origin and evolution of therapy-related acute myel... | BeFree,CTD_mouse,GAD,LHGDN | 25487151 | Detail |
0.157 | Leukemia, Myelocytic, Acute | Consistent with these data, expression of JAK2V617F combined with Tp53 loss led ... | BeFree,CTD_mouse,GAD,LHGDN | 25516983 | Detail |
0.157 | Leukemia, Myelocytic, Acute | TP53 mutations are highly and similarly prevalent in t-MDS and t-AML but mutatio... | BeFree,CTD_mouse,GAD,LHGDN | 25573287 | Detail |
0.157 | Leukemia, Myelocytic, Acute | Other mechanisms linked to PU.1 downregulation in human AML include TP53 deletio... | BeFree,CTD_mouse,GAD,LHGDN | 25750172 | Detail |
0.157 | Leukemia, Myelocytic, Acute | Mutations in FLT3, DNMT3A, NRAS, NF1 and TP53 occur in persons of predominately ... | BeFree,CTD_mouse,GAD,LHGDN | 25858894 | Detail |
0.157 | Leukemia, Myelocytic, Acute | TP53 mutation characteristics in therapy-related myelodysplastic syndromes and a... | BeFree,CTD_mouse,GAD,LHGDN | 25952993 | Detail |
0.014 | myeloid leukemia | NA | BeFree,GAD,LHGDN | Detail | |
0.024 | Myeloid Leukemia, Chronic | NA | BeFree,GAD,LHGDN | Detail | |
0.002 | Leukemia, Myeloid, Chronic-Phase | NA | BeFree | Detail | |
<0.001 | Leukemia, Myelomonocytic, Chronic | NA | BeFree | Detail | |
0.001 | Leukemia, Plasma Cell | NA | BeFree | Detail | |
0.001 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pr... | BeFree | 25589462 | Detail |
<0.001 | prolymphocytic leukemia | NA | BeFree | Detail | |
0.002 | acute promyelocytic leukemia | According to our results, the pharmacological inhibition of autophagy and p53 mu... | BeFree | 25322811 | Detail |
0.003 | Leukemia, T-Cell | NA | BeFree | Detail | |
0.007 | Adult T-Cell Lymphoma/Leukemia | NA | BeFree | Detail | |
0.005 | Leukoencephalopathy, Progressive Multifocal | NA | BeFree,GAD | Detail | |
<0.001 | leukopenia | NA | BeFree | Detail | |
0.009 | Leukoplakia | NA | BeFree,GAD | Detail | |
0.088 | Leukoplakia, Oral | NA | BeFree,GAD,RGD | Detail | |
<0.001 | Leydig cell tumor | NA | BeFree | Detail | |
0.007 | Lichen Sclerosus et Atrophicus | NA | BeFree,LHGDN | Detail | |
<0.001 | mucopolysaccharidosis I | NA | BeFree | Detail | |
0.001 | lipoma | NA | BeFree | Detail | |
0.006 | liposarcoma | NA | BeFree | Detail | |
0.012 | liver cirrhosis | NA | BeFree,GAD,LHGDN | Detail | |
0.004 | Liver diseases | NA | BeFree,LHGDN | Detail | |
0.120 | Liver Diseases, Parasitic | NA | CTD_human | Detail | |
0.184 | Liver neoplasms | An inverse correlation existed between miR-1228 and p53 expression in hepatoma t... | BeFree,CTD_human,GAD,LHGDN | 25422913 | Detail |
0.184 | Liver neoplasms | Tumorigenesis studies using an established liver tumor cell line confirmed a pos... | BeFree,CTD_human,GAD,LHGDN | 25526090 | Detail |
0.184 | Liver neoplasms | In addition, α-PA up-regulated nuclear p53 and down-regulated cytoplasmic p53 ex... | BeFree,CTD_human,GAD,LHGDN | 25649747 | Detail |
0.184 | Liver neoplasms | Apoptosis of Bel-7402 human hepatoma cells induced by a ruthenium(II) complex co... | BeFree,CTD_human,GAD,LHGDN | 25651236 | Detail |
0.120 | Liver Neoplasms, Experimental | NA | CTD_human | Detail | |
<0.001 | Lung diseases | NA | BeFree | Detail | |
0.130 | Chronic Obstructive Airway Disease | These findings suggest that HBEC apoptosis is increased in COPD, and that this i... | BeFree,CTD_human,GAD | 24871992 | Detail |
0.327 | Lung Neoplasms | A total of 189 lung cancer patients were enrolled to determine nickel levels in ... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 24711049 | Detail |
0.327 | Lung Neoplasms | At the molecular level, reduced activation of ERK MAPK, but not Akt, was observe... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 24727895 | Detail |
0.327 | Lung Neoplasms | In this work, we found that PNAS-4 expression in lung tumor tissues is significa... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25918161 | Detail |
0.009 | Lupus Erythematosus, Systemic | NA | BeFree,GAD,LHGDN | Detail | |
0.014 | Lymphatic Metastasis | NA | GAD | Detail | |
0.163 | lymphoma | In addition, the protein levels of p53 and alternative reading frame (ARF) were ... | BeFree,CTD_mouse,GAD,LHGDN | 25175815 | Detail |
0.163 | lymphoma | Genomic studies of ALCL-11 showed the TP53 loss and the in vivo subclonal expans... | BeFree,CTD_mouse,GAD,LHGDN | 25533804 | Detail |
0.163 | lymphoma | p53 is a well-known tumor suppressor.However, the regulatory mechanism(s) for p5... | BeFree,CTD_mouse,GAD,LHGDN | 25544504 | Detail |
0.163 | lymphoma | Activation of p53 mediated glycolytic inhibition-oxidative stress-apoptosis path... | BeFree,CTD_mouse,GAD,LHGDN | 25576833 | Detail |
0.163 | lymphoma | Molecular analysis of lymphomas revealed that arginine methylation of p53 select... | BeFree,CTD_mouse,GAD,LHGDN | 25582697 | Detail |
0.163 | lymphoma | We used isogenic lymphoma cell line models to prove p53 dependence of NEAT1 and ... | BeFree,CTD_mouse,GAD,LHGDN | 25971364 | Detail |
0.018 | Lymphoma, Follicular | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Small Cell Lymphoma | NA | BeFree | Detail | |
0.010 | Lymphoproliferative Disorders | PUMA protein in p53 regulatory molecule pattern determines the prognosis for pat... | BeFree,GAD,LHGDN | 24824714 | Detail |
<0.001 | Machado-Joseph disease | We report that persistent accumulation of DNA damage/strand breaks and chronic a... | BeFree | 25590633 | Detail |
<0.001 | Maffucci syndrome | NA | BeFree | Detail | |
<0.001 | malaria | NA | BeFree | Detail | |
<0.001 | Primary malignant neoplasm of liver | NA | BeFree | Detail | |
0.017 | Animal Mammary Neoplasms | NA | GAD | Detail | |
0.080 | Mammary Neoplasms, Experimental | NA | RGD | Detail | |
<0.001 | Mastocytoma | NA | BeFree | Detail | |
0.022 | medulloblastoma | Whilst drugs directly targeting SIRT1, were potent to trigger cell death at high... | BeFree,GAD | 25250818 | Detail |
0.022 | medulloblastoma | Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidl... | BeFree,GAD | 25533335 | Detail |
0.022 | medulloblastoma | WNT activation by lithium abrogates TP53 mutation associated radiation resistanc... | BeFree,GAD | 25539912 | Detail |
0.022 | medulloblastoma | Treatment of Med in Ptch1(+/-) Trp53(-/-) mice with the antiestrogen chemotherap... | BeFree,GAD | 25885794 | Detail |
<0.001 | megaesophagus | NA | BeFree | Detail | |
<0.001 | multiple endocrine neoplasia type 1 | To understand the phenotypic similarities/differences between lung carcinoids an... | BeFree | 25143124 | Detail |
<0.001 | multiple endocrine neoplasia type 2A | NA | BeFree | Detail | |
0.005 | Meningeal Neoplasms | NA | GAD | Detail | |
0.029 | meningioma | NA | BeFree,GAD,LHGDN | Detail | |
0.003 | Mental Retardation | NA | BeFree,GAD | Detail | |
0.089 | Mesothelioma | NA | BeFree,CTD_mouse,LHGDN | Detail | |
<0.001 | Metabolic Diseases | These results uncover a new mechanism of p53 inactivation providing an interesti... | BeFree | 25260780 | Detail |
0.007 | Metaplasia | NA | GAD,LHGDN | Detail | |
<0.001 | Microphthalmos | NA | BeFree | Detail | |
<0.001 | mitral valve stenosis | NA | BeFree | Detail | |
0.015 | Mixed Salivary Gland Tumor | In addition, we tested if Hsp27 protein levels correlated with p53 expression an... | BeFree,LHGDN | 25230790 | Detail |
<0.001 | Monoclonal Gammopathy of Undetermined Significance | NA | BeFree | Detail | |
0.007 | Monosomy | NA | BeFree | Detail | |
<0.001 | Mouth Diseases | NA | BeFree | Detail | |
0.341 | Mouth Neoplasms | NA | BeFree,CTD_human,CTD_mouse,GAD,LHGDN,RGD | Detail | |
<0.001 | Mucopolysaccharidoses | NA | BeFree | Detail | |
0.031 | multiple myeloma | The expression of nine of them is higher in MM plasma cells than in healthy dono... | BeFree,GAD,LHGDN | 24798859 | Detail |
0.031 | multiple myeloma | Moreover, silencing of p53 in two TP53(mutated) cell lines failed to inhibit apo... | BeFree,GAD,LHGDN | 24927749 | Detail |
0.031 | multiple myeloma | This review summarizes different modes of p53 inactivation in myeloma and highli... | BeFree,GAD,LHGDN | 25028664 | Detail |
0.031 | multiple myeloma | ANKHD1 downregulation modulates cell cycle gene expression and upregulates p21 i... | BeFree,GAD,LHGDN | 25483783 | Detail |
0.031 | multiple myeloma | Features of extramedullary disease of multiple myeloma: high frequency of p53 de... | BeFree,GAD,LHGDN | 25640025 | Detail |
0.003 | multiple sclerosis | NA | BeFree,GAD | Detail | |
<0.001 | muscular atrophy | NA | BeFree | Detail | |
<0.001 | spinal muscular atrophy | NA | BeFree | Detail | |
<0.001 | muscular dystrophy | NA | BeFree | Detail | |
<0.001 | Mycoplasma Infections | NA | BeFree | Detail | |
<0.001 | Mycoses | NA | BeFree | Detail | |
0.002 | mycosis fungoides | Additionally, the mutation data identified 2 other potential contributing factor... | BeFree | 26082451 | Detail |
0.003 | Myelodysplasia | NA | BeFree | Detail | |
<0.001 | myelofibrosis | NA | BeFree | Detail | |
<0.001 | Myelomonocytic leukemia | NA | BeFree | Detail | |
0.001 | Myeloproliferative disease | We performed genomic profiling of post-MPN AML samples; these studies demonstrat... | BeFree | 25516983 | Detail |
0.081 | myocardial infarction | NA | BeFree,CTD_mouse | Detail | |
0.080 | Myocardial Reperfusion Injury | NA | RGD | Detail | |
<0.001 | Myxoma | NA | BeFree | Detail | |
<0.001 | Nasal Polyps | NA | BeFree | Detail | |
0.012 | Nasopharyngeal Neoplasms | NA | GAD | Detail | |
0.003 | Neck Neoplasms | NA | BeFree | Detail | |
0.012 | Neoplasm Invasiveness | NA | GAD | Detail | |
0.009 | Neoplasm Recurrence, Local | NA | GAD | Detail | |
0.080 | Neoplasms, Experimental | NA | CTD_mouse | Detail | |
<0.001 | multiple endocrine neoplasia | NA | BeFree | Detail | |
0.005 | Neoplasms, Radiation-Induced | NA | GAD | Detail | |
0.122 | Neoplastic Syndromes, Hereditary | Almost all identified high-penetrance gene mutations in those families fulfill t... | BeFree,CLINVAR | 25927356 | Detail |
0.122 | Neoplastic Syndromes, Hereditary | A significant percentage (5-10%) of pediatric cancers are associated with heredi... | BeFree,CLINVAR | 26248253 | Detail |
0.009 | nephroblastoma | TP53 mutational status is a potential marker for risk stratification in Wilms tu... | BeFree | 25313908 | Detail |
0.009 | nephroblastoma | We show that (i) in the choroid plexus carcinoma, the germline mutation was dete... | BeFree | 25787918 | Detail |
0.081 | nervous system disorder | NA | BeFree,CTD_mouse | Detail | |
<0.001 | Nervous System Neoplasms | Exome DNA sequencing of blood samples from a Li-Fraumeni family with a TP53 germ... | BeFree | 25041856 | Detail |
0.002 | Neural Tube Defects | NA | GAD | Detail | |
0.003 | neurilemmoma | Two family members without a TP53 germline mutation who developed peripheral sch... | BeFree,GAD | 25041856 | Detail |
0.003 | neurilemmoma | Here we investigated p53 regulation and its role in proliferation and survival o... | BeFree,GAD | 25217104 | Detail |
0.127 | neuroblastoma | CFM-1, -4, and -5 inhibited NB cell growth, in vitro, independent of their p53 a... | BeFree,CTD_mouse,LHGDN | 25033461 | Detail |
0.127 | neuroblastoma | Simultaneous Adrenocortical Carcinoma and Neuroblastoma in an Infant With a Nove... | BeFree,CTD_mouse,LHGDN | 25374282 | Detail |
0.127 | neuroblastoma | Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. | BeFree,CTD_mouse,LHGDN | 25502557 | Detail |
0.127 | neuroblastoma | Treatment of wild-type TP53 neuroblastoma cell lines with both GSK2830371 and ei... | BeFree,CTD_mouse,LHGDN | 25658463 | Detail |
0.127 | neuroblastoma | Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma. | BeFree,CTD_mouse,LHGDN | 25762502 | Detail |
0.005 | neurofibroma | NA | BeFree,GAD | Detail | |
0.004 | neurofibromatosis 1 | The most common predisposition syndromes include germline TP53 mutations and con... | BeFree | 25893277 | Detail |
0.003 | Neurofibromatosis 2 | NA | BeFree,GAD | Detail | |
0.006 | acoustic neuroma | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | neutropenia | NA | BeFree | Detail | |
0.002 | Nevus | NA | BeFree | Detail | |
0.003 | Melanocytic nevus | NA | BeFree | Detail | |
0.003 | Nodule | The whitish nodule corresponded to the sarcomatoid component, and the spindled a... | BeFree | 25424516 | Detail |
0.002 | obesity | Inhibition of endothelial p53 improves metabolic abnormalities related to dietar... | BeFree | 24857662 | Detail |
0.002 | obesity | These results uncover a new mechanism of p53 inactivation providing an interesti... | BeFree | 25260780 | Detail |
0.002 | obesity | Prostaglandin E2 inhibits p53 in human breast adipose stromal cells: a novel mec... | BeFree | 25634217 | Detail |
0.002 | Occupational Diseases | NA | GAD | Detail | |
0.002 | ocular hypertension | NA | GAD | Detail | |
<0.001 | Odontogenic Cysts | NA | BeFree | Detail | |
0.021 | oligodendroglioma | Those tumors that lacked LOH 1p19q showed a high frequency of IDH1 mutations and... | BeFree,GAD,LHGDN | 24444336 | Detail |
0.021 | oligodendroglioma | The mean of Olig2 LI of gliomas with 1p/19q loss ± IDH1/2 mutation, the majority... | BeFree,GAD,LHGDN | 25085214 | Detail |
0.021 | oligodendroglioma | We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX... | BeFree,GAD,LHGDN | 25257301 | Detail |
0.021 | oligodendroglioma | The TP53 and HIST1H3A genes were the hub nodes in the PPI network of DEGs from G... | BeFree,GAD,LHGDN | 25351872 | Detail |
0.021 | oligodendroglioma | Thus, we analyzed the expression of p-CREB in a series of astrocytomas and oligo... | BeFree,GAD,LHGDN | 25476123 | Detail |
0.001 | oral submucous fibrosis | NA | BeFree | Detail | |
0.005 | Oropharyngeal Neoplasms | NA | GAD | Detail | |
0.004 | Degenerative polyarthritis | NA | BeFree,GAD | Detail | |
<0.001 | Synovial osteochondromatosis | NA | BeFree | Detail | |
0.003 | Bone necrosis | NA | LHGDN | Detail | |
0.382 | osteosarcoma | Overexpression of RASSF5 markedly suppressed cell proliferation and invasion, an... | BeFree,CLINVAR,CTD_human,GAD,LHGDN,MGD | 25109282 | Detail |
0.382 | osteosarcoma | Prognostic value of p53 alterations in human osteosarcoma: a meta analysis. | BeFree,CLINVAR,CTD_human,GAD,LHGDN,MGD | 25400752 | Detail |
0.382 | osteosarcoma | p53-dependent activation of microRNA-34a in response to etoposide-induced DNA da... | BeFree,CLINVAR,CTD_human,GAD,LHGDN,MGD | 25490093 | Detail |
0.382 | osteosarcoma | Inactivation of p53 and/or Rb pathways restrains osteoblasts from cell-cycle exi... | BeFree,CLINVAR,CTD_human,GAD,LHGDN,MGD | 25853231 | Detail |
0.382 | osteosarcoma | Here, we established patient-derived iPSCs from a Li-Fraumeni syndrome (LFS) fam... | BeFree,CLINVAR,CTD_human,GAD,LHGDN,MGD | 25860607 | Detail |
0.382 | osteosarcoma | Germline TP53 variants and susceptibility to osteosarcoma. | BeFree,CLINVAR,CTD_human,GAD,LHGDN,MGD | 25896519 | Detail |
0.382 | osteosarcoma | To identify the genes driving osteosarcoma development and metastasis, we perfor... | BeFree,CLINVAR,CTD_human,GAD,LHGDN,MGD | 25961939 | Detail |
0.085 | ovarian carcinoma | Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer. | BeFree,GAD | 24586866 | Detail |
0.085 | ovarian carcinoma | In this study, the nuclear expression levels of γ-H2AX and p53 using immunohisto... | BeFree,GAD | 24681744 | Detail |
0.085 | ovarian carcinoma | Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovari... | BeFree,GAD | 24880464 | Detail |
0.085 | ovarian carcinoma | Association between a single nucleotide polymorphism in the TP53 region and risk... | BeFree,GAD | 25060098 | Detail |
0.085 | ovarian carcinoma | The observed upregulation of pro-apoptotic genes and apoptosis in cancer cells w... | BeFree,GAD | 25096914 | Detail |
0.085 | ovarian carcinoma | We demonstrated that in a unique population of HGSOC cancer cells with cancer st... | BeFree,GAD | 25263447 | Detail |
0.085 | ovarian carcinoma | Genomic classification of serous ovarian cancer with adjacent borderline differe... | BeFree,GAD | 25316818 | Detail |
0.085 | ovarian carcinoma | TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based stan... | BeFree,GAD | 25385265 | Detail |
0.085 | ovarian carcinoma | TP53 remains as the most frequently altered gene in high grade serous ovarian ca... | BeFree,GAD | 25404506 | Detail |
0.085 | ovarian carcinoma | Detection of somatic TP53 mutations in tampons of patients with high-grade serou... | BeFree,GAD | 25437714 | Detail |
0.085 | ovarian carcinoma | Molecular characterization of an intact p53 pathway subtype in high-grade serous... | BeFree,GAD | 25460179 | Detail |
0.085 | ovarian carcinoma | Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors ... | BeFree,GAD | 25473022 | Detail |
0.085 | ovarian carcinoma | Co-immunoprecipitation and western blotting showed significantly lower levels of... | BeFree,GAD | 25510663 | Detail |
0.085 | ovarian carcinoma | The present study aimed to clarify the role of PLK1, P53 and P21WAF1 in the prog... | BeFree,GAD | 25592872 | Detail |
0.085 | ovarian carcinoma | CR389, a benzoimidazolyl pyridinone analog, induces cell cycle arrest and apopto... | BeFree,GAD | 25639717 | Detail |
0.085 | ovarian carcinoma | Overall, FBN1, acts at the downstream of Aur A and BRCA2, promotes ovarian cance... | BeFree,GAD | 25749384 | Detail |
0.085 | ovarian carcinoma | First, we observed the upregulation protein level of p53 target genes in cisplat... | BeFree,GAD | 25820823 | Detail |
0.085 | ovarian carcinoma | There is a link between miR-7 expression and TP53 status and tumour grade in ser... | BeFree,GAD | 25862909 | Detail |
0.085 | ovarian carcinoma | TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule s... | BeFree,GAD | 25958320 | Detail |
0.085 | ovarian carcinoma | We propose that this unique ability of APR-246/MQ to bind to cysteines in both m... | BeFree,GAD | 26086967 | Detail |
0.085 | ovarian carcinoma | The study found a high expression of P53 (64%) and MIB1 (72%) and an expression ... | BeFree,GAD | 26204652 | Detail |
0.001 | Pancreatic Diseases | NA | BeFree | Detail | |
0.237 | Pancreatic Neoplasm | Autophagy is critical for pancreatic tumor growth and progression in tumors with... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 24875860 | Detail |
<0.001 | pancreatitis | NA | BeFree | Detail | |
<0.001 | pancytopenia | NA | BeFree | Detail | |
0.021 | papilloma | CD24 silencing prevents functional inactivation of p53 by both somatic mutation ... | BeFree,LHGDN | 25600590 | Detail |
<0.001 | Papillon-Lefevre disease | NA | BeFree | Detail | |
<0.001 | paraganglioma | NA | BeFree | Detail | |
<0.001 | Parathyroid Neoplasms | NA | BeFree | Detail | |
<0.001 | Parotid Neoplasms | NA | BeFree | Detail | |
0.125 | Penile Neoplasms | NA | CTD_human,GAD | Detail | |
0.003 | Peptic Ulcer | NA | BeFree,GAD | Detail | |
<0.001 | pericardial effusion | NA | BeFree | Detail | |
<0.001 | periodontitis | NA | BeFree | Detail | |
<0.001 | peritonitis | NA | BeFree | Detail | |
0.002 | Peutz-Jeghers syndrome | NA | BeFree | Detail | |
0.005 | Pharyngeal Neoplasms | NA | GAD | Detail | |
0.002 | pheochromocytoma | NA | BeFree | Detail | |
0.002 | pituitary adenoma | NA | BeFree | Detail | |
0.001 | Pituitary Diseases | NA | BeFree | Detail | |
0.004 | Pituitary Neoplasms | NA | BeFree,LHGDN | Detail | |
0.003 | Pleural effusion disorder | NA | BeFree,LHGDN | Detail | |
0.003 | pleurisy | NA | BeFree,LHGDN | Detail | |
<0.001 | pneumonia | In Wild-type (WT) mice with passive CSE (PCSE), p53 and PAI-1 expression and apo... | BeFree | 25932922 | Detail |
<0.001 | Rothmund-Thomson syndrome | NA | BeFree | Detail | |
<0.001 | polycythemia vera | Moreover, inhibition of p53 in PV erythroblasts resulted in more gamma-H2Ax (γ-H... | BeFree | 25288776 | Detail |
0.018 | Adenomatous Polyposis Coli | NA | BeFree,GAD | Detail | |
0.005 | polyps | NA | BeFree | Detail | |
0.005 | Postoperative Complications | NA | GAD | Detail | |
0.116 | Precancerous Conditions | NA | BeFree,CTD_mouse,GAD | Detail | |
<0.001 | progeria | NA | BeFree | Detail | |
<0.001 | prolactinoma | NA | BeFree | Detail | |
0.169 | Prostatic Neoplasms | Met was amplified in 67% of prostate tumors from Pten p53 prostate conditional n... | BeFree,CTD_human,GAD,LHGDN | 25381262 | Detail |
<0.001 | Protein Deficiency | NA | BeFree | Detail | |
<0.001 | pseudomyxoma peritonei | NA | BeFree | Detail | |
<0.001 | Pseudotumor | NA | BeFree | Detail | |
0.125 | psoriasis | NA | BeFree,CTD_human,LHGDN | Detail | |
0.010 | pterygium | NA | BeFree,GAD | Detail | |
0.001 | pulmonary fibrosis | NA | BeFree | Detail | |
<0.001 | Radicular Cyst | NA | BeFree | Detail | |
0.025 | Rectal Neoplasms | Elevated p57Kip2 induces G1/S phase cell cycle arrest but inhibits cell death in... | BeFree,GAD,LHGDN | 25195859 | Detail |
<0.001 | kidney failure | Proteins encoded by CDK2, TP53, and RELA have been associated with the progressi... | BeFree | 24997640 | Detail |
0.080 | Reperfusion Injury | NA | RGD | Detail | |
<0.001 | Reticuloendotheliosis, X-linked | NA | BeFree | Detail | |
<0.001 | retinal detachment | NA | BeFree | Detail | |
<0.001 | Retinal Diseases | NA | BeFree | Detail | |
0.061 | retinoblastoma | In the current study, genetically engineered mice were generated to determine th... | BeFree,LHGDN | 24469052 | Detail |
0.061 | retinoblastoma | In addition, loss-of-function mutations in p53 (TP53) as well as deleterious mut... | BeFree,LHGDN | 25593300 | Detail |
0.061 | retinoblastoma | Following further examination of cell cycle-related factors, MCM2 knockdown inhi... | BeFree,LHGDN | 25738322 | Detail |
0.061 | retinoblastoma | It is unique among the epithelial carcinomas as two distinct pathways to tumouri... | BeFree,LHGDN | 26274747 | Detail |
<0.001 | Retroviridae Infections | NA | BeFree | Detail | |
0.012 | rhabdomyosarcoma | The purpose of the present study was to investigate the role of sirtuin expressi... | BeFree,GAD | 25341037 | Detail |
0.012 | rhabdomyosarcoma | We also demonstrate that miR-605 overexpression leads to a decrease in cell prol... | BeFree,GAD | 25683625 | Detail |
0.006 | Kaposi sarcoma | Kaposi's sarcoma-associated herpesvirus (KSHV)-related malignancies express wild... | BeFree,GAD | 24469037 | Detail |
<0.001 | Burn scar | NA | BeFree | Detail | |
0.004 | schistosomiasis | NA | BeFree,LHGDN | Detail | |
0.151 | schizophrenia | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
<0.001 | localized scleroderma | NA | BeFree | Detail | |
<0.001 | systemic scleroderma | NA | BeFree | Detail | |
<0.001 | Seizures | NA | BeFree | Detail | |
0.002 | seminoma | NA | BeFree | Detail | |
<0.001 | Age-related cataract | MicroRNA-125b inhibits lens epithelial cell apoptosis by targeting p53 in age-re... | BeFree | 25312242 | Detail |
0.121 | Sezary syndrome | NA | BeFree,CTD_human | Detail | |
0.003 | Dermatologic disorders | NA | BeFree,GAD | Detail | |
0.261 | Skin Neoplasms | NA | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | Detail | |
<0.001 | smallpox | The detection limits for analyzing the Smallpox and TP53 genes correspond to 0.1... | BeFree | 25369533 | Detail |
0.001 | Soft Tissue Neoplasms | NA | BeFree | Detail | |
<0.001 | Splenic Neoplasms | NA | BeFree | Detail | |
<0.001 | status epilepticus | NA | BeFree | Detail | |
<0.001 | stereotypic movement disorder | NA | BeFree | Detail | |
<0.001 | Stomach Diseases | NA | BeFree | Detail | |
0.005 | gastric ulcer | NA | BeFree,GAD | Detail | |
<0.001 | post-traumatic stress disorder | Three other genes, TP53, EP300 and CALM1 might also contribute to the pathogenes... | BeFree | 25219830 | Detail |
0.003 | Cerebrovascular accident | NA | BeFree,LHGDN | Detail | |
0.002 | Subarachnoid Hemorrhage | NA | GAD | Detail | |
0.007 | Sunburn | NA | GAD,LHGDN | Detail | |
0.004 | synovial sarcoma | The purpose of the present study was to investigate the role of sirtuin expressi... | BeFree,LHGDN | 25341037 | Detail |
<0.001 | synovitis | NA | BeFree | Detail | |
<0.001 | telangiectasis | NA | BeFree | Detail | |
0.001 | Giant Cell Arteritis | NA | BeFree | Detail | |
<0.001 | tendinitis | NA | BeFree | Detail | |
0.005 | teratoma | NA | BeFree,LHGDN | Detail | |
0.002 | Testicular Neoplasms | NA | BeFree | Detail | |
0.121 | Thrombocythemia, Essential | NA | BeFree,ORPHANET | Detail | |
0.121 | thymoma | NA | BeFree,CTD_human | Detail | |
0.002 | Thyroid Diseases | NA | GAD | Detail | |
0.153 | Thyroid Neoplasm | A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encode... | BeFree,CTD_human,GAD,LHGDN | 25880213 | Detail |
0.003 | Thyroid Nodule | NA | BeFree,GAD | Detail | |
<0.001 | thyroiditis | NA | BeFree | Detail | |
0.002 | Tobacco use disorder | NA | GAD | Detail | |
0.167 | Tongue Neoplasms | NA | CTD_mouse,GAD,LHGDN,RGD | Detail | |
0.003 | Trisomy | NA | BeFree | Detail | |
<0.001 | Trophoblastic Neoplasms | NA | BeFree | Detail | |
0.003 | Chagas disease | NA | BeFree,GAD | Detail | |
0.003 | tuberculosis | NA | BeFree,LHGDN | Detail | |
<0.001 | pleural tuberculosis | NA | BeFree | Detail | |
0.001 | tuberous sclerosis | NA | BeFree | Detail | |
0.024 | Tumor Virus Infections | NA | GAD | Detail | |
0.001 | Turner syndrome | Genomic profile of a Li-Fraumeni-like syndrome patient with a 45,X/46,XX karyoty... | BeFree | 25935441 | Detail |
0.080 | Adverse reaction to drug | NA | CTD_mouse | Detail | |
<0.001 | Erythema | NA | BeFree | Detail | |
0.002 | uremia | NA | GAD | Detail | |
0.123 | Genitourinary Neoplasms | NA | CTD_human,LHGDN | Detail | |
0.120 | Urologic Neoplasms | NA | CTD_human | Detail | |
0.004 | Uterine Fibroids | NA | BeFree | Detail | |
0.002 | Uterine Neoplasms | NA | GAD | Detail | |
0.003 | Varicose Ulcer | NA | LHGDN | Detail | |
0.003 | Vascular Diseases | NA | BeFree,LHGDN | Detail | |
<0.001 | viral hepatitis | NA | BeFree | Detail | |
0.005 | Virus Diseases | To address the unmet need, we recently developed RapidCaP mice, which endogenous... | BeFree | 25592467 | Detail |
0.005 | Virus Diseases | Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcin... | BeFree | 26341700 | Detail |
<0.001 | vitiligo | NA | BeFree | Detail | |
<0.001 | common wart | NA | BeFree | Detail | |
0.001 | Werner syndrome | Erythroblasts negative for WRN immunostaining were only observed in two patients... | BeFree | 25503078 | Detail |
0.010 | xeroderma pigmentosum | NA | BeFree,GAD | Detail | |
<0.001 | Fibromatosis, Aggressive | NA | BeFree | Detail | |
<0.001 | Hallopeau-Siemens Disease | NA | BeFree | Detail | |
0.014 | Helicobacter Infections | NA | GAD | Detail | |
0.004 | Ichthyosis, X-Linked | NA | BeFree | Detail | |
0.039 | B-Cell Lymphomas | TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and B... | BeFree,GAD,LHGDN | 24679006 | Detail |
0.039 | B-Cell Lymphomas | Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to sp... | BeFree,GAD,LHGDN | 24787013 | Detail |
0.039 | B-Cell Lymphomas | MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas. | BeFree,GAD,LHGDN | 25915824 | Detail |
0.039 | B-Cell Lymphomas | Consequently, miR-200-induced T2D is suppressed by interfering with the signalin... | BeFree,GAD,LHGDN | 25985365 | Detail |
0.039 | B-Cell Lymphomas | Mechanistically, 4-MU led to increased p53 mRNA expression, elevated cytoplasmic... | BeFree,GAD,LHGDN | 26408682 | Detail |
0.002 | High Grade Lymphoma (neoplasm) | NA | BeFree | Detail | |
0.001 | Lymphoma, Large-Cell, Follicular | NA | BeFree | Detail | |
<0.001 | Low Grade Lymphoma (neoplasm) | NA | BeFree | Detail | |
<0.001 | Precursor cell lymphoblastic lymphoma | NA | BeFree | Detail | |
0.001 | Lymphoma, Small Noncleaved-Cell | NA | BeFree | Detail | |
0.127 | T-Cell Lymphoma | NA | BeFree,CTD_human,LHGDN | Detail | |
0.125 | Lymphoma, T-Cell, Cutaneous | These alterations were accompanied by increased forkhead box O3 (FoxO3) in sever... | BeFree,CTD_human,LHGDN | 24343700 | Detail |
<0.001 | peripheral T-cell lymphoma | NA | BeFree | Detail | |
0.002 | spina bifida | NA | GAD | Detail | |
<0.001 | Lysosomal Storage Diseases | NA | BeFree | Detail | |
<0.001 | motor neuron disease | NA | BeFree | Detail | |
0.002 | severe combined immunodeficiency | NA | BeFree | Detail | |
0.122 | Central Nervous System Neoplasms | NA | BeFree,CTD_human | Detail | |
0.003 | Choroid Plexus Neoplasms | NA | BeFree,GAD | Detail | |
0.009 | Neoplasms, Second Primary | NA | BeFree,GAD | Detail | |
0.003 | Adult-Onset Still Disease | NA | LHGDN | Detail | |
<0.001 | encephalitozoonosis | NA | BeFree | Detail | |
<0.001 | Arthritis, Reactive | NA | BeFree | Detail | |
<0.001 | polymyositis | NA | BeFree | Detail | |
<0.001 | Secondary carcinoma | NA | BeFree | Detail | |
0.006 | acute leukemia | Our meta-analysis demonstrates that TP53 codon 72 polymorphism may not be a risk... | BeFree | 26402821 | Detail |
0.002 | Chronic cholecystitis | NA | BeFree | Detail | |
<0.001 | Chronic gastritis | NA | BeFree | Detail | |
<0.001 | Monocytosis | NA | BeFree | Detail | |
<0.001 | Adenosis of Breast | NA | BeFree | Detail | |
0.009 | benign neoplasm | NA | BeFree | Detail | |
<0.001 | Sicca Syndrome | NA | BeFree | Detail | |
0.003 | Pancreatitis, Chronic | NA | BeFree | Detail | |
<0.001 | Adnexal mass | NA | BeFree | Detail | |
0.017 | Epstein-Barr Virus Infections | We found that resistance to spindle poison-induced apoptosis could be reverted i... | BeFree,GAD,LHGDN | 24787013 | Detail |
0.017 | Epstein-Barr Virus Infections | In the presented studies p53 and bcl-2 proteins expression were evaluated in sam... | BeFree,GAD,LHGDN | 26638529 | Detail |
0.004 | Squamous cell carcinoma of lung | In non-small cell lung cancer (NSCLC), both USP7 expression and p53 gene status ... | BeFree | 25519684 | Detail |
0.004 | Squamous cell carcinoma of lung | Correlation between squamous cell carcinoma of the lung and human papillomavirus... | BeFree | 25544708 | Detail |
0.001 | Gastric adenoma | NA | BeFree | Detail | |
0.260 | Small cell carcinoma of lung | The PTEN/PIK3CA pathway was interrogated using an AdenoCre-driven mouse model of... | BeFree,CTD_human,LHGDN,ORPHANET | 24482365 | Detail |
0.260 | Small cell carcinoma of lung | In comparison to the carcinoids, LCNEC/SCLC tumors presented a stronger loss of ... | BeFree,CTD_human,LHGDN,ORPHANET | 25884169 | Detail |
0.004 | Adenocarcinoma of rectum | NA | BeFree | Detail | |
0.001 | Atrophic condition of skin | NA | BeFree | Detail | |
0.001 | Oral Cavity Carcinoma | NA | BeFree | Detail | |
<0.001 | renal fibrosis | NA | BeFree | Detail | |
0.006 | Cutaneous Melanoma | NA | BeFree | Detail | |
0.095 | Adenocarcinoma of lung (disorder) | Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated... | BeFree,CTD_mouse,GAD | 24169260 | Detail |
0.095 | Adenocarcinoma of lung (disorder) | LATS2 mRNA level was found to be a significant independent predictor for surviva... | BeFree,CTD_mouse,GAD | 24976335 | Detail |
0.095 | Adenocarcinoma of lung (disorder) | Proteomic signatures associated with p53 mutational status in lung adenocarcinom... | BeFree,CTD_mouse,GAD | 25331784 | Detail |
0.095 | Adenocarcinoma of lung (disorder) | PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis a... | BeFree,CTD_mouse,GAD | 25466965 | Detail |
<0.001 | Complete trisomy 18 syndrome | NA | BeFree | Detail | |
0.003 | low tension glaucoma | NA | BeFree,GAD | Detail | |
<0.001 | Cancer of Lip | NA | BeFree | Detail | |
0.002 | Malignant neoplasm of tongue | TP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in es... | BeFree | 25436609 | Detail |
0.002 | Malignant neoplasm of tongue | The increased expression of pS(21)GSK3α and pS(9)GSK3β not only correlated posit... | BeFree | 25645517 | Detail |
0.029 | Malignant neoplasm of mouth | Phenethyl isothiocyanate induces DNA damage-associated G2/M arrest and subsequen... | BeFree,GAD | 24952138 | Detail |
0.029 | Malignant neoplasm of mouth | The detection limits, established as 3σ, were estimated to be 0.03 and 0.06 fmol... | BeFree,GAD | 25493424 | Detail |
0.029 | Malignant neoplasm of mouth | The expression of total and phosphorylated GSK3α/β as well as cyclin D1 and p53 ... | BeFree,GAD | 25645517 | Detail |
0.002 | Malignant neoplasm of oropharynx | Among these biomarkers, p53 is the strongest prognostic marker in OPC and p53 in... | BeFree | 25380690 | Detail |
0.002 | Malignant neoplasm of oropharynx | The biology of HPV-positive oropharyngeal cancer is distinct; it includes p53 de... | BeFree | 26563006 | Detail |
0.002 | Malignant neoplasm of nasopharynx | NA | BeFree | Detail | |
0.001 | Malignant neoplasm of anus | NA | BeFree | Detail | |
0.007 | Malignant neoplasm of gallbladder | High frequency of TP53 but not K-ras gene mutations in Bolivian patients with ga... | BeFree | 25041017 | Detail |
<0.001 | Malignant tumor of extrahepatic bile duct | NA | BeFree | Detail | |
<0.001 | Malignant Uterine Corpus Neoplasm | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of fallopian tube | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of penis | NA | BeFree | Detail | |
0.006 | Malignant neoplasm of brain | Alternative lengthening of telomeres is enriched in, and impacts survival of TP5... | BeFree,GAD | 25315281 | Detail |
<0.001 | Malignant neoplasm of endocrine gland | NA | BeFree | Detail | |
0.003 | Secondary malignant neoplasm of lung | Our study, for the first time, demonstrates that GINS2 is an independent prognos... | BeFree | 25348432 | Detail |
0.003 | Secondary malignant neoplasm of lung | Interestingly, the combined silencing of p53 and Toca-1 led to a partial rescue ... | BeFree | 25547174 | Detail |
0.003 | Secondary malignant neoplasm of lung | Tumor cells expressing high-risk TP53 mutations were more invasive and tumorigen... | BeFree | 25634208 | Detail |
<0.001 | Secondary malignant neoplasm of bone | NA | BeFree | Detail | |
<0.001 | Stage 0 Breast Carcinoma | NA | BeFree | Detail | |
<0.001 | Carcinoma in situ of bladder | NA | BeFree | Detail | |
<0.001 | Corneal pannus | NA | BeFree | Detail | |
<0.001 | Recurrent pterygium | NA | BeFree | Detail | |
<0.001 | endometriosis of ovary | Autophagy is upregulated in ovarian endometriosis: a possible interplay with p53... | BeFree | 25772769 | Detail |
<0.001 | Cleft palate with cleft lip | NA | BeFree | Detail | |
<0.001 | Infections specific to perinatal period | NA | BeFree | Detail | |
<0.001 | acute intermittent porphyria | NA | BeFree | Detail | |
0.002 | Skin Diseases, Bacterial | NA | GAD | Detail | |
0.002 | Skin Diseases, Viral | NA | GAD | Detail | |
<0.001 | Angelman syndrome | NA | BeFree | Detail | |
<0.001 | Neurofibromatoses | NA | BeFree | Detail | |
0.003 | Cicatrix, Hypertrophic | NA | BeFree,LHGDN | Detail | |
<0.001 | porokeratosis | NA | BeFree | Detail | |
<0.001 | Aortic Aneurysm, Abdominal | NA | BeFree | Detail | |
0.007 | Agenesis of corpus callosum | Somatic mutations in ACC-associated genes included TP53 (8/41 tumors, 19.5%) and... | BeFree | 25490274 | Detail |
0.007 | Agenesis of corpus callosum | TP53 mutations are prevalent in children with ACC but decline with age. | BeFree | 25584008 | Detail |
0.007 | Agenesis of corpus callosum | The TP53 mutation detection rate in children presenting with ACC or choroid plex... | BeFree | 26014290 | Detail |
0.082 | Tumor Progression | On the contrary, p53 loss led to increased apoptosis that had to be overcome for... | BeFree,GAD | 24469052 | Detail |
0.082 | Tumor Progression | Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression i... | BeFree,GAD | 24632606 | Detail |
0.082 | Tumor Progression | This study provides the first time evidence that RRM2B is transcriptionally and ... | BeFree,GAD | 24947616 | Detail |
0.082 | Tumor Progression | It is therefore important to elucidate the role of these downstream targets in p... | BeFree,GAD | 25119697 | Detail |
0.082 | Tumor Progression | These findings are relevant to human basal-like tumor progression in vivo, since... | BeFree,GAD | 25123132 | Detail |
0.082 | Tumor Progression | These results uncover a new mechanism of p53 inactivation providing an interesti... | BeFree,GAD | 25260780 | Detail |
0.082 | Tumor Progression | Moreover, by two-dimensional gel electrophoresis and mass spectrometry we discov... | BeFree,GAD | 25263447 | Detail |
0.082 | Tumor Progression | Emerging from the shade of p53 mutants: N-terminally truncated variants of the p... | BeFree,GAD | 25270260 | Detail |
0.082 | Tumor Progression | The p53 and NFκB sequence-specific transcription factors play crucial roles in c... | BeFree,GAD | 25401416 | Detail |
0.082 | Tumor Progression | Many cancers express mutant p53 proteins that have lost wild-type tumor suppress... | BeFree,GAD | 25417702 | Detail |
0.082 | Tumor Progression | These results suggest that stroma-derived p53 plays a pivotal role in epithelial... | BeFree,GAD | 25512506 | Detail |
0.082 | Tumor Progression | However, the presence of p53 mutations in skin premalignant lesions suggests tha... | BeFree,GAD | 25639555 | Detail |
0.082 | Tumor Progression | The 14-3-3ζ-driven contextual changes of Smad partners from p53 to Gli2 may serv... | BeFree,GAD | 25670079 | Detail |
0.082 | Tumor Progression | The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer ... | BeFree,GAD | 26032560 | Detail |
<0.001 | Microinvasive tumor | NA | BeFree | Detail | |
0.001 | Adenocarcinoma, Tubular | NA | BeFree | Detail | |
<0.001 | follicular adenoma | NA | BeFree | Detail | |
<0.001 | Carcinoid, Goblet Cell | NA | BeFree | Detail | |
0.004 | Anaplastic carcinoma | NA | BeFree | Detail | |
0.001 | Carcinoma, Spindle-Cell | NA | BeFree | Detail | |
0.005 | Undifferentiated carcinoma | NA | BeFree | Detail | |
0.001 | Dysplastic Nevus | NA | BeFree | Detail | |
<0.001 | subependymal giant cell astrocytoma | NA | BeFree | Detail | |
0.366 | choroid plexus papilloma | NA | BeFree,CLINVAR,CTD_human,GAD,LHGDN,ORPHANET | Detail | |
<0.001 | Liposarcoma, Dedifferentiated | NA | BeFree | Detail | |
<0.001 | Liposarcoma, Pleomorphic | NA | BeFree | Detail | |
0.005 | Germ cell tumor | NA | BeFree | Detail | |
<0.001 | Papilloma, Squamous Cell | NA | BeFree | Detail | |
<0.001 | Papillomatosis | NA | BeFree | Detail | |
<0.001 | Sarcoma, Epithelioid | NA | BeFree | Detail | |
0.001 | thymic carcinoma | Massively parallel sequencing identifies recurrent mutations in TP53 in thymic c... | BeFree | 25299233 | Detail |
0.001 | thymic carcinoma | TP53 was the most frequently mutated gene in TETs (n = 13; 17%), especially in T... | BeFree | 25482724 | Detail |
<0.001 | Lung Diseases, Interstitial | NA | BeFree | Detail | |
0.002 | Neuroectodermal Tumors | NA | BeFree | Detail | |
0.008 | Lichen Planus, Oral | NA | BeFree,GAD,LHGDN | Detail | |
0.004 | Ki-1+ Anaplastic Large Cell Lymphoma | Genomic studies of ALCL-11 showed the TP53 loss and the in vivo subclonal expans... | BeFree | 25533804 | Detail |
0.003 | adenosquamous carcinoma | NA | BeFree,GAD | Detail | |
<0.001 | Mixed Tumor, Mullerian | NA | BeFree | Detail | |
<0.001 | pulmonary blastoma | NA | BeFree | Detail | |
<0.001 | endometrial stromal sarcoma | NA | BeFree | Detail | |
<0.001 | angiomyolipoma | NA | BeFree | Detail | |
<0.001 | Liposarcoma, Myxoid | NA | BeFree | Detail | |
<0.001 | Giant Cell Tumor of Bone | NA | BeFree | Detail | |
<0.001 | Histiocytoma, Benign Fibrous | NA | BeFree | Detail | |
0.003 | Dermatofibrosarcoma | NA | LHGDN | Detail | |
0.002 | Fibroadenoma | NA | BeFree | Detail | |
<0.001 | leiomyomatosis | NA | BeFree | Detail | |
<0.001 | alveolar rhabdomyosarcoma | NA | BeFree | Detail | |
0.001 | Rhabdomyosarcoma, Embryonal | NA | BeFree | Detail | |
0.004 | embryonal carcinoma | NA | BeFree | Detail | |
0.007 | Neuroectodermal Tumor, Primitive | NA | BeFree,GAD | Detail | |
<0.001 | teratocarcinoma | NA | BeFree | Detail | |
<0.001 | adrenal cortical adenoma | NA | BeFree | Detail | |
0.003 | hepatocellular adenoma | NA | BeFree,GAD | Detail | |
<0.001 | Adenomatous Polyps | NA | BeFree | Detail | |
0.124 | Adenocarcinoma, Clear Cell | NA | BeFree,CTD_human,GAD | Detail | |
0.005 | Follicular thyroid carcinoma | NA | BeFree,GAD | Detail | |
0.002 | sebaceous adenocarcinoma | UV-independent p53 mutations in sebaceous carcinoma of the eyelid. | BeFree | 24777261 | Detail |
0.001 | acinar cell carcinoma | NA | BeFree | Detail | |
0.261 | adrenocortical carcinoma | NA | BeFree,CTD_human,LHGDN,ORPHANET | Detail | |
0.015 | Carcinoma, Endometrioid | ECCCs had SCA-like features with rare expression of estrogen receptor/progestero... | BeFree,GAD,LHGDN | 25473756 | Detail |
<0.001 | Carcinoma, Lobular | NA | BeFree | Detail | |
0.002 | Medullary carcinoma | NA | BeFree | Detail | |
0.002 | mucoepidermoid carcinoma | NA | BeFree | Detail | |
0.001 | Carcinoma, Neuroendocrine | A missense mutation in TP53 exon 7 (c.734G>C) and strong nuclear immunostaining ... | BeFree | 24327102 | Detail |
0.213 | cholangiocarcinoma | CCA with Ov shows significantly higher incidence of the TP53 gene mutation, wher... | BeFree,CTD_human,CTD_mouse,LHGDN | 24532422 | Detail |
0.213 | cholangiocarcinoma | Interestingly, there is a significant difference in the frequency of mutated gen... | BeFree,CTD_human,CTD_mouse,LHGDN | 25693006 | Detail |
0.003 | Cystadenocarcinoma, Mucinous | NA | BeFree,LHGDN | Detail | |
0.003 | Cystadenocarcinoma, Papillary | NA | LHGDN | Detail | |
0.014 | Cystadenocarcinoma, Serous | The overall mutation profile of this cohort of endometrial CCC appears to be mor... | BeFree,GAD | 25308272 | Detail |
<0.001 | Klatskin tumor | NA | BeFree | Detail | |
0.005 | Carcinoma, Large Cell | In non-small cell lung cancer (NSCLC), both USP7 expression and p53 gene status ... | BeFree,LHGDN | 25519684 | Detail |
0.007 | verrucous carcinoma | Diffuse p16 expression was associated with younger age at presentation (P<0.0001... | BeFree,LHGDN | 26171917 | Detail |
0.001 | Cystadenoma, Serous | NA | BeFree | Detail | |
0.002 | Basal Cell Neoplasm | NA | GAD | Detail | |
0.006 | ganglioglioma | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | olfactory neuroblastoma | NA | BeFree | Detail | |
<0.001 | ganglioneuroblastoma | NA | BeFree | Detail | |
<0.001 | central neurocytoma | NA | BeFree | Detail | |
0.008 | Squamous Cell Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
0.006 | inverted papilloma | No variation of p16, p21, PLUNC (palate, lung, and nasal epithelium clone protei... | BeFree,LHGDN | 25013792 | Detail |
<0.001 | Sex cord-stromal tumor | NA | BeFree | Detail | |
0.121 | gliosarcoma | NA | BeFree,ORPHANET | Detail | |
0.087 | Nerve Sheath Tumors | NA | BeFree,CTD_mouse,GAD,LHGDN | Detail | |
<0.001 | Angiofibroma | NA | BeFree | Detail | |
<0.001 | Strawberry nevus of skin | NA | BeFree | Detail | |
<0.001 | Rhabdoid Tumor | NA | BeFree | Detail | |
0.006 | Neuroendocrine Tumors | Genetic alterations in human cancers and murine models indicate that retinoblast... | BeFree,LHGDN | 24469052 | Detail |
0.006 | Neuroendocrine Tumors | The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine n... | BeFree,LHGDN | 25837868 | Detail |
<0.001 | Nevi and Melanomas | NA | BeFree | Detail | |
<0.001 | childhood brain tumor | Interestingly, ALT attenuated the poor outcome conferred by TP53 mutations in sp... | BeFree | 25315281 | Detail |
<0.001 | childhood rhabdomyosarcoma | NA | BeFree | Detail | |
<0.001 | Adult Acute Myeloblastic Leukemia | NA | BeFree | Detail | |
<0.001 | pediatric acute myeloblastic leukemia | NA | BeFree | Detail | |
0.002 | uveal melanoma | NA | BeFree | Detail | |
0.020 | Lip and oral cavity carcinoma | Phenethyl isothiocyanate induces DNA damage-associated G2/M arrest and subsequen... | BeFree | 24952138 | Detail |
0.020 | Lip and oral cavity carcinoma | The detection limits, established as 3σ, were estimated to be 0.03 and 0.06 fmol... | BeFree | 25493424 | Detail |
0.020 | Lip and oral cavity carcinoma | The expression of total and phosphorylated GSK3α/β as well as cyclin D1 and p53 ... | BeFree | 25645517 | Detail |
<0.001 | childhood soft tissue sarcoma | NA | BeFree | Detail | |
<0.001 | Renal Pelvis and Ureter Urothelial Carcinoma | NA | BeFree | Detail | |
0.002 | Metastatic malignant neoplasm to brain | NA | BeFree | Detail | |
<0.001 | Congenital defects | NA | BeFree | Detail | |
<0.001 | Adult type dermatomyositis | NA | BeFree | Detail | |
0.002 | Comedone | NA | BeFree | Detail | |
<0.001 | Juvenile polyp | NA | BeFree | Detail | |
<0.001 | Lesion of brain | NA | BeFree | Detail | |
0.001 | Premature aging syndrome | NA | BeFree | Detail | |
<0.001 | Fibrosing adenosis | NA | BeFree | Detail | |
0.002 | Malignant neoplasm of female breast | Mutational profiling of familial male breast cancers reveals similarities with l... | BeFree | 25490678 | Detail |
0.009 | gallbladder carcinoma | High frequency of TP53 but not K-ras gene mutations in Bolivian patients with ga... | BeFree | 25041017 | Detail |
0.009 | gallbladder carcinoma | All MSI tumors were negative for HER2 amplification, and TP53 and NRAS mutations... | BeFree | 25680569 | Detail |
0.157 | pancreatic carcinoma | Other genetic alterations, including telomere shortening and the inactivation of... | BeFree,CLINVAR | 24445769 | Detail |
0.157 | pancreatic carcinoma | Taken together, our data indicate that PRIMA-1 induces apoptosis in p53 mutant p... | BeFree,CLINVAR | 24838627 | Detail |
0.157 | pancreatic carcinoma | Together, our data support the critical role of autophagy in pancreatic cancer a... | BeFree,CLINVAR | 24875860 | Detail |
0.157 | pancreatic carcinoma | Studies of the molecular pathology of pancreatic cancer have revealed that activ... | BeFree,CLINVAR | 25152585 | Detail |
0.157 | pancreatic carcinoma | pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advan... | BeFree,CLINVAR | 25164437 | Detail |
0.157 | pancreatic carcinoma | We investigated the prevalence of germline mutations in APC, ATM, BRCA1, BRCA2, ... | BeFree,CLINVAR | 25479140 | Detail |
0.157 | pancreatic carcinoma | Chromosomal rearrangements leading to gene disruption were prevalent, affecting ... | BeFree,CLINVAR | 25719666 | Detail |
0.157 | pancreatic carcinoma | Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Ab... | BeFree,CLINVAR | 26113084 | Detail |
0.157 | pancreatic carcinoma | Here we report a systematic definition of how pancreatic cancer cells harboring ... | BeFree,CLINVAR | 26141863 | Detail |
0.157 | pancreatic carcinoma | Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of ... | BeFree,CLINVAR | 26189069 | Detail |
0.002 | Substance-Related Disorders | NA | GAD | Detail | |
<0.001 | adnexal lesion | NA | BeFree | Detail | |
<0.001 | Carcinoma of extrahepatic bile duct | NA | BeFree | Detail | |
<0.001 | Breast Phyllodes Tumor | NA | BeFree | Detail | |
0.001 | Carcinoma of male breast | NA | BeFree | Detail | |
<0.001 | Intraductal papilloma of breast | NA | BeFree | Detail | |
0.002 | fallopian tube carcinoma | NA | BeFree | Detail | |
<0.001 | gallbladder adenoma | NA | BeFree | Detail | |
0.008 | Gastrointestinal Stromal Tumors | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | Polyp of larynx | NA | BeFree | Detail | |
<0.001 | Muscular Dystrophy, Facioscapulohumeral | NA | BeFree | Detail | |
0.002 | Cancer of Nasopharynx | NA | BeFree | Detail | |
<0.001 | Hereditary pancreatitis | NA | BeFree | Detail | |
0.001 | Squamous cell carcinoma of penis | Epigenetic silencing of miR-218 is a common feature in HR-HPV(+) PSCCs and in HR... | BeFree | 25455689 | Detail |
<0.001 | Renal Pelvis Urothelial Carcinoma | NA | BeFree | Detail | |
0.002 | Medullary carcinoma of thyroid | In the current study, genetically engineered mice were generated to determine th... | BeFree | 24469052 | Detail |
0.006 | Papillary thyroid carcinoma | By simultaneously activating Kras and deleting p53 (Trp53) in thyroid follicular... | BeFree | 25012986 | Detail |
0.006 | Papillary thyroid carcinoma | In immunohistochemical studies, DSVPTC showed different expression patterns of e... | BeFree | 25577570 | Detail |
0.006 | Papillary thyroid carcinoma | Pri-Mir-34b/C and Tp-53 Polymorphisms are Associated With The Susceptibility of ... | BeFree | 26402809 | Detail |
<0.001 | Interstitial fibrosis | NA | BeFree | Detail | |
<0.001 | Angiomyolipoma of kidney | NA | BeFree | Detail | |
<0.001 | islet cell tumor | NA | BeFree | Detail | |
0.160 | Malignant neoplasm of lung | Ectopic expression of miR-506 inhibits NF-κB p65 expression, induces ROS accumul... | BeFree,GAD | 24469051 | Detail |
0.160 | Malignant neoplasm of lung | Nickel accumulation in lung tissues is associated with increased risk of p53 mut... | BeFree,GAD | 24711049 | Detail |
0.160 | Malignant neoplasm of lung | Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates act... | BeFree,GAD | 24915467 | Detail |
0.160 | Malignant neoplasm of lung | TP53 mutations and lung cancer: not all mutations are created equal. | BeFree,GAD | 24916693 | Detail |
0.160 | Malignant neoplasm of lung | Caveolin-1 regulates lung cancer stem-like cell induction and p53 inactivation i... | BeFree,GAD | 24939878 | Detail |
0.160 | Malignant neoplasm of lung | AP-2α downregulation by cigarette smoke condensate is counteracted by p53 in hum... | BeFree,GAD | 25050743 | Detail |
0.160 | Malignant neoplasm of lung | β-Elemene against human lung cancer via up-regulation of P53 protein expression ... | BeFree,GAD | 25204604 | Detail |
0.160 | Malignant neoplasm of lung | We evaluated 23 single nucleotide polymorphisms (SNPs) in the five nicotinic rec... | BeFree,GAD | 25233467 | Detail |
0.160 | Malignant neoplasm of lung | Evaluation of the mutagenicity of anti-B[a]P-diol epoxide with B[a]P-7,8-dione o... | BeFree,GAD | 25279998 | Detail |
0.160 | Malignant neoplasm of lung | Loss of p53 function may result in upregulation of 14-3-3γ in lung cancers. | BeFree,GAD | 25384678 | Detail |
0.160 | Malignant neoplasm of lung | In addition, we used lung cancer cell lines with different p53 gene background (... | BeFree,GAD | 25398693 | Detail |
0.160 | Malignant neoplasm of lung | Finally, we provide an analysis of discerning epidemiological data obtained from... | BeFree,GAD | 25433984 | Detail |
0.160 | Malignant neoplasm of lung | SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptos... | BeFree,GAD | 25435374 | Detail |
0.160 | Malignant neoplasm of lung | Moreover, co-treatment of MML and p53 inhibitor would be more effective in human... | BeFree,GAD | 25490748 | Detail |
0.160 | Malignant neoplasm of lung | Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-κB signa... | BeFree,GAD | 25499080 | Detail |
0.160 | Malignant neoplasm of lung | Our finding supports that mir-660 acts as a tumor suppressor miRNA and we sugges... | BeFree,GAD | 25501825 | Detail |
0.160 | Malignant neoplasm of lung | These results suggest that stroma-derived p53 plays a pivotal role in epithelial... | BeFree,GAD | 25512506 | Detail |
0.160 | Malignant neoplasm of lung | Association of a p53 codon 72 gene polymorphism with environmental factors and r... | BeFree,GAD | 25605155 | Detail |
0.160 | Malignant neoplasm of lung | We identified mutations in both tumors, including KEAP1 (commonly mutated in lun... | BeFree,GAD | 25850996 | Detail |
0.160 | Malignant neoplasm of lung | Treatment of cells with curcumin induced both p53 and the related protein p73 in... | BeFree,GAD | 25910231 | Detail |
0.160 | Malignant neoplasm of lung | TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population. | BeFree,GAD | 25921167 | Detail |
0.160 | Malignant neoplasm of lung | Furthermore, using data generated by The Cancer Genome Atlas consortium, we demo... | BeFree,GAD | 26063617 | Detail |
0.160 | Malignant neoplasm of lung | These results demonstrate that p53 is able to respond to exposure of arsenic or ... | BeFree,GAD | 26091798 | Detail |
0.160 | Malignant neoplasm of lung | However, p53-targeted therapies have limited application in lung cancer, since p... | BeFree,GAD | 26093302 | Detail |
0.160 | Malignant neoplasm of lung | This RNA aptamer (p53R175H-APT) has a significantly stronger affinity to p53R175... | BeFree,GAD | 26216949 | Detail |
0.001 | Mandibulofacial Dysostosis | NA | BeFree | Detail | |
<0.001 | Parkinsonian Disorders | NA | BeFree | Detail | |
<0.001 | Drug usage | NA | BeFree | Detail | |
<0.001 | Residual Cancer | NA | BeFree | Detail | |
0.002 | Neoplasm, Residual | With regards to overall survival, factors predictive of an unfavorable outcome w... | BeFree | 24700492 | Detail |
0.002 | Isochromosomes | NA | BeFree | Detail | |
0.009 | Mucosa-Associated Lymphoid Tissue Lymphoma | NA | BeFree,GAD | Detail | |
0.003 | Disease Progression | NA | LHGDN | Detail | |
<0.001 | Malignant neoplasm of male breast | NA | BeFree | Detail | |
<0.001 | Proliferative vitreoretinopathy | NA | BeFree | Detail | |
<0.001 | mixed gliomas | NA | BeFree | Detail | |
0.001 | Malignant Meningioma | NA | BeFree | Detail | |
0.002 | Multiple tumors | The inability of mice to develop HCC when autophagy was impaired was associated ... | BeFree | 25526090 | Detail |
<0.001 | Carcinoma of ampulla of Vater | NA | BeFree | Detail | |
0.127 | Carcinoma, Small Cell | The pathogenesis of prostatic SCNC involves a p53 and Aurora Kinase A signaling ... | BeFree,CTD_human,LHGDN | 25512615 | Detail |
0.001 | parathyroid adenoma | NA | BeFree | Detail | |
<0.001 | Vagina Carcinoma | NA | BeFree | Detail | |
0.004 | Acute respiratory failure | NA | BeFree | Detail | |
<0.001 | Chronic heart failure | NA | BeFree | Detail | |
<0.001 | Cardiac dilatation | NA | BeFree | Detail | |
0.002 | Miller Dieker syndrome | TP53 overexpression is a predictor of poor outcome in patients with MDS-F. | BeFree | 26123119 | Detail |
0.001 | Turcot syndrome (disorder) | NA | BeFree | Detail | |
<0.001 | CHARGE syndrome | NA | BeFree | Detail | |
<0.001 | Chromosome 20, trisomy | NA | BeFree | Detail | |
<0.001 | dyskeratosis congenita | Together, the results of this study support PARN as a DC-associated gene and sug... | BeFree | 25893598 | Detail |
<0.001 | Congenital absence of liver | NA | BeFree | Detail | |
0.001 | Exencephaly | NA | BeFree | Detail | |
<0.001 | Congenital ear anomaly NOS (disorder) | NA | BeFree | Detail | |
<0.001 | Erythroplakia of mouth | NA | BeFree | Detail | |
<0.001 | Actinic cheilitis | NA | BeFree | Detail | |
<0.001 | Gastric dysplasia | NA | BeFree | Detail | |
<0.001 | Intestinal metaplasia of gastric mucosa | NA | BeFree | Detail | |
<0.001 | Chronic colitis | NA | BeFree | Detail | |
<0.001 | hepatobiliary disease | NA | BeFree | Detail | |
<0.001 | Xeroderma Pigmentosum, Complementation Group D | NA | BeFree | Detail | |
<0.001 | Simple renal cyst | NA | BeFree | Detail | |
<0.001 | Endometrioma | Moreover, a significant decrease of p53 protein and a significant increase of he... | BeFree | 25772769 | Detail |
<0.001 | Germinal inclusion cyst of ovary | NA | BeFree | Detail | |
<0.001 | Spastic syndrome | NA | BeFree | Detail | |
<0.001 | Shwachman syndrome | NA | BeFree | Detail | |
<0.001 | Chronic idiopathic thrombocytopenic purpura | NA | BeFree | Detail | |
<0.001 | Coinfection | NA | BeFree | Detail | |
<0.001 | Canarypox (disorder) | NA | BeFree | Detail | |
<0.001 | Verruca plana | NA | BeFree | Detail | |
<0.001 | Chronic viral hepatitis | NA | BeFree | Detail | |
0.002 | Stage III Colon Cancer | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of colon stage IV | Functional TP53 mutations have no impact on response to cytotoxic agents in meta... | BeFree | 25609485 | Detail |
<0.001 | Breast cancer stage II | NA | BeFree | Detail | |
<0.001 | Stage III Breast Cancer AJCC v6 | NA | BeFree | Detail | |
0.002 | Carcinoma breast stage IV | NA | BeFree | Detail | |
<0.001 | Breast cancer recurrent | NA | BeFree | Detail | |
0.002 | Non-small cell lung cancer stage I | NA | BeFree | Detail | |
<0.001 | Non-small cell lung cancer stage III | NA | BeFree | Detail | |
<0.001 | Medulloblastoma, Childhood | NA | BeFree | Detail | |
<0.001 | Osteosarcoma localised | NA | BeFree | Detail | |
<0.001 | Metastatic osteosarcoma | NA | BeFree | Detail | |
<0.001 | Non-small cell lung cancer recurrent | NA | BeFree | Detail | |
<0.001 | recurrent childhood acute lymphoblastic leukemia | NA | BeFree | Detail | |
0.002 | inflammatory breast carcinoma | Furthermore a minimal IBC-related predictive set of 4 miRNAs associated with the... | BeFree | 25471792 | Detail |
<0.001 | Metastatic Renal Cell Cancer | NA | BeFree | Detail | |
<0.001 | Ovarian epithelial cancer stage III | NA | BeFree | Detail | |
0.001 | Ovarian epithelial cancer recurrent | NA | BeFree | Detail | |
<0.001 | Neuroblastoma recurrent | NA | BeFree | Detail | |
0.006 | gastric adenocarcinoma | The obtained results allow the conclusion, that H. pylori (cagA+)-associated dev... | BeFree | 26638529 | Detail |
0.001 | Malignant Childhood Neoplasm | A significant percentage (5-10%) of pediatric cancers are associated with heredi... | BeFree | 26248253 | Detail |
<0.001 | Small cell lung cancer extensive stage | NA | BeFree | Detail | |
0.002 | Chronic lymphocytic leukaemia refractory | We investigated the safety and activity of ibrutinib in previously untreated and... | BeFree | 25555420 | Detail |
<0.001 | Endometrial neoplasm malignant stage I | NA | BeFree | Detail | |
<0.001 | Recurrent Endometrial Cancer | NA | BeFree | Detail | |
<0.001 | Prostate cancer recurrent | NA | BeFree | Detail | |
<0.001 | Medulloblastoma, Adult | NA | BeFree | Detail | |
0.002 | Metastatic melanoma | NA | BeFree | Detail | |
<0.001 | Non-small cell lung cancer metastatic | NA | BeFree | Detail | |
0.033 | Cancer of Head and Neck | Phase I dendritic cell p53 peptide vaccine for head and neck cancer. | BeFree,GAD | 24583792 | Detail |
0.033 | Cancer of Head and Neck | TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mut... | BeFree,GAD | 25119136 | Detail |
0.033 | Cancer of Head and Neck | Anomalous altered expressions of downstream gene-targets in TP53-miRNA pathways ... | BeFree,GAD | 25186767 | Detail |
0.033 | Cancer of Head and Neck | Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk... | BeFree,GAD | 25504633 | Detail |
0.033 | Cancer of Head and Neck | Salivary adenoid cystic carcinoma (SACC) is a malignant tumor that is characteri... | BeFree,GAD | 25625376 | Detail |
0.033 | Cancer of Head and Neck | Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with... | BeFree,GAD | 25634208 | Detail |
0.033 | Cancer of Head and Neck | Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Resp... | BeFree,GAD | 25691460 | Detail |
0.033 | Cancer of Head and Neck | The role of HPV RNA transcription, immune response-related gene expression and d... | BeFree,GAD | 26095926 | Detail |
0.005 | Liver and Intrahepatic Biliary Tract Carcinoma | One such example is hepatitis virus-induced liver cancer whereby p53 is inactiva... | BeFree | 25404244 | Detail |
0.005 | Liver and Intrahepatic Biliary Tract Carcinoma | NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiat... | BeFree | 26174965 | Detail |
<0.001 | Philadelphia chromosome positive chronic myelogenous leukemia | NA | BeFree | Detail | |
<0.001 | Lobular carcinoma in situ of breast | NA | BeFree | Detail | |
0.001 | Invasive lobular breast carcinoma | NA | BeFree | Detail | |
<0.001 | T-cell childhood acute lymphoblastic leukemia | NA | BeFree | Detail | |
<0.001 | Fibroblastic osteosarcoma | NA | BeFree | Detail | |
<0.001 | Small cell osteosarcoma | NA | BeFree | Detail | |
0.230 | Squamous cell carcinoma of esophagus | Association between SNPs in P53 binding regions and risk of esophageal squamous ... | BeFree,CTD_human,CTD_mouse,GAD | 24474449 | Detail |
0.230 | Squamous cell carcinoma of esophagus | LINE-1 hypomethylation of ESCC was significantly associated with lymph node meta... | BeFree,CTD_human,CTD_mouse,GAD | 24898425 | Detail |
0.230 | Squamous cell carcinoma of esophagus | Combined effects of leukocyte telomere length, p53 polymorphism and human papill... | BeFree,CTD_human,CTD_mouse,GAD | 25153662 | Detail |
0.230 | Squamous cell carcinoma of esophagus | Esophageal cells overexpressing epidermal growth factor receptor (EGFR) and TP53... | BeFree,CTD_human,CTD_mouse,GAD | 25795715 | Detail |
0.441 | Li-Fraumeni syndrome 1 | These findings identify an important subgroup of young patients with cancer who ... | UNIPROT | 1565144 | Detail |
0.441 | Li-Fraumeni syndrome 1 | Database of mutations in the p53 and APC tumor suppressor genes designed to faci... | UNIPROT | 8829653 | Detail |
0.132 | Adenocarcinoma Of Esophagus | Combining the techniques detected TP53 abnormalities in 100% of patients with LG... | BeFree,CTD_human,GAD | 25284618 | Detail |
0.132 | Adenocarcinoma Of Esophagus | Barrett's esophagus is thought to progress to esophageal adenocarcinoma (EAC) th... | BeFree,CTD_human,GAD | 26192918 | Detail |
0.441 | Li-Fraumeni syndrome 1 | p53 mutations in human cancers. | UNIPROT | 1905840 | Detail |
0.002 | anal carcinoma | NA | BeFree | Detail | |
<0.001 | gallbladder adenocarcinoma | Expression of cell cycle-related proteins, p16, p53 and p63 as important prognos... | BeFree | 24178677 | Detail |
0.004 | cervical squamous cell carcinoma | To investigate protein expression and mutations in phosphatase and tensin homolo... | BeFree | 25003471 | Detail |
0.003 | cervical adenocarcinoma | NA | BeFree | Detail | |
0.012 | Transitional cell carcinoma of bladder | NA | BeFree | Detail | |
<0.001 | bladder adenocarcinoma | The expression patterns of p53 and p16 and an analysis of a possible role of HPV... | BeFree | 24752337 | Detail |
0.001 | Conventional (Clear Cell) Renal Cell Carcinoma | Ubiquitin E3 ligase UHRF1 regulates p53 ubiquitination and p53-dependent cell ap... | BeFree | 26102039 | Detail |
<0.001 | endometrial clear cell adenocarcinoma | NA | BeFree | Detail | |
0.003 | extraosseous Ewings sarcoma-primitive neuroepithelial tumor | NA | BeFree | Detail | |
<0.001 | Carcinoid tumor of lung | NA | BeFree | Detail | |
0.015 | Solid tumour | These studies showed that TP53 and PI3KCA are the two most mutated genes in all ... | BeFree | 24833724 | Detail |
0.015 | Solid tumour | The human cervical cancer oncogene (HCCR) has been shown to be over-expressed in... | BeFree | 25034723 | Detail |
<0.001 | Acute Undifferentiated Leukemia | Genetic deletion of the telomerase subunit Terc in a retroviral mouse AML model ... | BeFree | 25479751 | Detail |
0.001 | stage, non-small cell lung cancer | The influence of TP53 mutations on the prognosis of patients with early stage no... | BeFree | 24038464 | Detail |
0.001 | stage, non-small cell lung cancer | TP53 mutations in early-stage non-small cell lung cancer (NSCLC) may be associat... | BeFree | 24696321 | Detail |
0.001 | stage, non-small cell lung cancer | Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphism... | BeFree | 25596702 | Detail |
<0.001 | stage, ovarian epithelial cancer | NA | BeFree | Detail | |
<0.001 | stage, endometrial cancer | NA | BeFree | Detail | |
<0.001 | stage, prostate cancer | NA | BeFree | Detail | |
<0.001 | Verrucous carcinoma of oral cavity | Exome sequencing showed that OVC samples lacked mutations in genes commonly asso... | BeFree | 26014678 | Detail |
0.002 | Squamous cell carcinoma of oropharynx | NA | BeFree | Detail | |
0.001 | Squamous cell carcinoma of the hypopharynx | NA | BeFree | Detail | |
0.006 | laryngeal squamous cell carcinoma | NA | BeFree,GAD | Detail | |
<0.001 | secondary acute myeloid leukemia | We show that (i) in the choroid plexus carcinoma, the germline mutation was dete... | BeFree | 25787918 | Detail |
<0.001 | de novo myelodysplastic syndromes | TP53 overexpression is an independent adverse prognostic factor in de novo myelo... | BeFree | 26123119 | Detail |
<0.001 | high-grade childhood cerebral astrocytoma | NA | BeFree | Detail | |
<0.001 | uterine carcinosarcoma | NA | BeFree | Detail | |
<0.001 | Leiomyosarcoma of uterus | NA | BeFree | Detail | |
<0.001 | Sarcoma of ovary | NA | BeFree | Detail | |
0.001 | juvenile pilocytic astrocytoma | NA | BeFree | Detail | |
0.004 | diffuse astrocytoma | NA | BeFree | Detail | |
<0.001 | anaplastic ependymoma | NA | BeFree | Detail | |
0.001 | mixed oligodendroglioma-astrocytoma | In all but one OA the combination of nuclear p53 accumulation and ATRX loss was ... | BeFree | 25143301 | Detail |
0.001 | mixed oligodendroglioma-astrocytoma | We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX... | BeFree | 25257301 | Detail |
0.003 | Squamous cell carcinoma of vulva | As most studies have focused on HPV infection and TP53 mutations, we suggest tha... | BeFree | 25448458 | Detail |
0.003 | bilateral breast cancer | NA | BeFree | Detail | |
0.009 | Adenocarcinoma of pancreas | TP53 mutation is a common event in many cancers, including pancreatic adenocarci... | BeFree,GAD | 24838627 | Detail |
<0.001 | benign meningioma | NA | BeFree | Detail | |
<0.001 | Condition, Preneoplastic | NA | BeFree | Detail | |
0.003 | interstitial cystitis | NA | BeFree,LHGDN | Detail | |
<0.001 | Myomatous neoplasm | NA | BeFree | Detail | |
0.005 | Prostatic Intraepithelial Neoplasias | NA | BeFree,GAD | Detail | |
<0.001 | Condyloma | NA | BeFree | Detail | |
0.213 | cervix carcinoma | Positive staining for p53 was observed in 15 (24.59%) cases of cervical intraepi... | BeFree,CLINVAR,GAD | 25151759 | Detail |
0.213 | cervix carcinoma | Association of a miR-502-binding site single nucleotide polymorphism in the 3'-u... | BeFree,CLINVAR,GAD | 25169478 | Detail |
0.213 | cervix carcinoma | Several factors may contribute to cervical cancer (CC) development, including ge... | BeFree,CLINVAR,GAD | 25181402 | Detail |
0.213 | cervix carcinoma | Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkp... | BeFree,CLINVAR,GAD | 25362645 | Detail |
0.213 | cervix carcinoma | Expression of the p53 target Wig-1 is associated with HPV status and patient sur... | BeFree,CLINVAR,GAD | 25379706 | Detail |
0.213 | cervix carcinoma | Berberine alters epigenetic modifications, disrupts microtubule network, and mod... | BeFree,CLINVAR,GAD | 25448308 | Detail |
0.213 | cervix carcinoma | The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinom... | BeFree,CLINVAR,GAD | 25502079 | Detail |
0.213 | cervix carcinoma | Overexpression of Nm23H1 but not H2 also inhibited tumorigenesis by human cervic... | BeFree,CLINVAR,GAD | 25748386 | Detail |
0.213 | cervix carcinoma | The mechanism and inhibitory effect of recombinant human P53 adenovirus injectio... | BeFree,CLINVAR,GAD | 25855930 | Detail |
0.122 | Arsenic Poisoning | NA | CTD_human,GAD | Detail | |
<0.001 | Anastomosis | NA | BeFree | Detail | |
0.006 | Restenosis | NA | BeFree,GAD | Detail | |
0.001 | Superficial ulcer | NA | BeFree | Detail | |
0.003 | Tumor necrosis | NA | BeFree | Detail | |
0.002 | Triploidy syndrome | NA | BeFree | Detail | |
0.002 | Squamous intraepithelial lesion | NA | BeFree | Detail | |
0.001 | High-Grade Squamous Intraepithelial Lesions | NA | BeFree | Detail | |
<0.001 | Focal Nodular Hyperplasia | NA | BeFree | Detail | |
0.003 | Hyperplastic Polyp | Formalin Fixed Paraffin Embedded tissue were studied for miRNA expression, KRAS,... | BeFree | 25496852 | Detail |
<0.001 | Lymphoid hyperplasia | NA | BeFree | Detail | |
<0.001 | Adenosis | NA | BeFree | Detail | |
<0.001 | Hamartomatous polyp | NA | BeFree | Detail | |
<0.001 | Bowenoid papulosis | NA | BeFree | Detail | |
<0.001 | Multiple polyps | NA | BeFree | Detail | |
<0.001 | inflammatory myofibroblastic tumor | NA | BeFree | Detail | |
<0.001 | pleomorphic carcinoma | NA | BeFree | Detail | |
<0.001 | Papillary squamous cell carcinoma | NA | BeFree | Detail | |
<0.001 | Intraepithelial Squamous Cell Carcinoma | NA | BeFree | Detail | |
<0.001 | Squamous cell carcinoma, metastatic | NA | BeFree | Detail | |
<0.001 | Squamous cell carcinoma, keratinizing | NA | BeFree | Detail | |
<0.001 | Squamous cell carcinoma, microinvasive | NA | BeFree | Detail | |
0.001 | Lymphoepithelial carcinoma | NA | BeFree | Detail | |
<0.001 | Transitional cell carcinoma in situ | NA | BeFree | Detail | |
<0.001 | Papillary transitional cell carcinoma | NA | BeFree | Detail | |
<0.001 | adenocarcinoma in situ | NA | BeFree | Detail | |
0.002 | Adenocarcinoma, intestinal type | NA | BeFree | Detail | |
<0.001 | Multiple adenomatous polyps | NA | BeFree | Detail | |
0.001 | Carcinoid tumor no ICD-O subtype | Although the status of RB1 and P53 between carcinoids and HGNETs were apparently... | BeFree | 25143124 | Detail |
<0.001 | Skin appendage adenoma | NA | BeFree | Detail | |
<0.001 | Sweat gland adenocarcinoma | NA | BeFree | Detail | |
0.002 | Papillary serous cystadenocarcinoma | NA | BeFree | Detail | |
<0.001 | Mucinous cystic tumor of borderline malignancy | TP53 mutation occurred more frequently in carcinomas than borderline tumors (56.... | BeFree | 25986173 | Detail |
<0.001 | Non-infiltrating lobular carcinoma | NA | BeFree | Detail | |
<0.001 | Leydig cell tumor, benign | NA | BeFree | Detail | |
<0.001 | Superficial spreading malignant melanoma of skin | NA | BeFree | Detail | |
0.003 | malignant fibrous histiocytoma | NA | BeFree | Detail | |
<0.001 | Round cell liposarcoma | NA | BeFree | Detail | |
<0.001 | Clear cell sarcoma of kidney | NA | BeFree | Detail | |
0.001 | Teratoma, Malignant | NA | BeFree | Detail | |
<0.001 | Hydatidiform Mole, Partial | NA | BeFree | Detail | |
<0.001 | Malignant Giant Cell Tumor of Bone | NA | BeFree | Detail | |
0.001 | gliomatosis cerebri | NA | BeFree | Detail | |
0.016 | anaplastic astrocytoma | NA | BeFree,GAD | Detail | |
0.001 | gemistocytic astrocytoma | NA | BeFree | Detail | |
0.001 | fibrillary astrocytoma | NA | BeFree | Detail | |
0.003 | pilocytic astrocytoma | NA | BeFree | Detail | |
<0.001 | pleomorphic xanthoastrocytoma | NA | BeFree | Detail | |
0.121 | giant cell glioblastoma | NA | BeFree,ORPHANET | Detail | |
0.004 | anaplastic oligodendroglioma | Those tumors that lacked LOH 1p19q showed a high frequency of IDH1 mutations and... | BeFree | 24444336 | Detail |
0.004 | anaplastic oligodendroglioma | The mean of Olig2 LI of gliomas with 1p/19q loss ± IDH1/2 mutation, the majority... | BeFree | 25085214 | Detail |
0.004 | anaplastic oligodendroglioma | We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX... | BeFree | 25257301 | Detail |
0.004 | anaplastic oligodendroglioma | The TP53 and HIST1H3A genes were the hub nodes in the PPI network of DEGs from G... | BeFree | 25351872 | Detail |
0.004 | anaplastic oligodendroglioma | Thus, we analyzed the expression of p-CREB in a series of astrocytomas and oligo... | BeFree | 25476123 | Detail |
0.004 | anaplastic oligodendroglioma | We find evidence of regional mutational heterogeneity in multiple tumors, includ... | BeFree | 25608559 | Detail |
<0.001 | Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation | NA | BeFree | Detail | |
0.012 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of... | BeFree,LHGDN | 24852242 | Detail |
0.012 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A an... | BeFree,LHGDN | 26022239 | Detail |
<0.001 | mast cell neoplasm | NA | BeFree | Detail | |
0.002 | Adenocarcinoma of colon | NA | BeFree | Detail | |
<0.001 | Chronic hyperplastic candidiasis | NA | BeFree | Detail | |
0.001 | Jaw Keratocyst | NA | BeFree | Detail | |
<0.001 | Gastric Hamartoma | NA | BeFree | Detail | |
<0.001 | Ulcerative jejunitis | NA | BeFree | Detail | |
<0.001 | Chronic liver disease | NA | BeFree | Detail | |
<0.001 | Epithelial tumor of ovary | NA | BeFree | Detail | |
<0.001 | Adrenocortical hyperplasia | NA | BeFree | Detail | |
0.008 | Human papilloma virus infection | Combined effects of leukocyte telomere length, p53 polymorphism and human papill... | BeFree | 25153662 | Detail |
0.008 | Human papilloma virus infection | Correlation between squamous cell carcinoma of the lung and human papillomavirus... | BeFree | 25544708 | Detail |
<0.001 | Penile warts | NA | BeFree | Detail | |
<0.001 | Macroprolactinoma | NA | BeFree | Detail | |
0.001 | Carcinoma ex pleomorphic adenoma | NA | BeFree | Detail | |
<0.001 | Carcinoma of parotid gland | NA | BeFree | Detail | |
0.011 | Malignant neoplasm of liver | One such example is hepatitis virus-induced liver cancer whereby p53 is inactiva... | BeFree,GAD | 25404244 | Detail |
0.011 | Malignant neoplasm of liver | NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiat... | BeFree,GAD | 26174965 | Detail |
0.003 | intrahepatic cholangiocarcinoma | NA | BeFree | Detail | |
0.001 | Angiosarcoma of liver | NA | BeFree | Detail | |
<0.001 | Large cell carcinoma of lung | NA | BeFree | Detail | |
0.003 | malignant mesothelioma | NA | BeFree | Detail | |
<0.001 | Solitary keratoacanthoma | NA | BeFree | Detail | |
<0.001 | Pilar tumor | NA | BeFree | Detail | |
0.001 | Atypical fibroxanthoma of skin | NA | BeFree | Detail | |
0.007 | Breast Cancer, Familial | However, only about 20% of familial breast cancer is attributed to mutations in ... | BeFree | 25736863 | Detail |
0.001 | Endometrioid carcinoma ovary | NA | BeFree | Detail | |
0.004 | Vulval intraepithelial neoplasia | Diffuse p16 expression was associated with younger age at presentation (P<0.0001... | BeFree | 26171917 | Detail |
<0.001 | pituitary carcinoma | NA | BeFree | Detail | |
<0.001 | Squamous cell carcinoma of conjunctiva | NA | BeFree | Detail | |
<0.001 | Malignant melanoma of choroid | NA | BeFree | Detail | |
0.002 | Malignant neoplasm of adrenal cortex | NA | BeFree | Detail | |
<0.001 | Multiple malignancy | NA | BeFree | Detail | |
<0.001 | intestinal cancer | NA | BeFree | Detail | |
0.039 | Malignant neoplasm of pancreas | Other genetic alterations, including telomere shortening and the inactivation of... | BeFree,GAD | 24445769 | Detail |
0.039 | Malignant neoplasm of pancreas | Taken together, our data indicate that PRIMA-1 induces apoptosis in p53 mutant p... | BeFree,GAD | 24838627 | Detail |
0.039 | Malignant neoplasm of pancreas | Together, our data support the critical role of autophagy in pancreatic cancer a... | BeFree,GAD | 24875860 | Detail |
0.039 | Malignant neoplasm of pancreas | Studies of the molecular pathology of pancreatic cancer have revealed that activ... | BeFree,GAD | 25152585 | Detail |
0.039 | Malignant neoplasm of pancreas | pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advan... | BeFree,GAD | 25164437 | Detail |
0.039 | Malignant neoplasm of pancreas | We investigated the prevalence of germline mutations in APC, ATM, BRCA1, BRCA2, ... | BeFree,GAD | 25479140 | Detail |
0.039 | Malignant neoplasm of pancreas | Chromosomal rearrangements leading to gene disruption were prevalent, affecting ... | BeFree,GAD | 25719666 | Detail |
0.039 | Malignant neoplasm of pancreas | Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Ab... | BeFree,GAD | 26113084 | Detail |
0.039 | Malignant neoplasm of pancreas | Here we report a systematic definition of how pancreatic cancer cells harboring ... | BeFree,GAD | 26141863 | Detail |
0.039 | Malignant neoplasm of pancreas | Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of ... | BeFree,GAD | 26189069 | Detail |
0.002 | Disseminated Malignant Neoplasm | NA | BeFree | Detail | |
<0.001 | Secondary malignant neoplasm of pancreas | NA | BeFree | Detail | |
<0.001 | Secondary malignant neoplasm of female breast | NA | BeFree | Detail | |
<0.001 | Anal intraepithelial neoplasia | NA | BeFree | Detail | |
<0.001 | Carcinoma in situ of fallopian tube | NA | BeFree | Detail | |
<0.001 | Polyp of duodenum | NA | BeFree | Detail | |
<0.001 | skin papilloma | Conversely, DEK loss results in cell death in HPV-positive cervical cancer cells... | BeFree | 24608431 | Detail |
<0.001 | Malignant neoplasm of central nervous system | NA | BeFree | Detail | |
0.001 | Cervical intraepithelial neoplasia grade 1 | NA | BeFree | Detail | |
0.001 | Cervical intraepithelial neoplasia grade 2 | NA | BeFree | Detail | |
0.002 | Early gastric cancer | NA | BeFree | Detail | |
0.001 | gastric lymphoma | NA | BeFree | Detail | |
<0.001 | Carcinoma of anal margin | NA | BeFree | Detail | |
<0.001 | Vulval intraepithelial neoplasia grade 3 | NA | BeFree | Detail | |
0.002 | Squamous cell carcinoma of tongue | Cantharidin inhibits cell proliferation and promotes apoptosis in tongue squamou... | BeFree | 25962755 | Detail |
<0.001 | Atypical endometrial hyperplasia | NA | BeFree | Detail | |
0.002 | Richter's syndrome | Somatic mutations contributing to the development of RS include TP53 disruption,... | BeFree | 25218362 | Detail |
0.002 | Splenic Marginal Zone B-Cell Lymphoma | NA | BeFree | Detail | |
<0.001 | Hairy cell leukemia variant | NA | BeFree | Detail | |
0.001 | juvenile myelomonocytic leukemia | NA | BeFree | Detail | |
<0.001 | Trichoepithelioma | NA | BeFree | Detail | |
<0.001 | Sarcoma of breast | NA | BeFree | Detail | |
0.003 | Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site | NA | BeFree | Detail | |
<0.001 | Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site | NA | BeFree | Detail | |
0.002 | Malignant neoplasm of vulva | NA | BeFree | Detail | |
0.007 | Hematologic Neoplasms | Detection p53 gene deletion in hematological malignancies using fluorescence in ... | BeFree | 26035937 | Detail |
0.002 | Roseolovirus Infections | NA | GAD | Detail | |
0.081 | Craniofacial Abnormalities | NA | BeFree,CTD_mouse | Detail | |
<0.001 | Roberts-SC phocomelia syndrome | NA | BeFree | Detail | |
0.001 | dermatofibrosarcoma protuberans | NA | BeFree | Detail | |
<0.001 | nasal type extranodal NK/T-cell lymphoma | NA | BeFree | Detail | |
<0.001 | Laryngeal papillomatosis | NA | BeFree | Detail | |
0.004 | Nijmegen breakage syndrome | NA | BeFree,GAD | Detail | |
<0.001 | Non-alcoholic Fatty Liver Disease | NA | BeFree | Detail | |
<0.001 | Chronic Kidney Insufficiency | NA | BeFree | Detail | |
<0.001 | Hereditary benign telangiectasia (disorder) | NA | BeFree | Detail | |
<0.001 | Rudiger syndrome 1 | NA | BeFree | Detail | |
0.327 | Lung Neoplasms | We found that four of the variants (rs3829787, rs3841324, rs588765 and rs3743073... | BeFree | 23011884 | Detail |
0.124 | choroid plexus carcinoma | For children with TP53 mutant malignant gliomas, one year overall survival was 6... | BeFree,CLINVAR | 25315281 | Detail |
0.124 | choroid plexus carcinoma | A greater number of copies of mutated TP53 were significantly associated to incr... | BeFree,CLINVAR | 25336695 | Detail |
0.124 | choroid plexus carcinoma | We show that (i) in the choroid plexus carcinoma, the germline mutation was dete... | BeFree,CLINVAR | 25787918 | Detail |
0.124 | choroid plexus carcinoma | The TP53 mutation detection rate in children presenting with ACC or choroid plex... | BeFree,CLINVAR | 26014290 | Detail |
0.004 | Trisomy 12 | NA | BeFree | Detail | |
<0.001 | Trisomy 11 | NA | BeFree | Detail | |
<0.001 | Chromosome 9, trisomy | NA | BeFree | Detail | |
<0.001 | Chromosome 8, trisomy | NA | BeFree | Detail | |
<0.001 | Microinvasive carcinoma | NA | BeFree | Detail | |
0.002 | neuropathy | NA | GAD | Detail | |
<0.001 | Desmoplastic infantile astrocytoma | NA | BeFree | Detail | |
<0.001 | Acute monoblastic leukemia | NA | BeFree | Detail | |
<0.001 | Follicular neoplasm | NA | BeFree | Detail | |
<0.001 | Benign pheochromocytoma | NA | BeFree | Detail | |
<0.001 | Plasma cell tumor, malignant | NA | BeFree | Detail | |
0.001 | Leukemia, Prolymphocytic, B-Cell | NA | BeFree | Detail | |
0.011 | Secondary malignant neoplasm of liver | Patients with p53 mutations were older (p<.0001) and had higher numbers of liver... | BeFree | 25003695 | Detail |
0.011 | Secondary malignant neoplasm of liver | Assessing the TP53 marker type in patients treated with or without neoadjuvant c... | BeFree | 25773284 | Detail |
<0.001 | Malignant tumor of eye | NA | BeFree | Detail | |
0.003 | dementia | NA | BeFree,LHGDN | Detail | |
<0.001 | Overweight | NA | BeFree | Detail | |
<0.001 | Benign neurologic neoplasms | NA | BeFree | Detail | |
<0.001 | Chronic active hepatitis | NA | BeFree | Detail | |
0.012 | Recurrent tumor | NA | BeFree | Detail | |
<0.001 | Granulomatosis | NA | BeFree | Detail | |
<0.001 | Associated symptom | NA | BeFree | Detail | |
<0.001 | Neurodegenerative Disorders | We discuss the shared properties of cancer and neurodegenerative diseases and ho... | BeFree | 24775734 | Detail |
0.011 | Hepatitis B, Chronic | The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role... | BeFree,GAD | 24461059 | Detail |
0.006 | Hepatitis C, Chronic | FBP1 is barely detectable in normal differentiated cells; its overexpression in ... | BeFree,GAD | 25995247 | Detail |
<0.001 | Environmental Carcinogenesis | NA | BeFree | Detail | |
<0.001 | Atherosclerotic occlusive disease | NA | BeFree | Detail | |
<0.001 | Myxoid/Round Cell Liposarcoma | Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma. | BeFree | 25393000 | Detail |
<0.001 | Recurrent Carcinoma | NA | BeFree | Detail | |
0.019 | Thyroid carcinoma | NA | BeFree | Detail | |
<0.001 | Oropharynx (excludes nasopharynx) | NA | BeFree | Detail | |
0.080 | Carcinoma of lung | For instance, a greater absolute risk reduction of lung and upper aerodigestive ... | BeFree | 19442246 | Detail |
0.004 | Ewings sarcoma | Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-associa... | BeFree | 25223734 | Detail |
0.004 | Ewings sarcoma | A growing collection of retrospective studies have suggested that TP53 mutations... | BeFree | 25464386 | Detail |
0.004 | Ewings sarcoma | CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway re... | BeFree | 25501132 | Detail |
0.004 | Ewings sarcoma | RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their T... | BeFree | 25801700 | Detail |
0.004 | Oropharyngeal disorders | NA | BeFree | Detail | |
0.160 | Malignant neoplasm of lung | For instance, a greater absolute risk reduction of lung and upper aerodigestive ... | BeFree | 19442246 | Detail |
0.005 | Squamous cell carcinoma of skin | To determine the presence of HPV in genital skin squamous cell carcinomas and to... | BeFree | 25035383 | Detail |
0.005 | Squamous cell carcinoma of skin | However, the presence of p53 mutations in skin premalignant lesions suggests tha... | BeFree | 25639555 | Detail |
0.016 | Malignant glioma | Formation of γH2AX foci (a marker of DNA double-strand breaks), rates of foci cl... | BeFree | 24971978 | Detail |
0.016 | Malignant glioma | For children with TP53 mutant malignant gliomas, one year overall survival was 6... | BeFree | 25315281 | Detail |
0.003 | tongue carcinoma | TP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in es... | BeFree | 25436609 | Detail |
0.003 | tongue carcinoma | The increased expression of pS(21)GSK3α and pS(9)GSK3β not only correlated posit... | BeFree | 25645517 | Detail |
<0.001 | Tonsillar Carcinoma | NA | BeFree | Detail | |
<0.001 | Carcinoma of anal canal | NA | BeFree | Detail | |
<0.001 | primary sclerosing cholangitis | NA | BeFree | Detail | |
<0.001 | Carotid Atherosclerosis | NA | BeFree | Detail | |
0.001 | Squamous cell carcinoma of mouth | NA | BeFree | Detail | |
0.031 | Osteosarcoma of bone | Overexpression of RASSF5 markedly suppressed cell proliferation and invasion, an... | BeFree | 25109282 | Detail |
0.031 | Osteosarcoma of bone | Prognostic value of p53 alterations in human osteosarcoma: a meta analysis. | BeFree | 25400752 | Detail |
0.031 | Osteosarcoma of bone | p53-dependent activation of microRNA-34a in response to etoposide-induced DNA da... | BeFree | 25490093 | Detail |
0.031 | Osteosarcoma of bone | Inactivation of p53 and/or Rb pathways restrains osteoblasts from cell-cycle exi... | BeFree | 25853231 | Detail |
0.031 | Osteosarcoma of bone | Here, we established patient-derived iPSCs from a Li-Fraumeni syndrome (LFS) fam... | BeFree | 25860607 | Detail |
0.031 | Osteosarcoma of bone | Germline TP53 variants and susceptibility to osteosarcoma. | BeFree | 25896519 | Detail |
0.031 | Osteosarcoma of bone | To identify the genes driving osteosarcoma development and metastasis, we perfor... | BeFree | 25961939 | Detail |
<0.001 | Esophageal dysplasia | NA | BeFree | Detail | |
<0.001 | Biliary Intraepithelial Neoplasia | In the printing company cases, immunohistochemical expression of p53 was observe... | BeFree | 25197345 | Detail |
<0.001 | Costello syndrome (disorder) | The most common predisposition syndromes include germline TP53 mutations and con... | BeFree | 25893277 | Detail |
0.009 | Carcinoma of larynx | Together, results suggested that miR-30b could modulate p53 pathway and enhance ... | BeFree | 25356506 | Detail |
<0.001 | Chemical Carcinogenesis | NA | BeFree | Detail | |
0.012 | Leukemogenesis | NA | BeFree | Detail | |
<0.001 | monocytic leukemia | NA | BeFree | Detail | |
0.003 | Tumor Initiation | Using an autochthonous model of pancreatic cancer driven by oncogenic Kras and t... | BeFree | 24875860 | Detail |
<0.001 | chronic interstitial cystitis | NA | BeFree | Detail | |
<0.001 | Malignant Cystosarcoma Phyllodes | NA | BeFree | Detail | |
0.003 | CARCINOMA OF VULVA | NA | BeFree | Detail | |
<0.001 | Carcinoma testes | NA | BeFree | Detail | |
0.003 | Hashimoto Disease | NA | BeFree,GAD | Detail | |
0.124 | Hereditary Breast and Ovarian Cancer Syndrome | NA | BeFree,ORPHANET | Detail | |
<0.001 | Brain Stem Neoplasms | NA | BeFree | Detail | |
0.163 | Epithelial ovarian cancer | High-grade serous ovarian cancer (HG-SOC), a major histologic type of epithelial... | BeFree,CTD_human,GAD | 24879340 | Detail |
0.163 | Epithelial ovarian cancer | Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovari... | BeFree,CTD_human,GAD | 24880464 | Detail |
0.163 | Epithelial ovarian cancer | We demonstrated that in a unique population of HGSOC cancer cells with cancer st... | BeFree,CTD_human,GAD | 25263447 | Detail |
0.163 | Epithelial ovarian cancer | TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based stan... | BeFree,CTD_human,GAD | 25385265 | Detail |
0.163 | Epithelial ovarian cancer | High-grade serous ovarian cancer (HGSOC) is the most aggressive histological typ... | BeFree,CTD_human,GAD | 25460179 | Detail |
0.163 | Epithelial ovarian cancer | Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovari... | BeFree,CTD_human,GAD | 25592872 | Detail |
0.163 | Epithelial ovarian cancer | To test if TP53 hot spot mutations (HSMs) confer differential chemotherapy resis... | BeFree,CTD_human,GAD | 25958320 | Detail |
0.163 | Epithelial ovarian cancer | The study found a high expression of P53 (64%) and MIB1 (72%) and an expression ... | BeFree,CTD_human,GAD | 26204652 | Detail |
0.007 | invasive cancer | Using an autochthonous model of pancreatic cancer driven by oncogenic Kras and t... | BeFree | 24875860 | Detail |
0.002 | Progressive Neoplastic Disease | Combined MYC family amplifications and P53 pathway defects commonly emerged at r... | BeFree | 25533335 | Detail |
<0.001 | Refractory cancer | NA | BeFree | Detail | |
<0.001 | Stage III Colorectal Cancer | NA | BeFree | Detail | |
<0.001 | Stage IV Colorectal Cancer | NA | BeFree | Detail | |
0.001 | Complete hydatidiform mole | NA | BeFree | Detail | |
<0.001 | Terminal illness | NA | BeFree | Detail | |
<0.001 | myeloblastosis | NA | BeFree | Detail | |
0.080 | Carcinoma of lung | Ectopic expression of miR-506 inhibits NF-κB p65 expression, induces ROS accumul... | BeFree | 24469051 | Detail |
0.080 | Carcinoma of lung | Nickel accumulation in lung tissues is associated with increased risk of p53 mut... | BeFree | 24711049 | Detail |
0.080 | Carcinoma of lung | Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates act... | BeFree | 24915467 | Detail |
0.080 | Carcinoma of lung | TP53 mutations and lung cancer: not all mutations are created equal. | BeFree | 24916693 | Detail |
0.080 | Carcinoma of lung | Caveolin-1 regulates lung cancer stem-like cell induction and p53 inactivation i... | BeFree | 24939878 | Detail |
0.080 | Carcinoma of lung | AP-2α downregulation by cigarette smoke condensate is counteracted by p53 in hum... | BeFree | 25050743 | Detail |
0.080 | Carcinoma of lung | β-Elemene against human lung cancer via up-regulation of P53 protein expression ... | BeFree | 25204604 | Detail |
0.080 | Carcinoma of lung | We evaluated 23 single nucleotide polymorphisms (SNPs) in the five nicotinic rec... | BeFree | 25233467 | Detail |
0.080 | Carcinoma of lung | Evaluation of the mutagenicity of anti-B[a]P-diol epoxide with B[a]P-7,8-dione o... | BeFree | 25279998 | Detail |
0.080 | Carcinoma of lung | Loss of p53 function may result in upregulation of 14-3-3γ in lung cancers. | BeFree | 25384678 | Detail |
0.080 | Carcinoma of lung | In addition, we used lung cancer cell lines with different p53 gene background (... | BeFree | 25398693 | Detail |
0.080 | Carcinoma of lung | Finally, we provide an analysis of discerning epidemiological data obtained from... | BeFree | 25433984 | Detail |
0.080 | Carcinoma of lung | SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptos... | BeFree | 25435374 | Detail |
0.080 | Carcinoma of lung | Moreover, co-treatment of MML and p53 inhibitor would be more effective in human... | BeFree | 25490748 | Detail |
0.080 | Carcinoma of lung | Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-κB signa... | BeFree | 25499080 | Detail |
0.080 | Carcinoma of lung | Our finding supports that mir-660 acts as a tumor suppressor miRNA and we sugges... | BeFree | 25501825 | Detail |
0.080 | Carcinoma of lung | These results suggest that stroma-derived p53 plays a pivotal role in epithelial... | BeFree | 25512506 | Detail |
0.080 | Carcinoma of lung | Association of a p53 codon 72 gene polymorphism with environmental factors and r... | BeFree | 25605155 | Detail |
0.080 | Carcinoma of lung | We identified mutations in both tumors, including KEAP1 (commonly mutated in lun... | BeFree | 25850996 | Detail |
0.080 | Carcinoma of lung | Treatment of cells with curcumin induced both p53 and the related protein p73 in... | BeFree | 25910231 | Detail |
0.080 | Carcinoma of lung | TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population. | BeFree | 25921167 | Detail |
0.080 | Carcinoma of lung | Furthermore, using data generated by The Cancer Genome Atlas consortium, we demo... | BeFree | 26063617 | Detail |
0.080 | Carcinoma of lung | These results demonstrate that p53 is able to respond to exposure of arsenic or ... | BeFree | 26091798 | Detail |
0.080 | Carcinoma of lung | However, p53-targeted therapies have limited application in lung cancer, since p... | BeFree | 26093302 | Detail |
0.080 | Carcinoma of lung | This RNA aptamer (p53R175H-APT) has a significantly stronger affinity to p53R175... | BeFree | 26216949 | Detail |
0.003 | Ewings sarcoma-primitive neuroectodermal tumor (PNET) | NA | BeFree | Detail | |
0.004 | Malignant neoplasm of gastrointestinal tract | To conduct a phase I trial of a modified vaccinia Ankara (MVA) vaccine deliverin... | BeFree | 24987057 | Detail |
<0.001 | CNS metastases | NA | BeFree | Detail | |
0.028 | Secondary malignant neoplasm of lymph node | LINE-1 hypomethylation of ESCC was significantly associated with lymph node meta... | BeFree | 24898425 | Detail |
0.028 | Secondary malignant neoplasm of lymph node | Increased p53 expression significantly correlated with high pathological grade a... | BeFree | 25697482 | Detail |
0.028 | Secondary malignant neoplasm of lymph node | Our findings underscore the importance of measuring the HPV16 RNA (E6*I) and TP5... | BeFree | 26095926 | Detail |
<0.001 | heavy drinking | NA | BeFree | Detail | |
<0.001 | Parathyroid Gland Adenocarcinoma | NA | BeFree | Detail | |
0.005 | Pregnancy loss | NA | GAD | Detail | |
0.064 | Carcinoma of bladder | Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. | BeFree | 25349305 | Detail |
0.064 | Carcinoma of bladder | Overall results suggest that phosphorylated HER3, ERK1/2 and p53 may be used as ... | BeFree | 25482142 | Detail |
0.064 | Carcinoma of bladder | Our findings confirm the alternative role of FGFR3 and TP53 mutations in the dev... | BeFree | 25537218 | Detail |
0.064 | Carcinoma of bladder | Recent developments in the field of molecular mutational pathway analyses based ... | BeFree | 25654736 | Detail |
0.064 | Carcinoma of bladder | Association of TP53 gene polymorphisms with susceptibility of bladder cancer in ... | BeFree | 25801242 | Detail |
<0.001 | Malignant Female Reproductive System Neoplasm | NA | BeFree | Detail | |
0.010 | skin carcinoma | NA | BeFree | Detail | |
0.037 | Central neuroblastoma | CFM-1, -4, and -5 inhibited NB cell growth, in vitro, independent of their p53 a... | BeFree | 25033461 | Detail |
0.037 | Central neuroblastoma | Simultaneous Adrenocortical Carcinoma and Neuroblastoma in an Infant With a Nove... | BeFree | 25374282 | Detail |
0.037 | Central neuroblastoma | Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. | BeFree | 25502557 | Detail |
0.037 | Central neuroblastoma | Treatment of wild-type TP53 neuroblastoma cell lines with both GSK2830371 and ei... | BeFree | 25658463 | Detail |
0.037 | Central neuroblastoma | Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma. | BeFree | 25762502 | Detail |
<0.001 | Ependymoblastoma | NA | BeFree | Detail | |
<0.001 | Dissecting aneurysm of the thoracic aorta | NA | BeFree | Detail | |
<0.001 | Carcinoma of glottis | NA | BeFree | Detail | |
<0.001 | bile duct carcinoma | NA | BeFree | Detail | |
0.002 | 5q-syndrome | L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q-... | BeFree | 25098371 | Detail |
0.001 | germ cell cancer | NA | BeFree | Detail | |
0.003 | Malignant neoplasm of kidney | NA | BeFree | Detail | |
0.001 | Poorly differentiated carcinoma | NA | BeFree | Detail | |
<0.001 | cervical cancer squamous cell | NA | BeFree | Detail | |
<0.001 | cyst benign | NA | BeFree | Detail | |
<0.001 | Febrile Neutropenia | NA | BeFree | Detail | |
<0.001 | Cancer of Parotid | NA | BeFree | Detail | |
<0.001 | early pregnancy | NA | BeFree | Detail | |
<0.001 | Sarcoma, metastatic | NA | BeFree | Detail | |
0.019 | Arnold-Chiari Malformation, Type I | NA | BeFree | Detail | |
0.001 | biliary tract cancer | NA | BeFree | Detail | |
0.002 | Brain Tumor, Primary | NA | BeFree | Detail | |
<0.001 | Primary malignant neoplasm of brain | Alternative lengthening of telomeres is enriched in, and impacts survival of TP5... | BeFree | 25315281 | Detail |
<0.001 | Cockayne Syndrome, Type II | NA | BeFree | Detail | |
<0.001 | Cancer, Embryonal | NA | BeFree | Detail | |
<0.001 | Radiation-Induced Cancer | NA | BeFree | Detail | |
0.009 | Well Differentiated Oligodendroglioma | Those tumors that lacked LOH 1p19q showed a high frequency of IDH1 mutations and... | BeFree | 24444336 | Detail |
0.009 | Well Differentiated Oligodendroglioma | The mean of Olig2 LI of gliomas with 1p/19q loss ± IDH1/2 mutation, the majority... | BeFree | 25085214 | Detail |
0.009 | Well Differentiated Oligodendroglioma | We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX... | BeFree | 25257301 | Detail |
0.009 | Well Differentiated Oligodendroglioma | The TP53 and HIST1H3A genes were the hub nodes in the PPI network of DEGs from G... | BeFree | 25351872 | Detail |
0.009 | Well Differentiated Oligodendroglioma | Thus, we analyzed the expression of p-CREB in a series of astrocytomas and oligo... | BeFree | 25476123 | Detail |
<0.001 | Malignant neoplasm tonsil | NA | BeFree | Detail | |
<0.001 | Genitourinary Cancer | NA | BeFree | Detail | |
0.001 | Cancer of Urinary Tract | NA | BeFree | Detail | |
0.001 | adult acute lymphocytic leukemia | NA | BeFree | Detail | |
<0.001 | Basal Cell Cancer | NA | BeFree | Detail | |
0.006 | Malignant Squamous Cell Neoplasm | NA | BeFree | Detail | |
<0.001 | peripheral nerve sheath neoplasm | NA | BeFree | Detail | |
0.008 | malignant peripheral nerve sheath tumor | Human gene copy number alteration data, microarray expression data, and TMA anal... | BeFree | 24832557 | Detail |
0.008 | malignant peripheral nerve sheath tumor | The pathological diagnosis of malignant schwannoma indicated that the p53 expres... | BeFree | 26146864 | Detail |
<0.001 | Lafora disease | We show that loss of laforin or malin results in the increased level and activit... | BeFree | 26102034 | Detail |
0.003 | brain infarction | NA | BeFree,GAD | Detail | |
<0.001 | spinocerebellar ataxia type 7 | In this study we identified a previously unreported mechanism, involving disrupt... | BeFree | 25647692 | Detail |
<0.001 | Spinal Cord Ischemia | NA | BeFree | Detail | |
0.002 | intracranial thrombosis | NA | GAD | Detail | |
<0.001 | Chromosome 1, monosomy 1p | There was no deletion 1p19q in 118 cases, codeletion 1p19q (57 cases), single de... | BeFree | 25261925 | Detail |
<0.001 | Chromosome 10, monosomy 10q | NA | BeFree | Detail | |
<0.001 | Smith-Magenis syndrome | NA | BeFree | Detail | |
<0.001 | Aicardi-Goutieres syndrome 1 | NA | BeFree | Detail | |
0.002 | malignant pleural mesothelioma | MDM2 is an important prognostic and predictive factor for platin-pemetrexed ther... | BeFree | 25668009 | Detail |
<0.001 | Stage I Endometrial Carcinoma | NA | BeFree | Detail | |
0.001 | Spots on skin | Polysomy 7, polysomy 18, p16 deletion, and p53 deletion were significantly more ... | BeFree | 25517961 | Detail |
0.001 | Spots on skin | More than 50% of human cancers contain a mutation or deletion of the p53 gene, a... | BeFree | 26216949 | Detail |
<0.001 | Uterine carcinoma | NA | BeFree | Detail | |
0.002 | Adenomatous polyp of colon | NA | BeFree | Detail | |
<0.001 | premalignant lesion | Using an autochthonous model of pancreatic cancer driven by oncogenic Kras and t... | BeFree | 24875860 | Detail |
<0.001 | premalignant lesion | However, the presence of p53 mutations in skin premalignant lesions suggests tha... | BeFree | 25639555 | Detail |
0.006 | Helicobacter pylori infection | Helicobacter pylori infection and a P53 codon 72 single nucleotide polymorphism:... | BeFree | 25422197 | Detail |
0.001 | Smoker's lung | NA | BeFree | Detail | |
<0.001 | In situ cancer | NA | BeFree | Detail | |
0.002 | Carcinoma in situ of uterine cervix | NA | BeFree | Detail | |
0.002 | Adenoviral infections | NA | BeFree | Detail | |
0.001 | penis carcinoma | NA | BeFree | Detail | |
0.004 | Invasive breast carcinoma | NA | BeFree | Detail | |
<0.001 | Hepatobiliary neoplasm | NA | BeFree | Detail | |
<0.001 | Pancreatic carcinoma resectable | NA | BeFree | Detail | |
<0.001 | Recurrent Chronic Lymphoid Leukemia | NA | BeFree | Detail | |
0.001 | Rhabdoid Tumor of the Kidney | Previous genetic studies on colorectal carcinomas (CRC) have identified multiple... | BeFree | 25617745 | Detail |
0.001 | Rhabdoid Tumor of the Kidney | Taken together, our results provide evidence for RTK/RAS pathway activation and ... | BeFree | 25795707 | Detail |
0.001 | Rhabdoid Tumor of the Kidney | Mutations in genes relating to genome integrity (TP53, BRCA2), chromatin remodel... | BeFree | 26364057 | Detail |
<0.001 | Adenocarcinoma of lung, stage I | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma of lung, stage IV | NA | BeFree | Detail | |
<0.001 | Recurrent Lung Carcinoma Cell Type Unspecified | NA | BeFree | Detail | |
<0.001 | Undifferentiated (Embryonal) Sarcoma | NA | BeFree | Detail | |
<0.001 | Small Lymphocytic Lymphoma | NA | BeFree | Detail | |
<0.001 | Acute GVH disease | NA | BeFree | Detail | |
0.122 | breast adenocarcinoma | The tumor suppressor TP53 is mutated in approximately 30% of breast adenocarcino... | BeFree,CLINVAR | 25351767 | Detail |
<0.001 | Posterior subcapsular cataract | NA | BeFree | Detail | |
0.002 | Carcinogenicity | NA | BeFree | Detail | |
<0.001 | Medullary carcinoma of breast | NA | BeFree | Detail | |
<0.001 | Malignant melanoma, metastatic | NA | BeFree | Detail | |
<0.001 | Hepatoma recurrent | NA | BeFree | Detail | |
<0.001 | Precursor B-lymphoblastic lymphoma/leukemia | NA | BeFree | Detail | |
0.001 | Borderline ovarian tumour | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma of the prostate metastatic | NA | BeFree | Detail | |
<0.001 | dedifferentiated chondrosarcoma | NA | BeFree | Detail | |
<0.001 | Ewing's tumour localised | Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in... | BeFree | 25464386 | Detail |
0.002 | Hyperkeratosis | NA | BeFree | Detail | |
<0.001 | latent infection | NA | BeFree | Detail | |
0.002 | Advanced cancer | Characteristics and survival of patients with advanced cancer and p53 mutations. | BeFree | 25003695 | Detail |
0.002 | Advanced cancer | Cancer genome studies document recurrent genetic inactivation of RB1 and TP53, a... | BeFree | 25486431 | Detail |
0.007 | Intraepithelial Neoplasia | NA | BeFree | Detail | |
0.080 | Cardiomyopathies | NA | CTD_mouse | Detail | |
<0.001 | Stromal Neoplasm | NA | BeFree | Detail | |
0.007 | Carcinoma, Pancreatic Ductal | NA | BeFree,GAD,LHGDN | Detail | |
0.003 | Optic Atrophy, Hereditary, Leber | NA | LHGDN | Detail | |
0.078 | ovarian neoplasm | In this study, we compared the immunoreactivities of Bcl-2, Bax and p53 proteins... | BeFree,GAD,LHGDN | 25108507 | Detail |
0.078 | ovarian neoplasm | Since mutations in TP53 occur in nearly all ovarian tumors, the objective of thi... | BeFree,GAD,LHGDN | 25385265 | Detail |
0.002 | Genomic Instability | NA | GAD | Detail | |
0.002 | Haematotoxicity | NA | GAD | Detail | |
0.009 | Microsatellite Instability | NA | GAD | Detail | |
0.002 | autoimmune thyroiditis | NA | GAD | Detail | |
0.002 | cancer recurrence | NA | BeFree | Detail | |
<0.001 | cancer regression | NA | BeFree | Detail | |
<0.001 | Renal ischaemia | NA | BeFree | Detail | |
0.002 | Metastatic Prostate Carcinoma | NA | BeFree | Detail | |
<0.001 | blastoma | NA | BeFree | Detail | |
0.009 | precancerous lesions | NA | BeFree | Detail | |
<0.001 | cholecystolithiasis | NA | BeFree | Detail | |
<0.001 | Ischemic stroke | NA | BeFree | Detail | |
<0.001 | Intestinal adenocarcinoma | In sporadic intestinal adenocarcinomas with strong p53 immunostaining (mutated T... | BeFree | 24770931 | Detail |
0.002 | Ovarian adenocarcinoma | Strong immunoreactivity of Bcl-2 and mild immunoreactivities of Bax and p53 were... | BeFree | 25108507 | Detail |
0.002 | Colorectal cancer metastatic | Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 muta... | BeFree | 25337237 | Detail |
0.002 | Colorectal cancer metastatic | Prognostic value of microsatellite instability and p53 expression in metastatic ... | BeFree | 25474278 | Detail |
<0.001 | coronary restenosis | NA | BeFree | Detail | |
<0.001 | Cancer of lymph node | NA | BeFree | Detail | |
<0.001 | Porokeratosis of Mibelli | NA | BeFree | Detail | |
<0.001 | Hurthle Cell Tumor | NA | BeFree | Detail | |
<0.001 | Tauopathies | NA | BeFree | Detail | |
0.088 | Papillomavirus Infections | NA | GAD,LHGDN | Detail | |
<0.001 | Arthritis, Experimental | NA | BeFree | Detail | |
<0.001 | Chromosome 17 trisomy | NA | BeFree | Detail | |
<0.001 | Bronchial dysplasia | NA | BeFree | Detail | |
0.008 | Invasive Ductal Breast Carcinoma | Somatic mutations or deletions of TP53 and PTEN in ductal carcinoma in situ lesi... | BeFree,GAD | 24531711 | Detail |
0.008 | Invasive Ductal Breast Carcinoma | Assessment of changes in the BRCA2 and P53 genes in breast invasive ductal carci... | BeFree,GAD | 25027116 | Detail |
0.008 | Invasive Ductal Breast Carcinoma | Mitochondrial DNA alterations correlate with the pathological status and the imm... | BeFree,GAD | 25845386 | Detail |
0.002 | Gestational Trophoblastic Neoplasms | NA | BeFree | Detail | |
<0.001 | Plasma cell dyscrasia | NA | BeFree | Detail | |
0.123 | Malignant neoplasm of ovary | Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer. | BeFree,GAD | 24586866 | Detail |
0.123 | Malignant neoplasm of ovary | In this study, the nuclear expression levels of γ-H2AX and p53 using immunohisto... | BeFree,GAD | 24681744 | Detail |
0.123 | Malignant neoplasm of ovary | This study shows that triptolide selectively kills ovarian cancer cells with dif... | BeFree,GAD | 24880464 | Detail |
0.123 | Malignant neoplasm of ovary | Association between a single nucleotide polymorphism in the TP53 region and risk... | BeFree,GAD | 25060098 | Detail |
0.123 | Malignant neoplasm of ovary | The observed upregulation of pro-apoptotic genes and apoptosis in cancer cells w... | BeFree,GAD | 25096914 | Detail |
0.123 | Malignant neoplasm of ovary | Genomic classification of serous ovarian cancer with adjacent borderline differe... | BeFree,GAD | 25316818 | Detail |
0.123 | Malignant neoplasm of ovary | Furthermore, tumors containing oncomorphic TP53 mutations displayed unique prote... | BeFree,GAD | 25385265 | Detail |
0.123 | Malignant neoplasm of ovary | TP53 remains as the most frequently altered gene in high grade serous ovarian ca... | BeFree,GAD | 25404506 | Detail |
0.123 | Malignant neoplasm of ovary | Detection of somatic TP53 mutations in tampons of patients with high-grade serou... | BeFree,GAD | 25437714 | Detail |
0.123 | Malignant neoplasm of ovary | Molecular characterization of an intact p53 pathway subtype in high-grade serous... | BeFree,GAD | 25460179 | Detail |
0.123 | Malignant neoplasm of ovary | Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors ... | BeFree,GAD | 25473022 | Detail |
0.123 | Malignant neoplasm of ovary | Co-immunoprecipitation and western blotting showed significantly lower levels of... | BeFree,GAD | 25510663 | Detail |
0.123 | Malignant neoplasm of ovary | The present study aimed to clarify the role of PLK1, P53 and P21WAF1 in the prog... | BeFree,GAD | 25592872 | Detail |
0.123 | Malignant neoplasm of ovary | CR389, a benzoimidazolyl pyridinone analog, induces cell cycle arrest and apopto... | BeFree,GAD | 25639717 | Detail |
0.123 | Malignant neoplasm of ovary | Overall, FBN1, acts at the downstream of Aur A and BRCA2, promotes ovarian cance... | BeFree,GAD | 25749384 | Detail |
0.123 | Malignant neoplasm of ovary | First, we observed the upregulation protein level of p53 target genes in cisplat... | BeFree,GAD | 25820823 | Detail |
0.123 | Malignant neoplasm of ovary | There is a link between miR-7 expression and TP53 status and tumour grade in ser... | BeFree,GAD | 25862909 | Detail |
0.123 | Malignant neoplasm of ovary | TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule s... | BeFree,GAD | 25958320 | Detail |
0.123 | Malignant neoplasm of ovary | We propose that this unique ability of APR-246/MQ to bind to cysteines in both m... | BeFree,GAD | 26086967 | Detail |
<0.001 | X-linked dyskeratosis congenita | NA | BeFree | Detail | |
0.004 | endometrial adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Stage I Gallbladder Carcinoma | NA | BeFree | Detail | |
<0.001 | Skin toxicity | NA | BeFree | Detail | |
<0.001 | Recurrent respiratory papillomatosis | NA | BeFree | Detail | |
<0.001 | High-Grade Prostatic Intraepithelial Neoplasia | NA | BeFree | Detail | |
0.172 | Squamous cell carcinoma of the head and neck | Mechanistic studies reveal that attenuated HNSCC cell growth in response to DEK ... | BeFree,CTD_human,GAD | 24608431 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head a... | BeFree,CTD_human,GAD | 24927258 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. | BeFree,CTD_human,GAD | 25108461 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | We previously showed that CK2 is often aberrantly expressed and activated in hea... | BeFree,CTD_human,GAD | 25379016 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | Emphasis is placed on the therapeutic implications of genes frequently altered i... | BeFree,CTD_human,GAD | 25440877 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | These results indicate that HNSCC cells expressing high-risk p53 mutations are s... | BeFree,CTD_human,GAD | 25504633 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | TP53 is the most frequently altered gene in head and neck squamous cell carcinom... | BeFree,CTD_human,GAD | 25634208 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | The EAp53 approach clearly identifies a subset of high-risk TP53 mutations assoc... | BeFree,CTD_human,GAD | 25691460 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and in... | BeFree,CTD_human,GAD | 25735654 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | Human papillomavirus (HPV), p16 expression, and TP53 mutations are known prognos... | BeFree,CTD_human,GAD | 25871546 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations an... | BeFree,CTD_human,GAD | 25886176 | Detail |
0.172 | Squamous cell carcinoma of the head and neck | Our findings underscore the importance of measuring the HPV16 RNA (E6*I) and TP5... | BeFree,CTD_human,GAD | 26095926 | Detail |
0.012 | Ductal Carcinoma | NA | BeFree,LHGDN | Detail | |
0.002 | Chromosomal Instability | NA | GAD | Detail | |
<0.001 | Mammary Carcinoma, Human | NA | BeFree | Detail | |
<0.001 | Myxoid cyst | NA | BeFree | Detail | |
0.003 | Anemia, Diamond-Blackfan | Haploinsufficiency of ribosomal proteins (RPs) and upregulation of the tumour su... | BeFree | 25098371 | Detail |
0.003 | Anemia, Diamond-Blackfan | In this study, we establish the DBA model in zebrafish using an RPS24 morpholino... | BeFree | 25189322 | Detail |
0.400 | sarcoma | Genetic depletion of Snail1 in MSCs that are deficient in p53 tumor suppressor d... | BeFree,CLINVAR,CTD_human,CTD_mouse,GAD,LHGDN | 24947186 | Detail |
0.400 | sarcoma | Most childhood sarcomas are TP53 wild type at diagnosis, although approximately ... | BeFree,CLINVAR,CTD_human,CTD_mouse,GAD,LHGDN | 25832557 | Detail |
<0.001 | Persistent infection | NA | BeFree | Detail | |
<0.001 | large cell neuroendocrine carcinoma | NA | BeFree | Detail | |
<0.001 | basaloid squamous cell carcinoma | NA | BeFree | Detail | |
<0.001 | Trichilemmocarcinoma | NA | BeFree | Detail | |
<0.001 | Papillary transitional cell neoplasm of low malignant potential | NA | BeFree | Detail | |
<0.001 | Traditional Serrated Adenoma | NA | BeFree | Detail | |
<0.001 | Atypical carcinoid tumor | NA | BeFree | Detail | |
<0.001 | sarcomatoid renal cell carcinoma | NA | BeFree | Detail | |
<0.001 | atypical follicular adenoma | NA | BeFree | Detail | |
<0.001 | eccrine porocarcinoma | NA | BeFree | Detail | |
<0.001 | Atypical medullary carcinoma | NA | BeFree | Detail | |
<0.001 | Thymic epithelial tumor | TP53 was the most frequently mutated gene in TETs (n = 13; 17%), especially in T... | BeFree | 25482724 | Detail |
<0.001 | Solitary fibrous tumor | Two dedifferentiated SFT cases harbored both TP53 and TERT promoter mutations. | BeFree | 25582503 | Detail |
0.001 | pleuropulmonary blastoma | Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of ... | BeFree | 24909177 | Detail |
<0.001 | Intratubular malignant germ cells | NA | BeFree | Detail | |
<0.001 | Nonseminomatous germ cell tumor | NA | BeFree | Detail | |
<0.001 | Intracortical osteosarcoma | NA | BeFree | Detail | |
<0.001 | clear cell chondrosarcoma | NA | BeFree | Detail | |
<0.001 | gliofibroma | NA | BeFree | Detail | |
<0.001 | Mild cognitive disorder | NA | BeFree | Detail | |
<0.001 | Tumor stage mycosis fungoides | NA | BeFree | Detail | |
<0.001 | Avellino corneal dystrophy | These accumulations were associated with decreased levels of Cyclin A1, B1, and ... | BeFree | 25450621 | Detail |
<0.001 | Transitional cell dysplasia | NA | BeFree | Detail | |
<0.001 | Cutaneous lymphoma | NA | BeFree | Detail | |
<0.001 | Vascular degeneration | NA | BeFree | Detail | |
<0.001 | Inflammatory disorder | NA | BeFree | Detail | |
<0.001 | Chronic inflammatory disorder | NA | BeFree | Detail | |
0.004 | Primary Effusion Lymphoma | NA | BeFree,LHGDN | Detail | |
0.004 | Precursor B-cell lymphoblastic leukemia | We identified a unique case of adult B-ALL with masked low hypodiploidy (mLH) by... | BeFree | 26185311 | Detail |
<0.001 | Therapy-related acute myeloid leukemia and myelodysplastic syndrome | Our findings support the recent notion that heterozygous TP53 mutation may be a ... | BeFree | 25952993 | Detail |
<0.001 | Aggressive natural killer-cell leukemia | NA | BeFree | Detail | |
<0.001 | Chronic myeloproliferative disorder | We performed genomic profiling of post-MPN AML samples; these studies demonstrat... | BeFree | 25516983 | Detail |
0.002 | Myelodysplastic Syndrome with Isolated del(5q) | L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q-... | BeFree | 25098371 | Detail |
0.001 | Therapy-related myelodysplastic syndrome | The early acquisition of TP53 mutations in the founding HSPC clone probably cont... | BeFree | 25487151 | Detail |
0.001 | Therapy-related myelodysplastic syndrome | TP53 mutations are highly and similarly prevalent in t-MDS and t-AML but mutatio... | BeFree | 25573287 | Detail |
0.001 | Therapy-related myelodysplastic syndrome | TP53 mutation characteristics in therapy-related myelodysplastic syndromes and a... | BeFree | 25952993 | Detail |
0.001 | Single tumor | NA | BeFree | Detail | |
<0.001 | Perivascular Epithelioid Cell Neoplasms | Coexistent TP53 mutations were identified in 63% of the TSC2-mutated PEComas. | BeFree | 25651471 | Detail |
0.001 | Pancreatic intraepithelial neoplasia | We explored lncRNAs profilings in PanIN cell line (SH-PAN) isolated from Pdx-1-C... | BeFree | 24469904 | Detail |
0.001 | Pancreatic intraepithelial neoplasia | The authors show that combined loss of autophagy and p53 dramatically promotes p... | BeFree | 24939064 | Detail |
<0.001 | Salivary duct carcinoma | NA | BeFree | Detail | |
<0.001 | Post-transplant lymphoproliferative disorder, polymorphic | NA | BeFree | Detail | |
0.012 | Adenoma of large intestine | NA | BeFree,GAD | Detail | |
<0.001 | chronic lymphocytic leukemia/small lymphocytic lymphoma | NA | BeFree | Detail | |
<0.001 | Low Grade Squamous Intraepithelial Neoplasia | NA | BeFree | Detail | |
<0.001 | ACTH-secreting pituitary adenoma | NA | BeFree | Detail | |
<0.001 | Ameloblastic carcinoma | This is the first case of ameloblastic carcinoma with a mutation of the p53 gene... | BeFree | 24906942 | Detail |
<0.001 | Astrocytoma, low grade | NA | BeFree | Detail | |
<0.001 | Liver regeneration disorder | NA | BeFree | Detail | |
<0.001 | Non-toxic nodular goiter | NA | BeFree | Detail | |
<0.001 | M5b Acute differentiated monocytic leukemia | NA | BeFree | Detail | |
<0.001 | Congenital melanocytic nevus | NA | BeFree | Detail | |
0.007 | Adenocarcinoma of large intestine | TP53 status regulates ACSL5-induced expression of mitochondrial mortalin in ente... | BeFree | 24770931 | Detail |
0.001 | Squamous cell carcinoma of pharynx | NA | BeFree | Detail | |
<0.001 | Blood in stool | NA | BeFree | Detail | |
<0.001 | Thymoma, type C | Massively parallel sequencing identifies recurrent mutations in TP53 in thymic c... | BeFree | 25299233 | Detail |
<0.001 | Thymoma, type C | TP53 was the most frequently mutated gene in TETs (n = 13; 17%), especially in T... | BeFree | 25482724 | Detail |
<0.001 | pancreatic endocrine carcinoma | NA | BeFree | Detail | |
<0.001 | Hormone refractory prostate cancer | NA | BeFree | Detail | |
<0.001 | Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome | NA | BeFree | Detail | |
<0.001 | Adenoid cystic breast carcinoma | NA | BeFree | Detail | |
<0.001 | Adult Diffuse Astrocytoma | NA | BeFree | Detail | |
<0.001 | Aggressive Non-Hodgkin Lymphoma | Chromosome instability induced by Mps1 and p53 mutation generates aggressive lym... | BeFree | 25197064 | Detail |
0.002 | Atypical Ductal Breast Hyperplasia | NA | BeFree | Detail | |
<0.001 | Breast Fibrocystic Change, Proliferative Type | NA | BeFree | Detail | |
<0.001 | Cerebellar Glioblastoma | NA | BeFree | Detail | |
<0.001 | Classical Hodgkin's Lymphoma | NA | BeFree | Detail | |
<0.001 | Colon Carcinoma Metastatic in the Liver | NA | BeFree | Detail | |
<0.001 | Endometrial intraepithelial neoplasia | NA | BeFree | Detail | |
<0.001 | endometrial squamous cell carcinoma | NA | BeFree | Detail | |
<0.001 | Esophageal Basaloid Carcinoma | NA | BeFree | Detail | |
0.008 | Hereditary Malignant Neoplasm | Five new TP53 mutations were identified in six pedigrees from hereditary cancer ... | BeFree | 25925845 | Detail |
0.001 | gastric cardia adenocarcinoma | NA | BeFree | Detail | |
<0.001 | gastric cardia carcinoma | NA | BeFree | Detail | |
<0.001 | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | NA | BeFree | Detail | |
<0.001 | Hepatitis B Virus-Related Hepatocellular Carcinoma | NA | BeFree | Detail | |
<0.001 | Hepatitis C Virus-Related Hepatocellular Carcinoma | NA | BeFree | Detail | |
0.005 | Hereditary Nonpolyposis Colorectal Cancer | NA | BeFree,GAD | Detail | |
<0.001 | Hereditary Ovarian Carcinoma | NA | BeFree | Detail | |
<0.001 | High Grade Cervical Intraepithelial Neoplasia | NA | BeFree | Detail | |
<0.001 | High Grade Intraepithelial Neoplasia | NA | BeFree | Detail | |
<0.001 | Human Papillomavirus-Related Esophageal Squamous Cell Carcinoma | NA | BeFree | Detail | |
<0.001 | Intermediate Grade Ductal Breast Carcinoma In Situ | NA | BeFree | Detail | |
<0.001 | Intramuscular Myxoma | NA | BeFree | Detail | |
0.008 | Invasive Carcinoma | NA | BeFree | Detail | |
<0.001 | Infiltrating Bladder Urothelial Carcinoma | NA | BeFree | Detail | |
<0.001 | Inverted Urothelial Papilloma | NA | BeFree | Detail | |
<0.001 | Low Grade Ductal Breast Carcinoma In Situ | NA | BeFree | Detail | |
0.001 | Malignant Mixed Mesodermal (Mullerian) Tumor | NA | BeFree | Detail | |
<0.001 | maxillary sinus squamous cell carcinoma | NA | BeFree | Detail | |
<0.001 | Metaplastic breast carcinoma | NA | BeFree | Detail | |
<0.001 | Multifocal osteosarcoma | NA | BeFree | Detail | |
<0.001 | nasal cavity adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Nodular Neoplasm | NA | BeFree | Detail | |
<0.001 | Non-Hereditary Clear Cell Renal Cell Carcinoma | Genetic inactivation of the TP53 gene in ccRCC is rare, suggesting that an alter... | BeFree | 24469044 | Detail |
<0.001 | Occupational Malignant Neoplasm | NA | BeFree | Detail | |
<0.001 | Oligodendroglial Neoplasm | Mutations in TP53 (20/28, 71%) and ATRX (15/28, 54%) were enriched in astrocytic... | BeFree | 25257301 | Detail |
<0.001 | Ovarian Mucinous Tumor | NA | BeFree | Detail | |
<0.001 | Ovarian Serous Adenocarcinoma | NA | BeFree | Detail | |
0.009 | pancreatic ductal adenocarcinoma | On the other hand, in well-differentiated PDACs measuring ≤ 1 cm, the incidence ... | BeFree | 24297432 | Detail |
0.009 | pancreatic ductal adenocarcinoma | We explored lncRNAs profilings in PanIN cell line (SH-PAN) isolated from Pdx-1-C... | BeFree | 24469904 | Detail |
0.009 | pancreatic ductal adenocarcinoma | Mutations in p53 and RAS potently cooperate in oncogenic transformation, and cor... | BeFree | 24794439 | Detail |
0.009 | pancreatic ductal adenocarcinoma | Based on these findings, we propose the existence of a hierarchical signaling ne... | BeFree | 25586376 | Detail |
0.009 | pancreatic ductal adenocarcinoma | Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal aden... | BeFree | 25734904 | Detail |
0.009 | pancreatic ductal adenocarcinoma | Using genetically engineered mouse models, we show that heterozygous mutation of... | BeFree | 26004068 | Detail |
<0.001 | Carcinoma ex pleomorphic adenoma of parotid gland | NA | BeFree | Detail | |
<0.001 | Conventional Chondrosarcoma | NA | BeFree | Detail | |
0.004 | Primary Carcinoma | NA | BeFree | Detail | |
<0.001 | Recurrent Head and Neck Carcinoma | NA | BeFree | Detail | |
<0.001 | Breast Sclerosing Adenosis | NA | BeFree | Detail | |
<0.001 | Vulvar Intraepithelial Neoplasia, Differentiated Type | NA | BeFree | Detail | |
<0.001 | Squamous Lung Dysplasia | NA | BeFree | Detail | |
<0.001 | Stage IIIB Cervical Carcinoma | NA | BeFree | Detail | |
0.004 | Carcinoma of urinary bladder, superficial | NA | BeFree | Detail | |
<0.001 | supratentorial primitive neuroectodermal tumor | NA | BeFree | Detail | |
<0.001 | Testicular Germ Cell Tumor | A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicu... | BeFree | 25231260 | Detail |
<0.001 | Treatment related acute myeloid leukaemia | NA | BeFree | Detail | |
<0.001 | Thymic Lymphoma | However, this interpretation has been challenged by a number of recent in vivo s... | BeFree | 25618545 | Detail |
<0.001 | thyroid lymphoma | NA | BeFree | Detail | |
<0.001 | Uterine Angiosarcoma | NA | BeFree | Detail | |
<0.001 | Endometrial Endometrioid Adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Well Differentiated Pancreatic Endocrine Tumor | We detected a total of 1,764 nonsynonymous single nucleotide variants at a rate ... | BeFree | 26087898 | Detail |
0.002 | differentiated thyroid gland carcinoma | NA | BeFree | Detail | |
<0.001 | Hypopharyngeal Carcinoma | NA | BeFree | Detail | |
0.007 | Epithelioma | NA | BeFree | Detail | |
<0.001 | mature teratoma | NA | BeFree | Detail | |
<0.001 | Granulosa cell tumor of the ovary | NA | BeFree | Detail | |
<0.001 | Liposarcoma, well differentiated | NA | BeFree | Detail | |
<0.001 | carcinoma of the renal pelvis and ureter | NA | BeFree | Detail | |
<0.001 | Prostate cancer stage C | NA | BeFree | Detail | |
<0.001 | Pleural Mesothelioma | NA | BeFree | Detail | |
<0.001 | Undifferentiated leukemia | Genetic deletion of the telomerase subunit Terc in a retroviral mouse AML model ... | BeFree | 25479751 | Detail |
0.003 | renal carcinoma | NA | BeFree | Detail | |
<0.001 | Metastatic Carcinoma | NA | BeFree | Detail | |
<0.001 | Conn Syndrome | NA | BeFree | Detail | |
0.002 | Primary Lesion | NA | BeFree | Detail | |
<0.001 | Vascular lesions | NA | BeFree | Detail | |
<0.001 | Infiltrating duct carcinoma | NA | BeFree | Detail | |
<0.001 | anal squamous cell carcinoma | NA | BeFree | Detail | |
<0.001 | Disseminated carcinoma | NA | BeFree | Detail | |
<0.001 | Chronic esophagitis | NA | BeFree | Detail | |
<0.001 | Posterior capsule opacification | NA | BeFree | Detail | |
0.004 | Cardiomyopathy, Familial Idiopathic | NA | BeFree | Detail | |
0.002 | Benign melanocytic nevus | NA | BeFree | Detail | |
0.353 | Mammary Neoplasms | We have predicted three deleterious coding non-synonymous single nucleotide poly... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25105660 | Detail |
0.353 | Mammary Neoplasms | Here, we investigated the role of p53 in breast tumor cell invasion, migration, ... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25257729 | Detail |
0.353 | Mammary Neoplasms | Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Typ... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25351767 | Detail |
0.353 | Mammary Neoplasms | A positive correlation was found between expression of mutant gene p53 protein a... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25403404 | Detail |
0.353 | Mammary Neoplasms | Through the described mechanism, elevated CXCR5 expression may contribute to abn... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 25786345 | Detail |
0.353 | Mammary Neoplasms | These results have translational relevance, demonstrating that TP53 mutant breas... | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | 26063617 | Detail |
<0.001 | histiocytoma | NA | BeFree | Detail | |
<0.001 | choroid plexus carcinoma, childhood | NA | BeFree | Detail | |
<0.001 | Epididymal Adenocarcinoma | Molecular genetic analysis revealed an uncommon mutation; 249: AGG →ATG in the T... | BeFree | 25839701 | Detail |
<0.001 | Angiogenic Switch | NA | BeFree | Detail | |
<0.001 | Desmoplastic | NA | BeFree | Detail | |
<0.001 | differentiating neuroblastoma | NA | BeFree | Detail | |
<0.001 | grade I meningioma | NA | BeFree | Detail | |
0.017 | Hepatocarcinogenesis | The aims of present study are to investigate the p53 mutation spectrum in HBV- a... | BeFree | 24461059 | Detail |
0.017 | Hepatocarcinogenesis | It is concluded that both of the non-structural genes, NS3 and NS5A, of HCV play... | BeFree | 24845365 | Detail |
0.017 | Hepatocarcinogenesis | Hepatitis B Virus Core Promoter A1762T/G1764A (TA)/T1753A/T1768A Mutations Contr... | BeFree | 25567052 | Detail |
<0.001 | Hereditary Melanoma | NA | BeFree | Detail | |
0.002 | Mammary Tumorigenesis | Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promot... | BeFree | 25573952 | Detail |
0.002 | Primary Glioblastoma | NA | BeFree | Detail | |
<0.001 | Primary Peritoneal Carcinoma | NA | BeFree | Detail | |
0.003 | Cancer Cell Growth | A cell-permeable TAT-p53LZ2 effectively inhibits the cancer cell growth in wild-... | BeFree | 24804811 | Detail |
0.003 | Cancer Cell Growth | However, whether INZ could suppress cancer cell growth independently of p53 acti... | BeFree | 25692307 | Detail |
0.002 | Serous Endometrial Intraepithelial Carcinoma | NA | BeFree | Detail | |
<0.001 | Ganglioneuroblastoma, Nodular | NA | BeFree | Detail | |
0.003 | Malignant Conversion | NA | BeFree | Detail | |
<0.001 | ovarian clear cell adenocarcinoma | NA | BeFree | Detail | |
0.002 | Secondary Glioblastoma | NA | BeFree | Detail | |
0.007 | Skin Carcinogenesis | NA | BeFree | Detail | |
0.004 | Tumor Angiogenesis | NA | BeFree | Detail | |
<0.001 | Tumor Immunity | NA | BeFree | Detail | |
<0.001 | Tumor Promotion | NA | BeFree | Detail | |
<0.001 | Type II Endometrial Adenocarcinoma | These results indicate that absence of CDH1 and TP53 in endometrial cells initia... | BeFree | 24998851 | Detail |
<0.001 | Undifferentiated Neuroblastoma | NA | BeFree | Detail | |
<0.001 | Urothelial Neoplasm | Our results support the idea that mutations of the FGFR3 and TP53 genes are rare... | BeFree | 24743222 | Detail |
<0.001 | Urothelial Neoplasm | In the Balkan and Taiwan, the relationship between exposure to aristolochic acid... | BeFree | 25184754 | Detail |
0.004 | Xenograft Model | Re-engineered p53 activates apoptosis in vivo and causes primary tumor regressio... | BeFree | 25077773 | Detail |
0.004 | Xenograft Model | In this study, Hep3B cells which are p53 null were used to investigate the anti-... | BeFree | 25371988 | Detail |
0.002 | Ductal Breast Carcinoma | NA | BeFree | Detail | |
<0.001 | Morphea | NA | BeFree | Detail | |
0.003 | Rectal Tumors | Elevated p57Kip2 induces G1/S phase cell cycle arrest but inhibits cell death in... | BeFree | 25195859 | Detail |
<0.001 | smoldering myeloma | NA | BeFree | Detail | |
<0.001 | Pneumocystis jiroveci pneumonia | Cytoplasmic/nuclear beta-catenin and P53 accumulation was observed in the majori... | BeFree | 24717047 | Detail |
0.003 | Rash and Dermatitis Adverse Event Associated with Chemoradiation | NA | BeFree | Detail | |
<0.001 | Non-Malignant Ascites Adverse Event | NA | BeFree | Detail | |
<0.001 | Chronic Kidney Diseases | NA | BeFree | Detail | |
0.002 | Adenocarcinoma, Endometrioid | ECCCs had SCA-like features with rare expression of estrogen receptor/progestero... | BeFree | 25473756 | Detail |
0.014 | Glioblastoma multiforme | However, p53 therapy for GBM is limited by lack of efficient delivery across the... | BeFree,GAD | 24811110 | Detail |
0.014 | Glioblastoma multiforme | A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide... | BeFree,GAD | 25240597 | Detail |
0.014 | Glioblastoma multiforme | Detection of p53 mutations in proliferating vascular cells in glioblastoma multi... | BeFree,GAD | 25415071 | Detail |
0.014 | Glioblastoma multiforme | It has been found that the reintroduction of WWOX induced p53-mutant GBM cells t... | BeFree,GAD | 25432984 | Detail |
0.002 | Cirrhosis | NA | BeFree | Detail | |
0.001 | androgen independent prostate cancer | NA | BeFree | Detail | |
<0.001 | Grade I Astrocytoma | NA | BeFree | Detail | |
0.002 | Benign Prostatic Hyperplasia | NA | BeFree | Detail | |
<0.001 | Enchondroma | NA | BeFree | Detail | |
<0.001 | Carcinoma of Endocrine Gland | NA | BeFree | Detail | |
<0.001 | Uterine Corpus Carcinosarcoma | NA | BeFree | Detail | |
<0.001 | Skin Pigmentation Disorder | NA | BeFree | Detail | |
<0.001 | Anaplastic Rhabdomyosarcoma | NA | BeFree | Detail | |
<0.001 | Colorectal Mucinous Adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Colorectal Signet Ring Cell Carcinoma | NA | BeFree | Detail | |
<0.001 | Colorectal Small Cell Neuroendocrine Carcinoma | NA | BeFree | Detail | |
<0.001 | hereditary diffuse gastric cancer | NA | BeFree | Detail | |
<0.001 | Keratocystic Odontogenic Tumor | The C/C genotype of P53 gene codon 72 increases the risk of developing sporadic ... | BeFree | 25773801 | Detail |
<0.001 | Low grade appendiceal mucinous neoplasm | Nuclear positive reaction of TP53 was lower in LAMN compared with those of other... | BeFree | 25155618 | Detail |
0.008 | Non-Neoplastic Disorder | In the printing company cases, immunohistochemical expression of p53 was observe... | BeFree | 25197345 | Detail |
0.008 | Non-Neoplastic Disorder | Non-neoplastic (n=28), noninvasive (n=28), and invasive (n=11) spots were then a... | BeFree | 25517961 | Detail |
<0.001 | Pyothorax-Associated Lymphoma | NA | BeFree | Detail | |
<0.001 | paranasal sinus and nasal cavity cancer | NA | BeFree | Detail | |
<0.001 | Unilateral Breast Carcinoma | NA | BeFree | Detail | |
0.003 | Meningioma, benign, no ICD-O subtype | NA | BeFree | Detail | |
0.003 | Idiopathic Pulmonary Fibrosis | NA | BeFree | Detail | |
0.002 | Chromosome 5, trisomy 5q | L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q-... | BeFree | 25098371 | Detail |
<0.001 | UV-sensitive syndrome | NA | BeFree | Detail | |
<0.001 | IMMUNE SUPPRESSION | NA | BeFree | Detail | |
<0.001 | MULTICYSTIC RENAL DYSPLASIA, BILATERAL | NA | BeFree | Detail | |
<0.001 | VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding) | NA | BeFree | Detail | |
<0.001 | Familial ependymoma | NA | BeFree | Detail | |
<0.001 | lateral meningocele syndrome | NA | BeFree | Detail | |
0.080 | DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT | NA | MGD | Detail | |
<0.001 | Prostate Cancer, Hereditary, 7 | NA | BeFree | Detail | |
<0.001 | BREAST CANCER 3 | NA | BeFree | Detail | |
0.120 | Adrenocortical carcinoma, hereditary | NA | CTD_human | Detail | |
0.120 | Adrenocortical carcinoma, pediatric | Prevalence and functional consequence of TP53 mutations in pediatric adrenocorti... | BeFree,CLINVAR | 25584008 | Detail |
0.120 | Leukemia, Megakaryoblastic, of Down Syndrome | NA | CTD_human | Detail | |
<0.001 | Breast Cancer, Familial Male | Mutational profiling of familial male breast cancers reveals similarities with l... | BeFree | 25490678 | Detail |
<0.001 | campomelic dysplasia | NA | BeFree | Detail | |
<0.001 | Amyotrophic Lateral Sclerosis, Sporadic | NA | BeFree | Detail | |
<0.001 | POROKERATOSIS, DISSEMINATED SUPERFICIAL ACTINIC, 1 | NA | BeFree | Detail | |
<0.001 | PHOTOPAROXYSMAL RESPONSE 1 | NA | BeFree | Detail | |
<0.001 | B-CELL MALIGNANCY, LOW-GRADE | NA | BeFree | Detail | |
0.002 | Inverted Squamous Cell Papilloma | No variation of p16, p21, PLUNC (palate, lung, and nasal epithelium clone protei... | BeFree | 25013792 | Detail |
0.003 | Malformations of Cortical Development | NA | LHGDN | Detail | |
<0.001 | Trichothiodystrophy Syndromes | NA | BeFree | Detail | |
0.007 | coronary artery disease | NA | BeFree,GAD | Detail | |
0.006 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Nucleostemin knocking-down causes cell cycle arrest and apoptosis in human T-cel... | BeFree,GAD | 24628257 | Detail |
0.139 | Precursor Cell Lymphoblastic Leukemia Lymphoma | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
<0.001 | low grade glioma | Mapping p53 mutations in low-grade glioma: a voxel-based neuroimaging analysis. | BeFree | 25104286 | Detail |
<0.001 | Leukemia, B-Cell | NA | BeFree | Detail | |
0.006 | Urothelial Carcinoma | We also found significant inverse correlation between FGFR3 mutations and TP53 a... | BeFree | 25537218 | Detail |
0.006 | Urothelial Carcinoma | Taken together, our results provide evidence for RTK/RAS pathway activation and ... | BeFree | 25795707 | Detail |
<0.001 | eyelids (symptom) | UV-independent p53 mutations in sebaceous carcinoma of the eyelid. | BeFree | 24777261 | Detail |
<0.001 | benign mastocytoma | NA | BeFree | Detail | |
<0.001 | Childhood myelodysplastic syndrome | NA | BeFree | Detail | |
<0.001 | Triple-negative breast carcinoma | NA | BeFree | Detail | |
0.003 | Oropharyngeal Carcinoma | Among these biomarkers, p53 is the strongest prognostic marker in OPC and p53 in... | BeFree | 25380690 | Detail |
0.003 | Oropharyngeal Carcinoma | The biology of HPV-positive oropharyngeal cancer is distinct; it includes p53 de... | BeFree | 26563006 | Detail |
<0.001 | T-cell prolymphocytic leukemia | NA | BeFree | Detail | |
<0.001 | Benign multiple sclerosis | NA | BeFree | Detail | |
0.120 | Acute kidney injury | NA | CTD_human | Detail | |
0.126 | Li-fraumeni-like syndrome | Targeted, massively parallel DNA sequencing and molecular inversion probe microa... | BeFree,CLINVAR | 25588929 | Detail |
0.126 | Li-fraumeni-like syndrome | She presented with a clinical diagnosis of Li-Fraumeni-like syndrome (LFL), show... | BeFree,CLINVAR | 25935441 | Detail |
0.126 | Li-fraumeni-like syndrome | A significant percentage (5-10%) of pediatric cancers are associated with heredi... | BeFree,CLINVAR | 26248253 | Detail |
<0.001 | Hypodiploid B Acute Lymphoblastic Leukemia | NA | BeFree | Detail | |
<0.001 | Dedifferentiated Solitary Fibrous Tumor | NA | BeFree | Detail | |
<0.001 | Hepatitis B and hepatitis C | NA | BeFree | Detail | |
<0.001 | Alcoholic Steatohepatitis | NA | BeFree | Detail | |
<0.001 | Sessile Serrated Adenoma/Polyp | NA | BeFree | Detail | |
<0.001 | Lentigo maligna melanoma | NA | BeFree | Detail | |
0.006 | Promyelocytic leukemia | NA | BeFree,GAD | Detail | |
0.002 | XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C | NA | BeFree | Detail | |
<0.001 | Treatment related leukaemia | NA | BeFree | Detail | |
<0.001 | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | NA | BeFree | Detail | |
0.006 | Chronic ulcerative colitis | NA | BeFree,GAD | Detail | |
<0.001 | Cavernous Hemangioma of Brain | NA | BeFree | Detail | |
0.120 | Pancreatic carcinoma, familial | NA | BeFree,ORPHANET | Detail | |
<0.001 | Desmoplastic cerebral astrocytoma of infancy | NA | BeFree | Detail | |
0.002 | Gestational trophoblastic disease | NA | BeFree | Detail | |
0.120 | Chromosome 17 deletion | NA | CTD_human | Detail | |
0.261 | Nasopharyngeal carcinoma | In addition, it stimulated p53 promoter activity and downregulated the protein e... | BeFree,CLINVAR,CTD_human,GAD | 25231528 | Detail |
0.261 | Nasopharyngeal carcinoma | Collectively, these results suggest that LOC401317 is directly regulated by p53 ... | BeFree,CLINVAR,CTD_human,GAD | 25422887 | Detail |
0.261 | Nasopharyngeal carcinoma | The results suggested that the Arg399Gln polymorphism of XRCC1 gene, the 1G/2G p... | BeFree,CLINVAR,CTD_human,GAD | 25481674 | Detail |
0.261 | Nasopharyngeal carcinoma | Association between p53 codon 72 polymorphisms and clinical outcome of nasophary... | BeFree,CLINVAR,CTD_human,GAD | 25526208 | Detail |
<0.001 | Obesity, Visceral | NA | BeFree | Detail | |
0.002 | Prostatic Hyperplasia | NA | GAD | Detail | |
<0.001 | myeloid neoplasm | Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulati... | BeFree | 24681953 | Detail |
<0.001 | aggressive cancer | Malignant melanoma is a highly aggressive cancer that retains functional p53 and... | BeFree | 25071017 | Detail |
<0.001 | childhood liver cancer | NA | BeFree | Detail | |
<0.001 | Refractory anemia, without ringed sideroblasts, without excess blasts | NA | BeFree | Detail | |
<0.001 | Bisphosphonate-associated osteonecrosis | NA | BeFree | Detail | |
<0.001 | Multicentric Breast Carcinoma | NA | BeFree | Detail | |
<0.001 | Early-Stage Breast Carcinoma | NA | BeFree | Detail | |
<0.001 | Esophageal Spindle Cell Carcinoma | NA | BeFree | Detail | |
<0.001 | Gastric Carcinoma with Lymphoid Stroma | NA | BeFree | Detail | |
<0.001 | Stage III Colorectal Cancer AJCC v7 | NA | BeFree | Detail | |
<0.001 | Stage IV Colorectal Cancer AJCC v7 | NA | BeFree | Detail | |
0.001 | Stage III Colon Cancer AJCC v7 | NA | BeFree | Detail | |
<0.001 | Stage III Breast Cancer AJCC v7 | NA | BeFree | Detail | |
<0.001 | GASTRIC CANCER, INTESTINAL | NA | BeFree | Detail | |
0.002 | Hypotension Adverse Event | NA | GAD | Detail | |
<0.001 | Chondrosarcoma of bone | NA | BeFree | Detail | |
<0.001 | Nonalcoholic Steatohepatitis | NA | BeFree | Detail | |
0.005 | Solar Erythema | NA | GAD | Detail | |
<0.001 | Condylomatous carcinoma | Diffuse p16 expression was associated with younger age at presentation (P<0.0001... | BeFree | 26171917 | Detail |
<0.001 | Ischemic Cerebrovascular Accident | NA | BeFree | Detail | |
<0.001 | Ulcerative Colitis-Associated Colorectal Adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Biliary System Disorder | NA | BeFree | Detail | |
0.002 | Hydatidiform mole, recurrent, 1 | NA | BeFree | Detail | |
0.004 | FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder) | Forty-two deleterious germline mutations were identified in 21 genes of 34 patie... | BeFree | 25927356 | Detail |
<0.001 | Micropapillary carcinoma | NA | BeFree | Detail | |
<0.001 | Neuroepithelioma, Peripheral | NA | BeFree | Detail | |
<0.001 | Lipomatosis, Multiple | NA | BeFree | Detail | |
<0.001 | Juvenile arthritis | NA | BeFree | Detail | |
0.002 | granulomatosis with polyangiitis | NA | GAD | Detail | |
<0.001 | Male Germ Cell Tumor | NA | BeFree | Detail | |
<0.001 | Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | NA | BeFree | Detail | |
0.002 | Progressive cGVHD | Combined MYC family amplifications and P53 pathway defects commonly emerged at r... | BeFree | 25533335 | Detail |
0.008 | Triple Negative Breast Neoplasms | The N+&C+ group was associated with larger tumor size, higher grade, negativity ... | BeFree | 24292333 | Detail |
0.008 | Triple Negative Breast Neoplasms | SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated ... | BeFree | 24531711 | Detail |
0.008 | Triple Negative Breast Neoplasms | Thymoquinone, a bioactive component of black caraway seeds, causes G1 phase cell... | BeFree | 24579801 | Detail |
0.008 | Triple Negative Breast Neoplasms | Only lymph node status was marginally significantly associated with poor prognos... | BeFree | 24945253 | Detail |
0.008 | Triple Negative Breast Neoplasms | Here, we used the high prevalence of TP53 mutations in triple negative breast ca... | BeFree | 25307450 | Detail |
0.008 | Triple Negative Breast Neoplasms | Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negat... | BeFree | 25330770 | Detail |
0.008 | Triple Negative Breast Neoplasms | In the present study, we used recombinant human p53 adenovirus (Ad-p53) and EGFR... | BeFree | 25501339 | Detail |
0.008 | Triple Negative Breast Neoplasms | Primary mouse mammary epithelial cells (mMEC) with defined genetic features were... | BeFree | 25602521 | Detail |
0.008 | Triple Negative Breast Neoplasms | Results indicated that TNBC patients with a p53-positive tumor had a shorter rel... | BeFree | 25698149 | Detail |
0.008 | Triple Negative Breast Neoplasms | Gain-of-function mutations in TP53 are a frequent occurrence in TNBC and have be... | BeFree | 25788226 | Detail |
0.008 | Triple Negative Breast Neoplasms | Another highly important mutation can occur in TP53 resulting in a triple negati... | BeFree | 25824734 | Detail |
0.008 | Triple Negative Breast Neoplasms | Further, our data suggest that loss of the p53 tumor suppressor cooperates with ... | BeFree | 25870263 | Detail |
0.008 | Triple Negative Breast Neoplasms | The expression of p53 was higher in luminal B, HER2-enriched, and triple-negativ... | BeFree | 25966200 | Detail |
<0.001 | Intracranial glioma | NA | BeFree | Detail | |
<0.001 | Melanocytic nevus of skin | NA | BeFree | Detail | |
<0.001 | Mammary adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Noninvasive carcinoma ex pleomorphic adenoma | NA | BeFree | Detail | |
0.049 | Infection | NA | LHGDN | Detail | |
<0.001 | Fibromyxosarcoma | NA | BeFree | Detail | |
0.001 | Lymphoma, Diffuse | NA | BeFree | Detail | |
<0.001 | Pneumonitis | NA | BeFree | Detail | |
0.080 | Thymus Neoplasms | NA | CTD_mouse | Detail | |
<0.001 | RETINOSCHISIS 1, X-LINKED, JUVENILE | NA | BeFree | Detail | |
0.003 | intellectual disability | NA | BeFree,LHGDN | Detail | |
<0.001 | juvenile rheumatoid arthritis | NA | BeFree | Detail | |
0.120 | Leukemia, acute lymphoblastic, susceptibility to, 3 | NA | ORPHANET | Detail | |
0.014 | Experimental Organism Basal Cell Carcinoma | Frequency and features of TP53 mutation in 30 Chinese patients with sporadic bas... | BeFree | 25196205 | Detail |
<0.001 | Radiation Damage | NA | BeFree | Detail | |
<0.001 | Mesenchymal Glioblastoma | NA | BeFree | Detail | |
0.003 | High grade serous carcinoma | Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs wi... | BeFree | 25038792 | Detail |
0.003 | High grade serous carcinoma | High-grade serous carcinomas (HGSC) are TP53-mutated and are thought to be rarel... | BeFree | 25316818 | Detail |
0.003 | High grade serous carcinoma | TP53 mutations are the single most commonly identified mutations in aggressive s... | BeFree | 25473022 | Detail |
0.003 | High grade serous carcinoma | Knockdown of p53 in immortalized FTE cells and in four HGSC-derived cell lines e... | BeFree | 26206555 | Detail |
0.003 | High grade serous carcinoma | Ovulation is the strongest risk factor for ovarian high-grade serous carcinoma (... | BeFree | 26363031 | Detail |
<0.001 | Abdominal Neoplasms | NA | BeFree | Detail | |
0.001 | Congenital Abnormality | Moreover, the p53 protein is able to interact with both wild type Nkx2.5 and its... | BeFree | 25677450 | Detail |
0.002 | Spontaneous abortion | NA | GAD | Detail | |
0.007 | Abortion, Habitual | NA | GAD | Detail | |
0.006 | acquired immunodeficiency syndrome | NA | BeFree,LHGDN | Detail | |
<0.001 | acromegaly | An analysis of granulation patterns, MIB-1 proliferation indices and p53 express... | BeFree | 25238988 | Detail |
0.511 | adenocarcinoma | Overexpression of p53 was detected only in high-grade dysplasia and invasive ade... | BeFree,CLINVAR,CTD_human,CTD_mouse,GAD,LHGDN | 24603588 | Detail |
0.511 | adenocarcinoma | The authors show that combined loss of autophagy and p53 dramatically promotes p... | BeFree,CLINVAR,CTD_human,CTD_mouse,GAD,LHGDN | 24939064 | Detail |
0.511 | adenocarcinoma | False-negative controls consisted in microdissecting fresh-frozen tumor tissues ... | BeFree,CLINVAR,CTD_human,CTD_mouse,GAD,LHGDN | 25184754 | Detail |
0.511 | adenocarcinoma | Formalin Fixed Paraffin Embedded tissue were studied for miRNA expression, KRAS,... | BeFree,CLINVAR,CTD_human,CTD_mouse,GAD,LHGDN | 25496852 | Detail |
<0.001 | adenofibroma | NA | BeFree | Detail | |
0.179 | adenoma | These methylation epigenotypes, with specific genomic aberrations, are mostly co... | BeFree,CTD_human,GAD,LHGDN | 24962701 | Detail |
0.179 | adenoma | Chk2, phosphorylated Chk2 (pChk2), and TP53 were immunostained in 4 cases of ade... | BeFree,CTD_human,GAD,LHGDN | 25155618 | Detail |
0.179 | adenoma | Formalin Fixed Paraffin Embedded tissue were studied for miRNA expression, KRAS,... | BeFree,CTD_human,GAD,LHGDN | 25496852 | Detail |
<0.001 | adenosarcoma | NA | BeFree | Detail | |
0.001 | Adenovirus Infections | NA | BeFree | Detail | |
<0.001 | Adrenal Gland Diseases | NA | BeFree | Detail | |
0.123 | Adrenal Gland Neoplasms | NA | BeFree,CTD_human | Detail | |
<0.001 | Primary myelofibrosis | NA | BeFree | Detail | |
<0.001 | agranulocytosis | NA | BeFree | Detail | |
0.003 | AIDS Dementia Complex | NA | LHGDN | Detail | |
0.006 | AIDS related complex | NA | BeFree,LHGDN | Detail | |
<0.001 | Albinism | NA | BeFree | Detail | |
0.002 | Alcoholic Intoxication, Chronic | NA | GAD | Detail | |
0.018 | Alzheimer's disease | NA | BeFree,GAD,LHGDN | Detail | |
0.005 | ameloblastoma | Ameloblastic carcinoma developing in preexisting ameloblastoma with a mutation o... | BeFree,GAD | 24906942 | Detail |
0.122 | amyotrophic lateral sclerosis | We found that hTERT expression level was significantly lower in ALS patients and... | BeFree,CTD_human | 25142509 | Detail |
0.010 | Anaplasia | TP53 mutational status is a potential marker for risk stratification in Wilms tu... | BeFree | 25313908 | Detail |
0.010 | Anaplasia | TP53 mutations, which result in its overexpression, in combination with TERT pro... | BeFree | 25582503 | Detail |
0.010 | Anaplasia | Mechanistically, active mTORC1 is required to prevent a likely upregulation of t... | BeFree | 25853231 | Detail |
0.002 | anemia | Haploinsufficiency of ribosomal proteins (RPs) and upregulation of the tumour su... | BeFree | 25098371 | Detail |
0.004 | aplastic anemia | NA | BeFree,LHGDN | Detail | |
<0.001 | Anemia, Macrocytic | NA | BeFree | Detail | |
0.001 | Refractory anemias | NA | BeFree | Detail | |
<0.001 | Refractory anaemia with excess blasts | NA | BeFree | Detail | |
0.002 | Aneuploidy | NA | GAD | Detail | |
<0.001 | Aneurysm | NA | BeFree | Detail | |
<0.001 | cutaneous fibrous histiocytoma | NA | BeFree | Detail | |
0.014 | Anoxia | NA | LHGDN | Detail | |
0.003 | Anus Neoplasms | NA | LHGDN | Detail | |
<0.001 | aortic valve insufficiency | NA | BeFree | Detail | |
0.004 | arteriosclerosis | NA | BeFree | Detail | |
0.003 | arthritis | NA | BeFree,GAD | Detail | |
0.003 | Arthritis, Psoriatic | NA | BeFree,GAD | Detail | |
0.031 | rheumatoid arthritis | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | asthma | NA | BeFree | Detail | |
0.260 | Astrocytoma | The majority of astrocytomas harbor concurrent TP53 and ATRX mutations, while mo... | BeFree,CLINVAR,CTD_mouse,GAD,LHGDN | 25143301 | Detail |
0.260 | Astrocytoma | We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX... | BeFree,CLINVAR,CTD_mouse,GAD,LHGDN | 25257301 | Detail |
0.260 | Astrocytoma | In addition, p-CREB expression correlated with higher Ki-67 labeling index (P = ... | BeFree,CLINVAR,CTD_mouse,GAD,LHGDN | 25476123 | Detail |
0.260 | Astrocytoma | These findings suggest that CDKN2A testing may provide further clinical aid in l... | BeFree,CLINVAR,CTD_mouse,GAD,LHGDN | 25853694 | Detail |
<0.001 | Ataxia | NA | BeFree | Detail | |
0.014 | ataxia telangiectasia | NA | BeFree | Detail | |
0.006 | atherosclerosis | NA | BeFree,GAD | Detail | |
<0.001 | Tooth Attrition | NA | BeFree | Detail | |
0.003 | autistic disorder | NA | BeFree,LHGDN | Detail | |
0.005 | Autoimmune Diseases | Role of p53 in systemic autoimmune diseases. | BeFree,GAD | 25597313 | Detail |
0.126 | Balkan nephropathy | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
0.009 | Barrett esophagus | Immunostaining for p53 is the only candidate biomarker deemed ready for prime ti... | BeFree,GAD,LHGDN | 24844657 | Detail |
0.009 | Barrett esophagus | Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves B... | BeFree,GAD,LHGDN | 25284618 | Detail |
0.009 | Barrett esophagus | Our analysis showed that oncogene amplification typically occurred as a late eve... | BeFree,GAD,LHGDN | 26192918 | Detail |
<0.001 | Basal Cell Nevus Syndrome | NA | BeFree | Detail | |
<0.001 | Beckwith-Wiedemann syndrome | NA | BeFree | Detail | |
0.001 | Benign Ovarian Neoplasm | NA | BeFree | Detail | |
0.002 | bipolar disorder | NA | GAD | Detail | |
0.121 | Malignant neoplasm of urinary bladder | Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. | BeFree,GAD | 25349305 | Detail |
0.121 | Malignant neoplasm of urinary bladder | Overall results suggest that phosphorylated HER3, ERK1/2 and p53 may be used as ... | BeFree,GAD | 25482142 | Detail |
0.121 | Malignant neoplasm of urinary bladder | Our findings confirm the alternative role of FGFR3 and TP53 mutations in the dev... | BeFree,GAD | 25537218 | Detail |
0.121 | Malignant neoplasm of urinary bladder | Recent developments in the field of molecular mutational pathway analyses based ... | BeFree,GAD | 25654736 | Detail |
0.121 | Malignant neoplasm of urinary bladder | Association of TP53 gene polymorphisms with susceptibility of bladder cancer in ... | BeFree,GAD | 25801242 | Detail |
0.264 | Bladder Neoplasm | NA | BeFree,CTD_human,CTD_mouse,GAD,LHGDN | Detail | |
0.010 | Blast Phase | NA | BeFree | Detail | |
0.002 | Bloom syndrome | NA | BeFree | Detail | |
0.080 | Bone Diseases, Developmental | NA | CTD_mouse | Detail | |
0.003 | Bone neoplasms | NA | BeFree,GAD | Detail | |
<0.001 | borderline personality disorder | NA | BeFree | Detail | |
0.166 | Brain Neoplasms | NA | BeFree,CTD_mouse,GAD,LHGDN | Detail | |
0.004 | Breast Diseases | NA | BeFree,LHGDN | Detail | |
<0.001 | Brenner Tumor | NA | BeFree | Detail | |
<0.001 | Bronchial Neoplasms | NA | BeFree | Detail | |
<0.001 | bronchopulmonary dysplasia | NA | BeFree | Detail | |
0.009 | Burkitt lymphoma | We identified TP53 mutations in MYC+/BCL2+ lymphomas at a frequency intermediate... | BeFree,LHGDN | 24679006 | Detail |
0.009 | Burkitt lymphoma | Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to sp... | BeFree,LHGDN | 24787013 | Detail |
0.009 | Burkitt lymphoma | INZ(c) treatment decreased c-Myc expression at both mRNA and protein level, and ... | BeFree,LHGDN | 25692307 | Detail |
0.004 | Carcinoid Tumor | Although the status of RB1 and P53 between carcinoids and HGNETs were apparently... | BeFree | 25143124 | Detail |
0.002 | female breast carcinoma | Mutational profiling of familial male breast cancers reveals similarities with l... | BeFree | 25490678 | Detail |
0.006 | Malignant neoplasm of larynx | NA | BeFree | Detail | |
0.005 | Adenocarcinoma of prostate | NA | BeFree | Detail | |
0.010 | Rectal Carcinoma | NA | BeFree | Detail | |
0.025 | Malignant neoplasm of skin | We propose that the mutation of a single p53 allele provides a pro-oncogenic fun... | BeFree | 25789975 | Detail |
0.008 | Malignant neoplasm of thyroid | NA | BeFree | Detail | |
0.255 | basal cell carcinoma | NA | CTD_human,GAD,GWASCAT,LHGDN | Detail | |
0.002 | Bronchioloalveolar Adenocarcinoma | NA | BeFree | Detail | |
0.002 | Bronchogenic Carcinoma | NA | BeFree | Detail | |
0.012 | Noninfiltrating Intraductal Carcinoma | Somatic mutations or deletions of TP53 and PTEN in ductal carcinoma in situ lesi... | BeFree,LHGDN | 24531711 | Detail |
0.005 | Merkel cell carcinoma | NA | BeFree,LHGDN | Detail | |
0.010 | mucinous adenocarcinoma | Chk2, phosphorylated Chk2 (pChk2), and TP53 were immunostained in 4 cases of ade... | BeFree,GAD,LHGDN | 25155618 | Detail |
0.010 | mucinous adenocarcinoma | TP53 mutation occurred more frequently in carcinomas than borderline tumors (56.... | BeFree,GAD,LHGDN | 25986173 | Detail |
0.219 | Non-small cell lung carcinoma | These results suggest that intratumor genetic heterogeneity may be an important ... | BeFree,CTD_human,GAD,LHGDN | 24038464 | Detail |
0.219 | Non-small cell lung carcinoma | Our study indicates that the detection of the KRAS and p53 mutations in BAL flui... | BeFree,CTD_human,GAD,LHGDN | 24519547 | Detail |
0.219 | Non-small cell lung carcinoma | Nondisruptive p53 mutations are associated with shorter survival in patients wit... | BeFree,CTD_human,GAD,LHGDN | 24696321 | Detail |
0.219 | Non-small cell lung carcinoma | Mutations in TP53 are common in non-small cell lung cancer. | BeFree,CTD_human,GAD,LHGDN | 24916693 | Detail |
0.219 | Non-small cell lung carcinoma | This is a revised case report of a 52 year old Caucasian female with Li-Fraumeni... | BeFree,CTD_human,GAD,LHGDN | 25047674 | Detail |
0.219 | Non-small cell lung carcinoma | Promotion of p53 expression and reactive oxidative stress production is involved... | BeFree,CTD_human,GAD,LHGDN | 25220870 | Detail |
0.219 | Non-small cell lung carcinoma | SETDB1 positively stimulated activity of the WNT-β-catenin pathway and diminishe... | BeFree,CTD_human,GAD,LHGDN | 25404354 | Detail |
0.219 | Non-small cell lung carcinoma | Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in pat... | BeFree,CTD_human,GAD,LHGDN | 25482940 | Detail |
0.219 | Non-small cell lung carcinoma | Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic l... | BeFree,CTD_human,GAD,LHGDN | 25519225 | Detail |
0.219 | Non-small cell lung carcinoma | In non-small cell lung cancer (NSCLC), both USP7 expression and p53 gene status ... | BeFree,CTD_human,GAD,LHGDN | 25519684 | Detail |
0.219 | Non-small cell lung carcinoma | USP22 promotes NSCLC tumorigenesis via MDMX up-regulation and subsequent p53 inh... | BeFree,CTD_human,GAD,LHGDN | 25547493 | Detail |
0.219 | Non-small cell lung carcinoma | Association of p53 and mdm2 in the development and progression of non-small cell... | BeFree,CTD_human,GAD,LHGDN | 25672611 | Detail |
0.219 | Non-small cell lung carcinoma | VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: ... | BeFree,CTD_human,GAD,LHGDN | 25672981 | Detail |
0.219 | Non-small cell lung carcinoma | Further experiments demonstrated that PANDAR expression was induced by p53, and ... | BeFree,CTD_human,GAD,LHGDN | 25719249 | Detail |
0.219 | Non-small cell lung carcinoma | We analyzed human non-small cell lung cancer (NSCLC) cell lines either wild type... | BeFree,CTD_human,GAD,LHGDN | 25796091 | Detail |
0.219 | Non-small cell lung carcinoma | Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Tr... | BeFree,CTD_human,GAD,LHGDN | 25911104 | Detail |
0.015 | Carcinoma, Papillary | NA | BeFree,GAD | Detail | |
0.150 | renal cell carcinoma | We observed a good overall stability between primary RCC and corresponding xenog... | BeFree,CTD_human,GAD,LHGDN | 25031714 | Detail |
0.150 | renal cell carcinoma | Here, we show that apoptosis-resistant RCC cells have a disconnect between activ... | BeFree,CTD_human,GAD,LHGDN | 25499216 | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
We also found significant inverse correlation between FGFR3 mutations and TP53 alterations in urothe... | DisGeNET | Detail |
Taken together, our results provide evidence for RTK/RAS pathway activation and p53 deficiency as a ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Specifically, 2 polymorphisms-an arginine-to-glutamine substitution at codon 399 (Q399R) in XRCC1 an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and color... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Association of a miR-502-binding site single nucleotide polymorphism in the 3'-untranslated region o... | DisGeNET | Detail |
Several factors may contribute to cervical cancer (CC) development, including genetic variants such ... | DisGeNET | Detail |
The p53 target gene WIG-1 (ZMAT3) is located in chromosomal region 3q26, that is frequently amplifie... | DisGeNET | Detail |
Berberine alters epigenetic modifications, disrupts microtubule network, and modulates HPV-18 E6-E7 ... | DisGeNET | Detail |
Thus, the polymorphism of p53 codon 72 in exon 4 does not seem to play a role in the development of ... | DisGeNET | Detail |
Overexpression of Nm23H1 but not H2 also inhibited tumorigenesis by human cervical cancer HeLa cells... | DisGeNET | Detail |
The mechanism and inhibitory effect of recombinant human P53 adenovirus injection combined with pacl... | DisGeNET | Detail |
Therefore, we hypothesized that the genetic variants in these three genes influence the predispositi... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We have previously reported that the common, functionally different variants Arg72Pro in p53 and Arg... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We have previously reported that the common, functionally different variants Arg72Pro in p53 and Arg... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Here we showed first that in human IBD colonic samples and in murine colitis the LMα1 and LMα5 chain... | DisGeNET | Detail |
Moreover, p53 is frequently mutated in the early stages of UC-associated cancer. | DisGeNET | Detail |
Patients with UC with presence of extraintestinal manifestations, complications, and positive staini... | DisGeNET | Detail |
TP53/p53 alterations and Aurora A expression in progressor and non-progressor colectomies from patie... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We have previously reported that the common, functionally different variants Arg72Pro in p53 and Arg... | DisGeNET | Detail |
Therefore, we hypothesized that the genetic variants in these three genes influence the predispositi... | DisGeNET | Detail |
Inactivation of TP53 pathway by TP53 mutations is observed in nearly half of colorectal tumors. | DisGeNET | Detail |
Multiplex Ligation-dependent Probe Amplification, TP53 sequencing, real-time polymerase chain reacti... | DisGeNET | Detail |
NA | DisGeNET | Detail |
We validated COLD-ddPCR on multiple mutations in TP53 and in EGFR using serial mutation dilutions an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and color... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The results suggested that the Arg399Gln polymorphism of XRCC1 gene, the 1G/2G polymorphism of MMP-1... | DisGeNET | Detail |
Downregulation of p53 promotes in vitro perineural invasive activity of human salivary adenoid cysti... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These results uncover a new mechanism of p53 inactivation providing an interesting novel molecular l... | DisGeNET | Detail |
NA | DisGeNET | Detail |
These results uncover a new mechanism of p53 inactivation providing an interesting novel molecular l... | DisGeNET | Detail |
Reduced LRP6 expression and increase in the interaction of GSK3β with p53 contribute to podocyte apo... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In recent years, miR-1246 has been identified as a transcriptional target of p53 in Down syndrome an... | DisGeNET | Detail |
Cell senescence was found to appear prematurely in DS cells as shown by SA-β-Gal assay and p21 asses... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Further, Cdh1(d/d)Trp53(d/d) tumors in 12-month-old mice were highly aggressive, and metastasized to... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
pERK expression may have an impact on OS in erlotinib-treated patients with advanced pancreatic canc... | DisGeNET | Detail |
Polysomy 7, polysomy 18, p16 deletion, and p53 deletion were significantly more frequent in invasive... | DisGeNET | Detail |
More than 50% of human cancers contain a mutation or deletion of the p53 gene, and p53R175 is one of... | DisGeNET | Detail |
Forty-two deleterious germline mutations were identified in 21 genes of 34 patients, including 18 (1... | DisGeNET | Detail |
NA | DisGeNET | Detail |
She presented with a clinical diagnosis of Li-Fraumeni-like syndrome (LFL), showing papillary thyroi... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
However, there is increased apoptosis in gastritis which may occur independent of H. pylori or p53 p... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Those tumors that lacked LOH 1p19q showed a high frequency of IDH1 mutations and loss of alpha thala... | DisGeNET | Detail |
Due to the structural homology between p53 and p73, a subtle balance among p53 family members and th... | DisGeNET | Detail |
A total of 157 diffuse gliomas (World Health Organization grades II-IV) were assessed by exon-by-exo... | DisGeNET | Detail |
Furthermore, AND did not induce apoptosis or activate ERK and p53 in primary cultured astrocyte cell... | DisGeNET | Detail |
Finally, p53 mutations correlated with alterations in ETC subunit composition and activity in primar... | DisGeNET | Detail |
In support of the functional interaction between CD24 and p53, in silico analyses reveal that TP53 m... | DisGeNET | Detail |
The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated ... | DisGeNET | Detail |
Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
ECCCs had SCA-like features with rare expression of estrogen receptor/progesterone receptor (18.8%/6... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
One such example is hepatitis virus-induced liver cancer whereby p53 is inactivated upon the binding... | DisGeNET | Detail |
One such example is hepatitis virus-induced liver cancer whereby p53 is inactivated upon the binding... | DisGeNET | Detail |
Chronic infection with hepatitis B virus (HBV) and exposure to aflatoxin B1 (AFB1) induces p53 mutat... | DisGeNET | Detail |
Finally, in HBV-related HCC, transcriptomic profiles were associated with specific gene mutations (H... | DisGeNET | Detail |
Hepatitis B Virus Core Promoter A1762T/G1764A (TA)/T1753A/T1768A Mutations Contribute to Hepatocarci... | DisGeNET | Detail |
Associations of mutations defined 3 groups of genes related to risk factors and centered on CTNNB1 (... | DisGeNET | Detail |
Moreover, the HBV-MLL4 integration occurred almost exclusively in CTNNB1 and TP53 wild-type patients... | DisGeNET | Detail |
Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcinoma and occult hepat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Results were correlated with immunoreactivity for USP7 (herpes virus-associated ubiquitin-specific p... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Uncommon non-oncogenic HPV genotypes, TP53 and MDM2 genes polymorphisms in HIV-infected women in Sou... | DisGeNET | Detail |
Host restriction and associated viral latency have been studied for several decades. p53 has been su... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We assessed cellular manganese handling to test for correlations with the ATM-p53 pathway, and we ob... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Genetic depletion of Snail1 in MSCs that are deficient in p53 tumor suppressor downregulates MSC mar... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Here we showed first that in human IBD colonic samples and in murine colitis the LMα1 and LMα5 chain... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Induction of p21 independently of p53 is also observed in transgenic mice overexpressing HCaRG durin... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
This study aimed to characterize the TP53 mutational spectrum in urothelial cancers consecutive to A... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Li-Fraumeni syndrome is caused by germline TP53 mutations and is clinically characterized by a predi... | DisGeNET | Detail |
Lastly, we validate the effectiveness of ALX as a chemotherapeutic agent in vivo by demonstrating it... | DisGeNET | Detail |
Expression of TP53 by CD34-positive cells was associated with shorter OS and leukaemia-free survival... | DisGeNET | Detail |
The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Me... | DisGeNET | Detail |
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing fir... | DisGeNET | Detail |
Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3... | DisGeNET | Detail |
Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and... | DisGeNET | Detail |
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukem... | DisGeNET | Detail |
From pioneering studies, we know that certain genetic events are found in the majority of chronic ly... | DisGeNET | Detail |
We first performed detailed genetic analyses in a CLL cohort (n=110) containing ATM, SF3B1 and TP53 ... | DisGeNET | Detail |
TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. | DisGeNET | Detail |
TP53 codon 72 single nucleotide polymorphism in chronic lymphocytic leukemia. | DisGeNET | Detail |
B-chronic lymphocytic leukemia (B-CLL) patients harboring p53 mutations are invariably refractory to... | DisGeNET | Detail |
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP5... | DisGeNET | Detail |
The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leu... | DisGeNET | Detail |
Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with c... | DisGeNET | Detail |
TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. | DisGeNET | Detail |
Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been considered as the treatment o... | DisGeNET | Detail |
Currently, these types of CLL are treated with approaches that do not target the p53 pathway, such a... | DisGeNET | Detail |
In addition to miRNAs, the long non-coding RNAs (lncRNAs) nuclear enriched abundant transcript 1 (NE... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Strong p53 expression in ≥ 1% of bone marrow progenitor cells, observed in 35% (30 of 85) of patient... | DisGeNET | Detail |
The regimen was active against patient-derived acute myelogenous leukemia (AML) cells harboring eith... | DisGeNET | Detail |
Results confirm high frequencies of RAS and other activated signaling mutations (10/12 AMLs) and ide... | DisGeNET | Detail |
MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study. | DisGeNET | Detail |
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. | DisGeNET | Detail |
Consistent with these data, expression of JAK2V617F combined with Tp53 loss led to fully penetrant A... | DisGeNET | Detail |
TP53 mutations are highly and similarly prevalent in t-MDS and t-AML but mutations in genes other th... | DisGeNET | Detail |
Other mechanisms linked to PU.1 downregulation in human AML include TP53 deletion, FLT3-ITD mutation... | DisGeNET | Detail |
Mutations in FLT3, DNMT3A, NRAS, NF1 and TP53 occur in persons of predominately European descent wit... | DisGeNET | Detail |
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemi... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblas... | DisGeNET | Detail |
NA | DisGeNET | Detail |
According to our results, the pharmacological inhibition of autophagy and p53 mutants are useful too... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
An inverse correlation existed between miR-1228 and p53 expression in hepatoma tissues compared with... | DisGeNET | Detail |
Tumorigenesis studies using an established liver tumor cell line confirmed a positive role of autoph... | DisGeNET | Detail |
In addition, α-PA up-regulated nuclear p53 and down-regulated cytoplasmic p53 expression in J5 cells... | DisGeNET | Detail |
Apoptosis of Bel-7402 human hepatoma cells induced by a ruthenium(II) complex coordinated by cordyce... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These findings suggest that HBEC apoptosis is increased in COPD, and that this involves p53 and casp... | DisGeNET | Detail |
A total of 189 lung cancer patients were enrolled to determine nickel levels in tumor-adjacent norma... | DisGeNET | Detail |
At the molecular level, reduced activation of ERK MAPK, but not Akt, was observed in lung tumours of... | DisGeNET | Detail |
In this work, we found that PNAS-4 expression in lung tumor tissues is significantly lower than that... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In addition, the protein levels of p53 and alternative reading frame (ARF) were decreased in lymphom... | DisGeNET | Detail |
Genomic studies of ALCL-11 showed the TP53 loss and the in vivo subclonal expansion of lymphoma cell... | DisGeNET | Detail |
p53 is a well-known tumor suppressor.However, the regulatory mechanism(s) for p53 expression in B ly... | DisGeNET | Detail |
Activation of p53 mediated glycolytic inhibition-oxidative stress-apoptosis pathway in Dalton's lymp... | DisGeNET | Detail |
Molecular analysis of lymphomas revealed that arginine methylation of p53 selectively suppresses exp... | DisGeNET | Detail |
We used isogenic lymphoma cell line models to prove p53 dependence of NEAT1 and lincRNA-p21. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
PUMA protein in p53 regulatory molecule pattern determines the prognosis for patients with lymphopro... | DisGeNET | Detail |
We report that persistent accumulation of DNA damage/strand breaks and chronic activation of the ser... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Whilst drugs directly targeting SIRT1, were potent to trigger cell death at high concentrations only... | DisGeNET | Detail |
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, thera... | DisGeNET | Detail |
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma... | DisGeNET | Detail |
Treatment of Med in Ptch1(+/-) Trp53(-/-) mice with the antiestrogen chemotherapeutic drug Faslodex ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
To understand the phenotypic similarities/differences between lung carcinoids and HGNETs, we compara... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These results uncover a new mechanism of p53 inactivation providing an interesting novel molecular l... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In addition, we tested if Hsp27 protein levels correlated with p53 expression and cell proliferation... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The expression of nine of them is higher in MM plasma cells than in healthy donor counterparts, sugg... | DisGeNET | Detail |
Moreover, silencing of p53 in two TP53(mutated) cell lines failed to inhibit apoptosis that was indu... | DisGeNET | Detail |
This review summarizes different modes of p53 inactivation in myeloma and highlights the current p53... | DisGeNET | Detail |
ANKHD1 downregulation modulates cell cycle gene expression and upregulates p21 irrespective of the T... | DisGeNET | Detail |
Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor surv... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Additionally, the mutation data identified 2 other potential contributing factors to MF, ultraviolet... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We performed genomic profiling of post-MPN AML samples; these studies demonstrate somatic tumor prot... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Almost all identified high-penetrance gene mutations in those families fulfill the typical phenotype... | DisGeNET | Detail |
A significant percentage (5-10%) of pediatric cancers are associated with hereditary cancer syndrome... | DisGeNET | Detail |
TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse an... | DisGeNET | Detail |
We show that (i) in the choroid plexus carcinoma, the germline mutation was detected in a homozygous... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Exome DNA sequencing of blood samples from a Li-Fraumeni family with a TP53 germline mutation (codon... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Two family members without a TP53 germline mutation who developed peripheral schwannomas also carrie... | DisGeNET | Detail |
Here we investigated p53 regulation and its role in proliferation and survival of human primary schw... | DisGeNET | Detail |
CFM-1, -4, and -5 inhibited NB cell growth, in vitro, independent of their p53 and MYCN status. | DisGeNET | Detail |
Simultaneous Adrenocortical Carcinoma and Neuroblastoma in an Infant With a Novel Germline p53 Mutat... | DisGeNET | Detail |
Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. | DisGeNET | Detail |
Treatment of wild-type TP53 neuroblastoma cell lines with both GSK2830371 and either doxorubicin or ... | DisGeNET | Detail |
Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
The most common predisposition syndromes include germline TP53 mutations and constitutive alteration... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The whitish nodule corresponded to the sarcomatoid component, and the spindled and pleomorphic tumor... | DisGeNET | Detail |
Inhibition of endothelial p53 improves metabolic abnormalities related to dietary obesity. | DisGeNET | Detail |
These results uncover a new mechanism of p53 inactivation providing an interesting novel molecular l... | DisGeNET | Detail |
Prostaglandin E2 inhibits p53 in human breast adipose stromal cells: a novel mechanism for the regul... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Those tumors that lacked LOH 1p19q showed a high frequency of IDH1 mutations and loss of alpha thala... | DisGeNET | Detail |
The mean of Olig2 LI of gliomas with 1p/19q loss ± IDH1/2 mutation, the majority of them being oligo... | DisGeNET | Detail |
We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX (60%, 9/15) at freq... | DisGeNET | Detail |
The TP53 and HIST1H3A genes were the hub nodes in the PPI network of DEGs from GBM, while CNTN2 was ... | DisGeNET | Detail |
Thus, we analyzed the expression of p-CREB in a series of astrocytomas and oligodendrogliomas of dif... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overexpression of RASSF5 markedly suppressed cell proliferation and invasion, and induced cell apopt... | DisGeNET | Detail |
Prognostic value of p53 alterations in human osteosarcoma: a meta analysis. | DisGeNET | Detail |
p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma... | DisGeNET | Detail |
Inactivation of p53 and/or Rb pathways restrains osteoblasts from cell-cycle exit and terminal diffe... | DisGeNET | Detail |
Here, we established patient-derived iPSCs from a Li-Fraumeni syndrome (LFS) family and investigated... | DisGeNET | Detail |
Germline TP53 variants and susceptibility to osteosarcoma. | DisGeNET | Detail |
To identify the genes driving osteosarcoma development and metastasis, we performed a Sleeping Beaut... | DisGeNET | Detail |
Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer. | DisGeNET | Detail |
In this study, the nuclear expression levels of γ-H2AX and p53 using immunohistochemical (IHC) study... | DisGeNET | Detail |
Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas. | DisGeNET | Detail |
Association between a single nucleotide polymorphism in the TP53 region and risk of ovarian cancer. | DisGeNET | Detail |
The observed upregulation of pro-apoptotic genes and apoptosis in cancer cells without p53 in respon... | DisGeNET | Detail |
We demonstrated that in a unique population of HGSOC cancer cells with cancer stem cell properties, ... | DisGeNET | Detail |
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway ... | DisGeNET | Detail |
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in... | DisGeNET | Detail |
TP53 remains as the most frequently altered gene in high grade serous ovarian cancer and Ion Torrent... | DisGeNET | Detail |
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. | DisGeNET | Detail |
Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer. | DisGeNET | Detail |
Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigat... | DisGeNET | Detail |
Co-immunoprecipitation and western blotting showed significantly lower levels of p53 and p53 Ser15-p... | DisGeNET | Detail |
The present study aimed to clarify the role of PLK1, P53 and P21WAF1 in the prognosis of ovarian can... | DisGeNET | Detail |
CR389, a benzoimidazolyl pyridinone analog, induces cell cycle arrest and apoptosis via p53 activati... | DisGeNET | Detail |
Overall, FBN1, acts at the downstream of Aur A and BRCA2, promotes ovarian cancer metastasis through... | DisGeNET | Detail |
First, we observed the upregulation protein level of p53 target genes in cisplatin-resistant or cisp... | DisGeNET | Detail |
There is a link between miR-7 expression and TP53 status and tumour grade in serous OC. | DisGeNET | Detail |
TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro ... | DisGeNET | Detail |
We propose that this unique ability of APR-246/MQ to bind to cysteines in both mutant p53 and glutat... | DisGeNET | Detail |
The study found a high expression of P53 (64%) and MIB1 (72%) and an expression of BCL2 (48%) in asc... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
CD24 silencing prevents functional inactivation of p53 by both somatic mutation and viral oncogenes,... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In Wild-type (WT) mice with passive CSE (PCSE), p53 and PAI-1 expression and apoptosis were increase... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Moreover, inhibition of p53 in PV erythroblasts resulted in more gamma-H2Ax (γ-H2Ax)-marked double-s... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Met was amplified in 67% of prostate tumors from Pten p53 prostate conditional null mice and in appr... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Elevated p57Kip2 induces G1/S phase cell cycle arrest but inhibits cell death in response to DNA dam... | DisGeNET | Detail |
Proteins encoded by CDK2, TP53, and RELA have been associated with the progression of renal failure ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In the current study, genetically engineered mice were generated to determine the role of Rb and p53... | DisGeNET | Detail |
In addition, loss-of-function mutations in p53 (TP53) as well as deleterious mutations in the tumor ... | DisGeNET | Detail |
Following further examination of cell cycle-related factors, MCM2 knockdown inhibited protein retino... | DisGeNET | Detail |
It is unique among the epithelial carcinomas as two distinct pathways to tumourigenesis appear to ex... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The purpose of the present study was to investigate the role of sirtuin expression, activity and inh... | DisGeNET | Detail |
We also demonstrate that miR-605 overexpression leads to a decrease in cell proliferation, clonogeni... | DisGeNET | Detail |
Kaposi's sarcoma-associated herpesvirus (KSHV)-related malignancies express wild-type p53. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
MicroRNA-125b inhibits lens epithelial cell apoptosis by targeting p53 in age-related cataract. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The detection limits for analyzing the Smallpox and TP53 genes correspond to 0.1 nM. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Three other genes, TP53, EP300 and CALM1 might also contribute to the pathogenesis of PTSD since the... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The purpose of the present study was to investigate the role of sirtuin expression, activity and inh... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial comp... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Genomic profile of a Li-Fraumeni-like syndrome patient with a 45,X/46,XX karyotype, presenting neith... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
To address the unmet need, we recently developed RapidCaP mice, which endogenously recreate human PT... | DisGeNET | Detail |
Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcinoma and occult hepat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Erythroblasts negative for WRN immunostaining were only observed in two patients, both of whom were ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and ... | DisGeNET | Detail |
Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exo... | DisGeNET | Detail |
MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas. | DisGeNET | Detail |
Consequently, miR-200-induced T2D is suppressed by interfering with the signaling of Trp53 and Bax, ... | DisGeNET | Detail |
Mechanistically, 4-MU led to increased p53 mRNA expression, elevated cytoplasmic protein levels of c... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These alterations were accompanied by increased forkhead box O3 (FoxO3) in several cell lines and in... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Our meta-analysis demonstrates that TP53 codon 72 polymorphism may not be a risk factor for acute le... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We found that resistance to spindle poison-induced apoptosis could be reverted in tumor protein p53 ... | DisGeNET | Detail |
In the presented studies p53 and bcl-2 proteins expression were evaluated in samples of gastric carc... | DisGeNET | Detail |
In non-small cell lung cancer (NSCLC), both USP7 expression and p53 gene status were reported to be ... | DisGeNET | Detail |
Correlation between squamous cell carcinoma of the lung and human papillomavirus infection and the r... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The PTEN/PIK3CA pathway was interrogated using an AdenoCre-driven mouse model of SCLC harboring inac... | DisGeNET | Detail |
In comparison to the carcinoids, LCNEC/SCLC tumors presented a stronger loss of nuclear and cytosoli... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinoma... | DisGeNET | Detail |
LATS2 mRNA level was found to be a significant independent predictor for survival status (disease-fr... | DisGeNET | Detail |
Proteomic signatures associated with p53 mutational status in lung adenocarcinoma. | DisGeNET | Detail |
PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferatio... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
TP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in esophageal cancer in I... | DisGeNET | Detail |
The increased expression of pS(21)GSK3α and pS(9)GSK3β not only correlated positively with cyclin D1... | DisGeNET | Detail |
Phenethyl isothiocyanate induces DNA damage-associated G2/M arrest and subsequent apoptosis in oral ... | DisGeNET | Detail |
The detection limits, established as 3σ, were estimated to be 0.03 and 0.06 fmol L(-1) for the p53 a... | DisGeNET | Detail |
The expression of total and phosphorylated GSK3α/β as well as cyclin D1 and p53 together with their ... | DisGeNET | Detail |
Among these biomarkers, p53 is the strongest prognostic marker in OPC and p53 in addition to p16 sup... | DisGeNET | Detail |
The biology of HPV-positive oropharyngeal cancer is distinct; it includes p53 degradation, retinobla... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
High frequency of TP53 but not K-ras gene mutations in Bolivian patients with gallbladder cancer. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric m... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Our study, for the first time, demonstrates that GINS2 is an independent prognostic marker and is as... | DisGeNET | Detail |
Interestingly, the combined silencing of p53 and Toca-1 led to a partial rescue of these effects of ... | DisGeNET | Detail |
Tumor cells expressing high-risk TP53 mutations were more invasive and tumorigenic and they exhibite... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Autophagy is upregulated in ovarian endometriosis: a possible interplay with p53 and heme oxygenase-... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Somatic mutations in ACC-associated genes included TP53 (8/41 tumors, 19.5%) and CTNNB1 (4/41, 9.8%)... | DisGeNET | Detail |
TP53 mutations are prevalent in children with ACC but decline with age. | DisGeNET | Detail |
The TP53 mutation detection rate in children presenting with ACC or choroid plexus carcinomas, and i... | DisGeNET | Detail |
On the contrary, p53 loss led to increased apoptosis that had to be overcome for tumor progression. | DisGeNET | Detail |
Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer. | DisGeNET | Detail |
This study provides the first time evidence that RRM2B is transcriptionally and functionally regulat... | DisGeNET | Detail |
It is therefore important to elucidate the role of these downstream targets in p53 regulated tumor p... | DisGeNET | Detail |
These findings are relevant to human basal-like tumor progression in vivo, since miR-146a is highly ... | DisGeNET | Detail |
These results uncover a new mechanism of p53 inactivation providing an interesting novel molecular l... | DisGeNET | Detail |
Moreover, by two-dimensional gel electrophoresis and mass spectrometry we discovered that the aggreg... | DisGeNET | Detail |
Emerging from the shade of p53 mutants: N-terminally truncated variants of the p53 family in EMT sig... | DisGeNET | Detail |
The p53 and NFκB sequence-specific transcription factors play crucial roles in cell proliferation an... | DisGeNET | Detail |
Many cancers express mutant p53 proteins that have lost wild-type tumor suppressor activity and, in ... | DisGeNET | Detail |
These results suggest that stroma-derived p53 plays a pivotal role in epithelial cancer progression ... | DisGeNET | Detail |
However, the presence of p53 mutations in skin premalignant lesions suggests that these represent ea... | DisGeNET | Detail |
The 14-3-3ζ-driven contextual changes of Smad partners from p53 to Gli2 may serve as biomarkers and ... | DisGeNET | Detail |
The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated ... | DisGeNET | Detail |
TP53 was the most frequently mutated gene in TETs (n = 13; 17%), especially in TCs (26%), and was as... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Genomic studies of ALCL-11 showed the TP53 loss and the in vivo subclonal expansion of lymphoma cell... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
UV-independent p53 mutations in sebaceous carcinoma of the eyelid. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
ECCCs had SCA-like features with rare expression of estrogen receptor/progesterone receptor (18.8%/6... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
A missense mutation in TP53 exon 7 (c.734G>C) and strong nuclear immunostaining for p53 were detecte... | DisGeNET | Detail |
CCA with Ov shows significantly higher incidence of the TP53 gene mutation, whereas CCA without Ov s... | DisGeNET | Detail |
Interestingly, there is a significant difference in the frequency of mutated genes between Ov-relate... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The overall mutation profile of this cohort of endometrial CCC appears to be more serous-like than e... | DisGeNET | Detail |
NA | DisGeNET | Detail |
In non-small cell lung cancer (NSCLC), both USP7 expression and p53 gene status were reported to be ... | DisGeNET | Detail |
Diffuse p16 expression was associated with younger age at presentation (P<0.0001), basaloid and wart... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
No variation of p16, p21, PLUNC (palate, lung, and nasal epithelium clone protein) and p53 expressio... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Genetic alterations in human cancers and murine models indicate that retinoblastoma (Rb) and p53 hav... | DisGeNET | Detail |
The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms. | DisGeNET | Detail |
NA | DisGeNET | Detail |
Interestingly, ALT attenuated the poor outcome conferred by TP53 mutations in specific pediatric bra... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Phenethyl isothiocyanate induces DNA damage-associated G2/M arrest and subsequent apoptosis in oral ... | DisGeNET | Detail |
The detection limits, established as 3σ, were estimated to be 0.03 and 0.06 fmol L(-1) for the p53 a... | DisGeNET | Detail |
The expression of total and phosphorylated GSK3α/β as well as cyclin D1 and p53 together with their ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Mutational profiling of familial male breast cancers reveals similarities with luminal A female brea... | DisGeNET | Detail |
High frequency of TP53 but not K-ras gene mutations in Bolivian patients with gallbladder cancer. | DisGeNET | Detail |
All MSI tumors were negative for HER2 amplification, and TP53 and NRAS mutations were only found in ... | DisGeNET | Detail |
Other genetic alterations, including telomere shortening and the inactivation of tumor suppressor ge... | DisGeNET | Detail |
Taken together, our data indicate that PRIMA-1 induces apoptosis in p53 mutant pancreatic cancer cel... | DisGeNET | Detail |
Together, our data support the critical role of autophagy in pancreatic cancer and show that inhibit... | DisGeNET | Detail |
Studies of the molecular pathology of pancreatic cancer have revealed that activation of KRAS, overe... | DisGeNET | Detail |
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cance... | DisGeNET | Detail |
We investigated the prevalence of germline mutations in APC, ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, ... | DisGeNET | Detail |
Chromosomal rearrangements leading to gene disruption were prevalent, affecting genes known to be im... | DisGeNET | Detail |
Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Functio... | DisGeNET | Detail |
Here we report a systematic definition of how pancreatic cancer cells harboring mutant p53 respond t... | DisGeNET | Detail |
Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Epigenetic silencing of miR-218 is a common feature in HR-HPV(+) PSCCs and in HR-HPV(-) PSCCs withou... | DisGeNET | Detail |
NA | DisGeNET | Detail |
In the current study, genetically engineered mice were generated to determine the role of Rb and p53... | DisGeNET | Detail |
By simultaneously activating Kras and deleting p53 (Trp53) in thyroid follicular cells, we have gene... | DisGeNET | Detail |
In immunohistochemical studies, DSVPTC showed different expression patterns of epithelial membrane a... | DisGeNET | Detail |
Pri-Mir-34b/C and Tp-53 Polymorphisms are Associated With The Susceptibility of Papillary Thyroid Ca... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Ectopic expression of miR-506 inhibits NF-κB p65 expression, induces ROS accumulation and then activ... | DisGeNET | Detail |
Nickel accumulation in lung tissues is associated with increased risk of p53 mutation in lung cancer... | DisGeNET | Detail |
Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 p... | DisGeNET | Detail |
TP53 mutations and lung cancer: not all mutations are created equal. | DisGeNET | Detail |
Caveolin-1 regulates lung cancer stem-like cell induction and p53 inactivation in carbon nanotube-dr... | DisGeNET | Detail |
AP-2α downregulation by cigarette smoke condensate is counteracted by p53 in human lung cancer cells... | DisGeNET | Detail |
β-Elemene against human lung cancer via up-regulation of P53 protein expression to promote the relea... | DisGeNET | Detail |
We evaluated 23 single nucleotide polymorphisms (SNPs) in the five nicotinic receptor related genes ... | DisGeNET | Detail |
Evaluation of the mutagenicity of anti-B[a]P-diol epoxide with B[a]P-7,8-dione on p53 showed that th... | DisGeNET | Detail |
Loss of p53 function may result in upregulation of 14-3-3γ in lung cancers. | DisGeNET | Detail |
In addition, we used lung cancer cell lines with different p53 gene background (p53 null and p53 wil... | DisGeNET | Detail |
Finally, we provide an analysis of discerning epidemiological data obtained from the IARC database a... | DisGeNET | Detail |
SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptosis by transcriptiona... | DisGeNET | Detail |
Moreover, co-treatment of MML and p53 inhibitor would be more effective in human lung cancer therapy... | DisGeNET | Detail |
Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-κB signaling to control chem... | DisGeNET | Detail |
Our finding supports that mir-660 acts as a tumor suppressor miRNA and we suggest the replacement of... | DisGeNET | Detail |
These results suggest that stroma-derived p53 plays a pivotal role in epithelial cancer progression ... | DisGeNET | Detail |
Association of a p53 codon 72 gene polymorphism with environmental factors and risk of lung cancer: ... | DisGeNET | Detail |
We identified mutations in both tumors, including KEAP1 (commonly mutated in lung cancers) in one, a... | DisGeNET | Detail |
Treatment of cells with curcumin induced both p53 and the related protein p73 in head and neck and l... | DisGeNET | Detail |
TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population. | DisGeNET | Detail |
Furthermore, using data generated by The Cancer Genome Atlas consortium, we demonstrate that the eff... | DisGeNET | Detail |
These results demonstrate that p53 is able to respond to exposure of arsenic or Cr(VI), suggesting t... | DisGeNET | Detail |
However, p53-targeted therapies have limited application in lung cancer, since p53 is found to be mu... | DisGeNET | Detail |
This RNA aptamer (p53R175H-APT) has a significantly stronger affinity to p53R175H than to the wild-t... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
With regards to overall survival, factors predictive of an unfavorable outcome were minimal residual... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The inability of mice to develop HCC when autophagy was impaired was associated with the induction o... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The pathogenesis of prostatic SCNC involves a p53 and Aurora Kinase A signaling mechanism, both pote... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
TP53 overexpression is a predictor of poor outcome in patients with MDS-F. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Together, the results of this study support PARN as a DC-associated gene and suggest a potential lin... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Moreover, a significant decrease of p53 protein and a significant increase of heme oxygenase-1 prote... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Furthermore a minimal IBC-related predictive set of 4 miRNAs associated with the TP53 mutational sta... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The obtained results allow the conclusion, that H. pylori (cagA+)-associated development of the gast... | DisGeNET | Detail |
A significant percentage (5-10%) of pediatric cancers are associated with hereditary cancer syndrome... | DisGeNET | Detail |
NA | DisGeNET | Detail |
We investigated the safety and activity of ibrutinib in previously untreated and relapsed or refract... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Phase I dendritic cell p53 peptide vaccine for head and neck cancer. | DisGeNET | Detail |
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa... | DisGeNET | Detail |
Anomalous altered expressions of downstream gene-targets in TP53-miRNA pathways in head and neck can... | DisGeNET | Detail |
Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in h... | DisGeNET | Detail |
Salivary adenoid cystic carcinoma (SACC) is a malignant tumor that is characterized by perineural in... | DisGeNET | Detail |
Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival ... | DisGeNET | Detail |
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Nec... | DisGeNET | Detail |
The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutat... | DisGeNET | Detail |
One such example is hepatitis virus-induced liver cancer whereby p53 is inactivated upon the binding... | DisGeNET | Detail |
NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Association between SNPs in P53 binding regions and risk of esophageal squamous cell carcinoma. | DisGeNET | Detail |
LINE-1 hypomethylation of ESCC was significantly associated with lymph node metastasis, lymphovascul... | DisGeNET | Detail |
Combined effects of leukocyte telomere length, p53 polymorphism and human papillomavirus infection o... | DisGeNET | Detail |
Esophageal cells overexpressing epidermal growth factor receptor (EGFR) and TP53 mutation can invade... | DisGeNET | Detail |
These findings identify an important subgroup of young patients with cancer who carry germline mutat... | DisGeNET | Detail |
Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epi... | DisGeNET | Detail |
Combining the techniques detected TP53 abnormalities in 100% of patients with LGD, HGD, and EAC. | DisGeNET | Detail |
Barrett's esophagus is thought to progress to esophageal adenocarcinoma (EAC) through a stepwise pro... | DisGeNET | Detail |
p53 mutations in human cancers. | DisGeNET | Detail |
NA | DisGeNET | Detail |
Expression of cell cycle-related proteins, p16, p53 and p63 as important prognostic markers in gallb... | DisGeNET | Detail |
To investigate protein expression and mutations in phosphatase and tensin homolog (PTEN) in patients... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The expression patterns of p53 and p16 and an analysis of a possible role of HPV in primary adenocar... | DisGeNET | Detail |
Ubiquitin E3 ligase UHRF1 regulates p53 ubiquitination and p53-dependent cell apoptosis in clear cel... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These studies showed that TP53 and PI3KCA are the two most mutated genes in all types of cancers and... | DisGeNET | Detail |
The human cervical cancer oncogene (HCCR) has been shown to be over-expressed in some solid tumors, ... | DisGeNET | Detail |
Genetic deletion of the telomerase subunit Terc in a retroviral mouse AML model induces cell-cycle a... | DisGeNET | Detail |
The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung ca... | DisGeNET | Detail |
TP53 mutations in early-stage non-small cell lung cancer (NSCLC) may be associated with worse surviv... | DisGeNET | Detail |
Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with e... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Exome sequencing showed that OVC samples lacked mutations in genes commonly associated with OSCC (TP... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We show that (i) in the choroid plexus carcinoma, the germline mutation was detected in a homozygous... | DisGeNET | Detail |
TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In all but one OA the combination of nuclear p53 accumulation and ATRX loss was mutually exclusive w... | DisGeNET | Detail |
We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX (60%, 9/15) at freq... | DisGeNET | Detail |
As most studies have focused on HPV infection and TP53 mutations, we suggest that more research shou... | DisGeNET | Detail |
NA | DisGeNET | Detail |
TP53 mutation is a common event in many cancers, including pancreatic adenocarcinoma, where it occur... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Positive staining for p53 was observed in 15 (24.59%) cases of cervical intraepithelial neoplasia an... | DisGeNET | Detail |
Association of a miR-502-binding site single nucleotide polymorphism in the 3'-untranslated region o... | DisGeNET | Detail |
Several factors may contribute to cervical cancer (CC) development, including genetic variants such ... | DisGeNET | Detail |
Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21, p... | DisGeNET | Detail |
Expression of the p53 target Wig-1 is associated with HPV status and patient survival in cervical ca... | DisGeNET | Detail |
Berberine alters epigenetic modifications, disrupts microtubule network, and modulates HPV-18 E6-E7 ... | DisGeNET | Detail |
The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women. | DisGeNET | Detail |
Overexpression of Nm23H1 but not H2 also inhibited tumorigenesis by human cervical cancer HeLa cells... | DisGeNET | Detail |
The mechanism and inhibitory effect of recombinant human P53 adenovirus injection combined with pacl... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Formalin Fixed Paraffin Embedded tissue were studied for miRNA expression, KRAS, BRAF, PIK3CA mutati... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Although the status of RB1 and P53 between carcinoids and HGNETs were apparently different, the DNTF... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
TP53 mutation occurred more frequently in carcinomas than borderline tumors (56.8 % and 11.5 %, resp... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Those tumors that lacked LOH 1p19q showed a high frequency of IDH1 mutations and loss of alpha thala... | DisGeNET | Detail |
The mean of Olig2 LI of gliomas with 1p/19q loss ± IDH1/2 mutation, the majority of them being oligo... | DisGeNET | Detail |
We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX (60%, 9/15) at freq... | DisGeNET | Detail |
The TP53 and HIST1H3A genes were the hub nodes in the PPI network of DEGs from GBM, while CNTN2 was ... | DisGeNET | Detail |
Thus, we analyzed the expression of p-CREB in a series of astrocytomas and oligodendrogliomas of dif... | DisGeNET | Detail |
We find evidence of regional mutational heterogeneity in multiple tumors, including mutations in TP5... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 1... | DisGeNET | Detail |
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Combined effects of leukocyte telomere length, p53 polymorphism and human papillomavirus infection o... | DisGeNET | Detail |
Correlation between squamous cell carcinoma of the lung and human papillomavirus infection and the r... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
One such example is hepatitis virus-induced liver cancer whereby p53 is inactivated upon the binding... | DisGeNET | Detail |
NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
However, only about 20% of familial breast cancer is attributed to mutations in BRCA1 and BRCA2, whi... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Diffuse p16 expression was associated with younger age at presentation (P<0.0001), basaloid and wart... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Other genetic alterations, including telomere shortening and the inactivation of tumor suppressor ge... | DisGeNET | Detail |
Taken together, our data indicate that PRIMA-1 induces apoptosis in p53 mutant pancreatic cancer cel... | DisGeNET | Detail |
Together, our data support the critical role of autophagy in pancreatic cancer and show that inhibit... | DisGeNET | Detail |
Studies of the molecular pathology of pancreatic cancer have revealed that activation of KRAS, overe... | DisGeNET | Detail |
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cance... | DisGeNET | Detail |
We investigated the prevalence of germline mutations in APC, ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, ... | DisGeNET | Detail |
Chromosomal rearrangements leading to gene disruption were prevalent, affecting genes known to be im... | DisGeNET | Detail |
Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Functio... | DisGeNET | Detail |
Here we report a systematic definition of how pancreatic cancer cells harboring mutant p53 respond t... | DisGeNET | Detail |
Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Conversely, DEK loss results in cell death in HPV-positive cervical cancer cells at least in part th... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Cantharidin inhibits cell proliferation and promotes apoptosis in tongue squamous cell carcinoma thr... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Somatic mutations contributing to the development of RS include TP53 disruption, c-myc activation, C... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Detection p53 gene deletion in hematological malignancies using fluorescence in situ hybridization: ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We found that four of the variants (rs3829787, rs3841324, rs588765 and rs3743073) were associated wi... | DisGeNET | Detail |
For children with TP53 mutant malignant gliomas, one year overall survival was 63 ± 12 and 23 ± 10 %... | DisGeNET | Detail |
A greater number of copies of mutated TP53 were significantly associated to increased tumor aggressi... | DisGeNET | Detail |
We show that (i) in the choroid plexus carcinoma, the germline mutation was detected in a homozygous... | DisGeNET | Detail |
The TP53 mutation detection rate in children presenting with ACC or choroid plexus carcinomas, and i... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Patients with p53 mutations were older (p<.0001) and had higher numbers of liver metastases (p=.005)... | DisGeNET | Detail |
Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for rese... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We discuss the shared properties of cancer and neurodegenerative diseases and how the prion-like pro... | DisGeNET | Detail |
The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatiti... | DisGeNET | Detail |
FBP1 is barely detectable in normal differentiated cells; its overexpression in HCC tumors with the ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
For instance, a greater absolute risk reduction of lung and upper aerodigestive cancers in smokers t... | DisGeNET | Detail |
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP... | DisGeNET | Detail |
A growing collection of retrospective studies have suggested that TP53 mutations and/or CDKN2A delet... | DisGeNET | Detail |
CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and coope... | DisGeNET | Detail |
RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status. | DisGeNET | Detail |
NA | DisGeNET | Detail |
For instance, a greater absolute risk reduction of lung and upper aerodigestive cancers in smokers t... | DisGeNET | Detail |
To determine the presence of HPV in genital skin squamous cell carcinomas and to see the relationshi... | DisGeNET | Detail |
However, the presence of p53 mutations in skin premalignant lesions suggests that these represent ea... | DisGeNET | Detail |
Formation of γH2AX foci (a marker of DNA double-strand breaks), rates of foci clearance and apoptosi... | DisGeNET | Detail |
For children with TP53 mutant malignant gliomas, one year overall survival was 63 ± 12 and 23 ± 10 %... | DisGeNET | Detail |
TP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in esophageal cancer in I... | DisGeNET | Detail |
The increased expression of pS(21)GSK3α and pS(9)GSK3β not only correlated positively with cyclin D1... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overexpression of RASSF5 markedly suppressed cell proliferation and invasion, and induced cell apopt... | DisGeNET | Detail |
Prognostic value of p53 alterations in human osteosarcoma: a meta analysis. | DisGeNET | Detail |
p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma... | DisGeNET | Detail |
Inactivation of p53 and/or Rb pathways restrains osteoblasts from cell-cycle exit and terminal diffe... | DisGeNET | Detail |
Here, we established patient-derived iPSCs from a Li-Fraumeni syndrome (LFS) family and investigated... | DisGeNET | Detail |
Germline TP53 variants and susceptibility to osteosarcoma. | DisGeNET | Detail |
To identify the genes driving osteosarcoma development and metastasis, we performed a Sleeping Beaut... | DisGeNET | Detail |
NA | DisGeNET | Detail |
In the printing company cases, immunohistochemical expression of p53 was observed in non-neoplastic ... | DisGeNET | Detail |
The most common predisposition syndromes include germline TP53 mutations and constitutive alteration... | DisGeNET | Detail |
Together, results suggested that miR-30b could modulate p53 pathway and enhance p53 gene therapy-ind... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Using an autochthonous model of pancreatic cancer driven by oncogenic Kras and the stochastic LOH of... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
High-grade serous ovarian cancer (HG-SOC), a major histologic type of epithelial ovarian cancer (EOC... | DisGeNET | Detail |
Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas. | DisGeNET | Detail |
We demonstrated that in a unique population of HGSOC cancer cells with cancer stem cell properties, ... | DisGeNET | Detail |
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in... | DisGeNET | Detail |
High-grade serous ovarian cancer (HGSOC) is the most aggressive histological type of epithelial ovar... | DisGeNET | Detail |
Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests p... | DisGeNET | Detail |
To test if TP53 hot spot mutations (HSMs) confer differential chemotherapy resistance or survival ou... | DisGeNET | Detail |
The study found a high expression of P53 (64%) and MIB1 (72%) and an expression of BCL2 (48%) in asc... | DisGeNET | Detail |
Using an autochthonous model of pancreatic cancer driven by oncogenic Kras and the stochastic LOH of... | DisGeNET | Detail |
Combined MYC family amplifications and P53 pathway defects commonly emerged at relapse, and all pati... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Ectopic expression of miR-506 inhibits NF-κB p65 expression, induces ROS accumulation and then activ... | DisGeNET | Detail |
Nickel accumulation in lung tissues is associated with increased risk of p53 mutation in lung cancer... | DisGeNET | Detail |
Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 p... | DisGeNET | Detail |
TP53 mutations and lung cancer: not all mutations are created equal. | DisGeNET | Detail |
Caveolin-1 regulates lung cancer stem-like cell induction and p53 inactivation in carbon nanotube-dr... | DisGeNET | Detail |
AP-2α downregulation by cigarette smoke condensate is counteracted by p53 in human lung cancer cells... | DisGeNET | Detail |
β-Elemene against human lung cancer via up-regulation of P53 protein expression to promote the relea... | DisGeNET | Detail |
We evaluated 23 single nucleotide polymorphisms (SNPs) in the five nicotinic receptor related genes ... | DisGeNET | Detail |
Evaluation of the mutagenicity of anti-B[a]P-diol epoxide with B[a]P-7,8-dione on p53 showed that th... | DisGeNET | Detail |
Loss of p53 function may result in upregulation of 14-3-3γ in lung cancers. | DisGeNET | Detail |
In addition, we used lung cancer cell lines with different p53 gene background (p53 null and p53 wil... | DisGeNET | Detail |
Finally, we provide an analysis of discerning epidemiological data obtained from the IARC database a... | DisGeNET | Detail |
SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptosis by transcriptiona... | DisGeNET | Detail |
Moreover, co-treatment of MML and p53 inhibitor would be more effective in human lung cancer therapy... | DisGeNET | Detail |
Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-κB signaling to control chem... | DisGeNET | Detail |
Our finding supports that mir-660 acts as a tumor suppressor miRNA and we suggest the replacement of... | DisGeNET | Detail |
These results suggest that stroma-derived p53 plays a pivotal role in epithelial cancer progression ... | DisGeNET | Detail |
Association of a p53 codon 72 gene polymorphism with environmental factors and risk of lung cancer: ... | DisGeNET | Detail |
We identified mutations in both tumors, including KEAP1 (commonly mutated in lung cancers) in one, a... | DisGeNET | Detail |
Treatment of cells with curcumin induced both p53 and the related protein p73 in head and neck and l... | DisGeNET | Detail |
TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population. | DisGeNET | Detail |
Furthermore, using data generated by The Cancer Genome Atlas consortium, we demonstrate that the eff... | DisGeNET | Detail |
These results demonstrate that p53 is able to respond to exposure of arsenic or Cr(VI), suggesting t... | DisGeNET | Detail |
However, p53-targeted therapies have limited application in lung cancer, since p53 is found to be mu... | DisGeNET | Detail |
This RNA aptamer (p53R175H-APT) has a significantly stronger affinity to p53R175H than to the wild-t... | DisGeNET | Detail |
NA | DisGeNET | Detail |
To conduct a phase I trial of a modified vaccinia Ankara (MVA) vaccine delivering wild-type human p5... | DisGeNET | Detail |
NA | DisGeNET | Detail |
LINE-1 hypomethylation of ESCC was significantly associated with lymph node metastasis, lymphovascul... | DisGeNET | Detail |
Increased p53 expression significantly correlated with high pathological grade and lymph node metast... | DisGeNET | Detail |
Our findings underscore the importance of measuring the HPV16 RNA (E6*I) and TP53-mutation status fo... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. | DisGeNET | Detail |
Overall results suggest that phosphorylated HER3, ERK1/2 and p53 may be used as biomarkers to determ... | DisGeNET | Detail |
Our findings confirm the alternative role of FGFR3 and TP53 mutations in the development of bladder ... | DisGeNET | Detail |
Recent developments in the field of molecular mutational pathway analyses based on next generation s... | DisGeNET | Detail |
Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi populati... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
CFM-1, -4, and -5 inhibited NB cell growth, in vitro, independent of their p53 and MYCN status. | DisGeNET | Detail |
Simultaneous Adrenocortical Carcinoma and Neuroblastoma in an Infant With a Novel Germline p53 Mutat... | DisGeNET | Detail |
Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. | DisGeNET | Detail |
Treatment of wild-type TP53 neuroblastoma cell lines with both GSK2830371 and either doxorubicin or ... | DisGeNET | Detail |
Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q- syndrome in a TP53-... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric m... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Those tumors that lacked LOH 1p19q showed a high frequency of IDH1 mutations and loss of alpha thala... | DisGeNET | Detail |
The mean of Olig2 LI of gliomas with 1p/19q loss ± IDH1/2 mutation, the majority of them being oligo... | DisGeNET | Detail |
We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX (60%, 9/15) at freq... | DisGeNET | Detail |
The TP53 and HIST1H3A genes were the hub nodes in the PPI network of DEGs from GBM, while CNTN2 was ... | DisGeNET | Detail |
Thus, we analyzed the expression of p-CREB in a series of astrocytomas and oligodendrogliomas of dif... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Human gene copy number alteration data, microarray expression data, and TMA analysis indicate that T... | DisGeNET | Detail |
The pathological diagnosis of malignant schwannoma indicated that the p53 expression was strongly po... | DisGeNET | Detail |
We show that loss of laforin or malin results in the increased level and activity of p53, both in ce... | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this study we identified a previously unreported mechanism, involving disruption of p53 and NADPH... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
There was no deletion 1p19q in 118 cases, codeletion 1p19q (57 cases), single deletion 1p (4 cases) ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant ple... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Polysomy 7, polysomy 18, p16 deletion, and p53 deletion were significantly more frequent in invasive... | DisGeNET | Detail |
More than 50% of human cancers contain a mutation or deletion of the p53 gene, and p53R175 is one of... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Using an autochthonous model of pancreatic cancer driven by oncogenic Kras and the stochastic LOH of... | DisGeNET | Detail |
However, the presence of p53 mutations in skin premalignant lesions suggests that these represent ea... | DisGeNET | Detail |
Helicobacter pylori infection and a P53 codon 72 single nucleotide polymorphism: a reason for an une... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Previous genetic studies on colorectal carcinomas (CRC) have identified multiple somatic mutations i... | DisGeNET | Detail |
Taken together, our results provide evidence for RTK/RAS pathway activation and p53 deficiency as a ... | DisGeNET | Detail |
Mutations in genes relating to genome integrity (TP53, BRCA2), chromatin remodeling (ARID1A), cell a... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The tumor suppressor TP53 is mutated in approximately 30% of breast adenocarcinomas, with varying fr... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with local... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Characteristics and survival of patients with advanced cancer and p53 mutations. | DisGeNET | Detail |
Cancer genome studies document recurrent genetic inactivation of RB1 and TP53, and the inactivation ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this study, we compared the immunoreactivities of Bcl-2, Bax and p53 proteins in ovarian tumors a... | DisGeNET | Detail |
Since mutations in TP53 occur in nearly all ovarian tumors, the objective of this study was to deter... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In sporadic intestinal adenocarcinomas with strong p53 immunostaining (mutated TP53), ACSL5-related ... | DisGeNET | Detail |
Strong immunoreactivity of Bcl-2 and mild immunoreactivities of Bax and p53 were detected in ovarian... | DisGeNET | Detail |
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in prima... | DisGeNET | Detail |
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer tr... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Somatic mutations or deletions of TP53 and PTEN in ductal carcinoma in situ lesions have been implic... | DisGeNET | Detail |
Assessment of changes in the BRCA2 and P53 genes in breast invasive ductal carcinoma in northeast Br... | DisGeNET | Detail |
Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, H... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer. | DisGeNET | Detail |
In this study, the nuclear expression levels of γ-H2AX and p53 using immunohistochemical (IHC) study... | DisGeNET | Detail |
This study shows that triptolide selectively kills ovarian cancer cells with different p53 status pr... | DisGeNET | Detail |
Association between a single nucleotide polymorphism in the TP53 region and risk of ovarian cancer. | DisGeNET | Detail |
The observed upregulation of pro-apoptotic genes and apoptosis in cancer cells without p53 in respon... | DisGeNET | Detail |
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway ... | DisGeNET | Detail |
Furthermore, tumors containing oncomorphic TP53 mutations displayed unique protein expression profil... | DisGeNET | Detail |
TP53 remains as the most frequently altered gene in high grade serous ovarian cancer and Ion Torrent... | DisGeNET | Detail |
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. | DisGeNET | Detail |
Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer. | DisGeNET | Detail |
Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigat... | DisGeNET | Detail |
Co-immunoprecipitation and western blotting showed significantly lower levels of p53 and p53 Ser15-p... | DisGeNET | Detail |
The present study aimed to clarify the role of PLK1, P53 and P21WAF1 in the prognosis of ovarian can... | DisGeNET | Detail |
CR389, a benzoimidazolyl pyridinone analog, induces cell cycle arrest and apoptosis via p53 activati... | DisGeNET | Detail |
Overall, FBN1, acts at the downstream of Aur A and BRCA2, promotes ovarian cancer metastasis through... | DisGeNET | Detail |
First, we observed the upregulation protein level of p53 target genes in cisplatin-resistant or cisp... | DisGeNET | Detail |
There is a link between miR-7 expression and TP53 status and tumour grade in serous OC. | DisGeNET | Detail |
TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro ... | DisGeNET | Detail |
We propose that this unique ability of APR-246/MQ to bind to cysteines in both mutant p53 and glutat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Mechanistic studies reveal that attenuated HNSCC cell growth in response to DEK loss was associated ... | DisGeNET | Detail |
Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma ce... | DisGeNET | Detail |
Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. | DisGeNET | Detail |
We previously showed that CK2 is often aberrantly expressed and activated in head and neck squamous ... | DisGeNET | Detail |
Emphasis is placed on the therapeutic implications of genes frequently altered in HNSCCs (i.e., TP53... | DisGeNET | Detail |
These results indicate that HNSCC cells expressing high-risk p53 mutations are significantly sensiti... | DisGeNET | Detail |
TP53 is the most frequently altered gene in head and neck squamous cell carcinoma, with mutations oc... | DisGeNET | Detail |
The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased... | DisGeNET | Detail |
Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metal... | DisGeNET | Detail |
Human papillomavirus (HPV), p16 expression, and TP53 mutations are known prognostic factors in head ... | DisGeNET | Detail |
Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head an... | DisGeNET | Detail |
Our findings underscore the importance of measuring the HPV16 RNA (E6*I) and TP53-mutation status fo... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Haploinsufficiency of ribosomal proteins (RPs) and upregulation of the tumour suppressor TP53 have b... | DisGeNET | Detail |
In this study, we establish the DBA model in zebrafish using an RPS24 morpholino and found that RPS2... | DisGeNET | Detail |
Genetic depletion of Snail1 in MSCs that are deficient in p53 tumor suppressor downregulates MSC mar... | DisGeNET | Detail |
Most childhood sarcomas are TP53 wild type at diagnosis, although approximately 5-10% have MDM2 ampl... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
TP53 was the most frequently mutated gene in TETs (n = 13; 17%), especially in TCs (26%), and was as... | DisGeNET | Detail |
Two dedifferentiated SFT cases harbored both TP53 and TERT promoter mutations. | DisGeNET | Detail |
Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These accumulations were associated with decreased levels of Cyclin A1, B1, and E1, and increased ex... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We identified a unique case of adult B-ALL with masked low hypodiploidy (mLH) by genomic duplication... | DisGeNET | Detail |
Our findings support the recent notion that heterozygous TP53 mutation may be a function of normal a... | DisGeNET | Detail |
NA | DisGeNET | Detail |
We performed genomic profiling of post-MPN AML samples; these studies demonstrate somatic tumor prot... | DisGeNET | Detail |
L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q- syndrome in a TP53-... | DisGeNET | Detail |
The early acquisition of TP53 mutations in the founding HSPC clone probably contributes to the frequ... | DisGeNET | Detail |
TP53 mutations are highly and similarly prevalent in t-MDS and t-AML but mutations in genes other th... | DisGeNET | Detail |
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemi... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Coexistent TP53 mutations were identified in 63% of the TSC2-mutated PEComas. | DisGeNET | Detail |
We explored lncRNAs profilings in PanIN cell line (SH-PAN) isolated from Pdx-1-Cre; LSL-Kras (G12D/+... | DisGeNET | Detail |
The authors show that combined loss of autophagy and p53 dramatically promotes progression from earl... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
This is the first case of ameloblastic carcinoma with a mutation of the p53 gene that has been assoc... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
TP53 status regulates ACSL5-induced expression of mitochondrial mortalin in enterocytes and colorect... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated ... | DisGeNET | Detail |
TP53 was the most frequently mutated gene in TETs (n = 13; 17%), especially in TCs (26%), and was as... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Five new TP53 mutations were identified in six pedigrees from hereditary cancer clinics. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Genetic inactivation of the TP53 gene in ccRCC is rare, suggesting that an alternate mechanism allev... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Mutations in TP53 (20/28, 71%) and ATRX (15/28, 54%) were enriched in astrocytic tumors compared to ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
On the other hand, in well-differentiated PDACs measuring ≤ 1 cm, the incidence of abnormal immunola... | DisGeNET | Detail |
We explored lncRNAs profilings in PanIN cell line (SH-PAN) isolated from Pdx-1-Cre; LSL-Kras (G12D/+... | DisGeNET | Detail |
Mutations in p53 and RAS potently cooperate in oncogenic transformation, and correspondingly, these ... | DisGeNET | Detail |
Based on these findings, we propose the existence of a hierarchical signaling network regulating PDA... | DisGeNET | Detail |
Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma. | DisGeNET | Detail |
Using genetically engineered mouse models, we show that heterozygous mutation of Dpc4/Smad4 attenuat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor. | DisGeNET | Detail |
NA | DisGeNET | Detail |
However, this interpretation has been challenged by a number of recent in vivo studies, demonstratin... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We detected a total of 1,764 nonsynonymous single nucleotide variants at a rate of 8 per Mb in BP-NE... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Genetic deletion of the telomerase subunit Terc in a retroviral mouse AML model induces cell-cycle a... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We have predicted three deleterious coding non-synonymous single nucleotide polymorphisms rs11540654... | DisGeNET | Detail |
Here, we investigated the role of p53 in breast tumor cell invasion, migration, and EMT and examined... | DisGeNET | Detail |
Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. | DisGeNET | Detail |
A positive correlation was found between expression of mutant gene p53 protein and the degree of mal... | DisGeNET | Detail |
Through the described mechanism, elevated CXCR5 expression may contribute to abnormal cell survival ... | DisGeNET | Detail |
These results have translational relevance, demonstrating that TP53 mutant breast tumor growth can b... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Molecular genetic analysis revealed an uncommon mutation; 249: AGG →ATG in the TP53 gene, which has ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The aims of present study are to investigate the p53 mutation spectrum in HBV- and AFB1-related hepa... | DisGeNET | Detail |
It is concluded that both of the non-structural genes, NS3 and NS5A, of HCV play important roles in ... | DisGeNET | Detail |
Hepatitis B Virus Core Promoter A1762T/G1764A (TA)/T1753A/T1768A Mutations Contribute to Hepatocarci... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigene... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
A cell-permeable TAT-p53LZ2 effectively inhibits the cancer cell growth in wild-type but not mutant ... | DisGeNET | Detail |
However, whether INZ could suppress cancer cell growth independently of p53 activity is still elusiv... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These results indicate that absence of CDH1 and TP53 in endometrial cells initiates chronic inflamma... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Our results support the idea that mutations of the FGFR3 and TP53 genes are rare or absent in urothe... | DisGeNET | Detail |
In the Balkan and Taiwan, the relationship between exposure to aristolochic acid and risk of urothel... | DisGeNET | Detail |
Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant nega... | DisGeNET | Detail |
In this study, Hep3B cells which are p53 null were used to investigate the anti-tumor effect of PBLs... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Elevated p57Kip2 induces G1/S phase cell cycle arrest but inhibits cell death in response to DNA dam... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Cytoplasmic/nuclear beta-catenin and P53 accumulation was observed in the majority of paediatric and... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
ECCCs had SCA-like features with rare expression of estrogen receptor/progesterone receptor (18.8%/6... | DisGeNET | Detail |
However, p53 therapy for GBM is limited by lack of efficient delivery across the blood brain barrier... | DisGeNET | Detail |
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival... | DisGeNET | Detail |
Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. | DisGeNET | Detail |
It has been found that the reintroduction of WWOX induced p53-mutant GBM cells to undergo apoptosis,... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The C/C genotype of P53 gene codon 72 increases the risk of developing sporadic KCOT and may be a us... | DisGeNET | Detail |
Nuclear positive reaction of TP53 was lower in LAMN compared with those of other tumors. | DisGeNET | Detail |
In the printing company cases, immunohistochemical expression of p53 was observed in non-neoplastic ... | DisGeNET | Detail |
Non-neoplastic (n=28), noninvasive (n=28), and invasive (n=11) spots were then analyzed for aneuploi... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q- syndrome in a TP53-... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a chi... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Mutational profiling of familial male breast cancers reveals similarities with luminal A female brea... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
No variation of p16, p21, PLUNC (palate, lung, and nasal epithelium clone protein) and p53 expressio... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Nucleostemin knocking-down causes cell cycle arrest and apoptosis in human T-cell acute lymphoblasti... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Mapping p53 mutations in low-grade glioma: a voxel-based neuroimaging analysis. | DisGeNET | Detail |
NA | DisGeNET | Detail |
We also found significant inverse correlation between FGFR3 mutations and TP53 alterations in urothe... | DisGeNET | Detail |
Taken together, our results provide evidence for RTK/RAS pathway activation and p53 deficiency as a ... | DisGeNET | Detail |
UV-independent p53 mutations in sebaceous carcinoma of the eyelid. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Among these biomarkers, p53 is the strongest prognostic marker in OPC and p53 in addition to p16 sup... | DisGeNET | Detail |
The biology of HPV-positive oropharyngeal cancer is distinct; it includes p53 degradation, retinobla... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Targeted, massively parallel DNA sequencing and molecular inversion probe microarray analysis reveal... | DisGeNET | Detail |
She presented with a clinical diagnosis of Li-Fraumeni-like syndrome (LFL), showing papillary thyroi... | DisGeNET | Detail |
A significant percentage (5-10%) of pediatric cancers are associated with hereditary cancer syndrome... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In addition, it stimulated p53 promoter activity and downregulated the protein expression of c-Myc i... | DisGeNET | Detail |
Collectively, these results suggest that LOC401317 is directly regulated by p53 and exerts antitumor... | DisGeNET | Detail |
The results suggested that the Arg399Gln polymorphism of XRCC1 gene, the 1G/2G polymorphism of MMP-1... | DisGeNET | Detail |
Association between p53 codon 72 polymorphisms and clinical outcome of nasopharyngeal carcinoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. | DisGeNET | Detail |
Malignant melanoma is a highly aggressive cancer that retains functional p53 and p73, and drug unres... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Diffuse p16 expression was associated with younger age at presentation (P<0.0001), basaloid and wart... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Forty-two deleterious germline mutations were identified in 21 genes of 34 patients, including 18 (1... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Combined MYC family amplifications and P53 pathway defects commonly emerged at relapse, and all pati... | DisGeNET | Detail |
The N+&C+ group was associated with larger tumor size, higher grade, negativity for estrogen and pro... | DisGeNET | Detail |
SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative brea... | DisGeNET | Detail |
Thymoquinone, a bioactive component of black caraway seeds, causes G1 phase cell cycle arrest and ap... | DisGeNET | Detail |
Only lymph node status was marginally significantly associated with poor prognosis of TNBC (P = 0.05... | DisGeNET | Detail |
Here, we used the high prevalence of TP53 mutations in triple negative breast cancer (TNBC) to compa... | DisGeNET | Detail |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer wi... | DisGeNET | Detail |
In the present study, we used recombinant human p53 adenovirus (Ad-p53) and EGFR inhibitor gefitinib... | DisGeNET | Detail |
Primary mouse mammary epithelial cells (mMEC) with defined genetic features were used to delineate t... | DisGeNET | Detail |
Results indicated that TNBC patients with a p53-positive tumor had a shorter relapse-free and overal... | DisGeNET | Detail |
Gain-of-function mutations in TP53 are a frequent occurrence in TNBC and have been demonstrated to r... | DisGeNET | Detail |
Another highly important mutation can occur in TP53 resulting in a triple negative breast cancer. | DisGeNET | Detail |
Further, our data suggest that loss of the p53 tumor suppressor cooperates with Mychigh/TXNIPlow-dri... | DisGeNET | Detail |
The expression of p53 was higher in luminal B, HER2-enriched, and triple-negative breast cancers, an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Frequency and features of TP53 mutation in 30 Chinese patients with sporadic basal cell carcinoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62 HGSCs wi... | DisGeNET | Detail |
High-grade serous carcinomas (HGSC) are TP53-mutated and are thought to be rarely associated with bo... | DisGeNET | Detail |
TP53 mutations are the single most commonly identified mutations in aggressive sporadic high-grade s... | DisGeNET | Detail |
Knockdown of p53 in immortalized FTE cells and in four HGSC-derived cell lines expressing different ... | DisGeNET | Detail |
Ovulation is the strongest risk factor for ovarian high-grade serous carcinoma (HGSC) that largely o... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Moreover, the p53 protein is able to interact with both wild type Nkx2.5 and its mutant ΔNkx2.5 (aa ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients ... | DisGeNET | Detail |
Overexpression of p53 was detected only in high-grade dysplasia and invasive adenocarcinoma. | DisGeNET | Detail |
The authors show that combined loss of autophagy and p53 dramatically promotes progression from earl... | DisGeNET | Detail |
False-negative controls consisted in microdissecting fresh-frozen tumor tissues both from a patient ... | DisGeNET | Detail |
Formalin Fixed Paraffin Embedded tissue were studied for miRNA expression, KRAS, BRAF, PIK3CA mutati... | DisGeNET | Detail |
NA | DisGeNET | Detail |
These methylation epigenotypes, with specific genomic aberrations, are mostly completed by the adeno... | DisGeNET | Detail |
Chk2, phosphorylated Chk2 (pChk2), and TP53 were immunostained in 4 cases of adenoma (AD), 5 non-muc... | DisGeNET | Detail |
Formalin Fixed Paraffin Embedded tissue were studied for miRNA expression, KRAS, BRAF, PIK3CA mutati... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Ameloblastic carcinoma developing in preexisting ameloblastoma with a mutation of the p53 gene: a ca... | DisGeNET | Detail |
We found that hTERT expression level was significantly lower in ALS patients and was correlated eith... | DisGeNET | Detail |
TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse an... | DisGeNET | Detail |
TP53 mutations, which result in its overexpression, in combination with TERT promoter mutations seem... | DisGeNET | Detail |
Mechanistically, active mTORC1 is required to prevent a likely upregulation of the cell-cycle inhibi... | DisGeNET | Detail |
Haploinsufficiency of ribosomal proteins (RPs) and upregulation of the tumour suppressor TP53 have b... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The majority of astrocytomas harbor concurrent TP53 and ATRX mutations, while most oligodendroglioma... | DisGeNET | Detail |
We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX (60%, 9/15) at freq... | DisGeNET | Detail |
In addition, p-CREB expression correlated with higher Ki-67 labeling index (P = .049) and p53 overex... | DisGeNET | Detail |
These findings suggest that CDKN2A testing may provide further clinical aid in lower-grade glioma su... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Role of p53 in systemic autoimmune diseases. | DisGeNET | Detail |
NA | DisGeNET | Detail |
Immunostaining for p53 is the only candidate biomarker deemed ready for prime time. This has been re... | DisGeNET | Detail |
Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus p... | DisGeNET | Detail |
Our analysis showed that oncogene amplification typically occurred as a late event and that TP53 mut... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. | DisGeNET | Detail |
Overall results suggest that phosphorylated HER3, ERK1/2 and p53 may be used as biomarkers to determ... | DisGeNET | Detail |
Our findings confirm the alternative role of FGFR3 and TP53 mutations in the development of bladder ... | DisGeNET | Detail |
Recent developments in the field of molecular mutational pathway analyses based on next generation s... | DisGeNET | Detail |
Association of TP53 gene polymorphisms with susceptibility of bladder cancer in Bangladeshi populati... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We identified TP53 mutations in MYC+/BCL2+ lymphomas at a frequency intermediate between diffuse lar... | DisGeNET | Detail |
Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exo... | DisGeNET | Detail |
INZ(c) treatment decreased c-Myc expression at both mRNA and protein level, and suppressed c-Myc tra... | DisGeNET | Detail |
Although the status of RB1 and P53 between carcinoids and HGNETs were apparently different, the DNTF... | DisGeNET | Detail |
Mutational profiling of familial male breast cancers reveals similarities with luminal A female brea... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We propose that the mutation of a single p53 allele provides a pro-oncogenic function early in skin ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Somatic mutations or deletions of TP53 and PTEN in ductal carcinoma in situ lesions have been implic... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Chk2, phosphorylated Chk2 (pChk2), and TP53 were immunostained in 4 cases of adenoma (AD), 5 non-muc... | DisGeNET | Detail |
TP53 mutation occurred more frequently in carcinomas than borderline tumors (56.8 % and 11.5 %, resp... | DisGeNET | Detail |
These results suggest that intratumor genetic heterogeneity may be an important factor in determinin... | DisGeNET | Detail |
Our study indicates that the detection of the KRAS and p53 mutations in BAL fluids could be a helpfu... | DisGeNET | Detail |
Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small... | DisGeNET | Detail |
Mutations in TP53 are common in non-small cell lung cancer. | DisGeNET | Detail |
This is a revised case report of a 52 year old Caucasian female with Li-Fraumeni syndrome with a rar... | DisGeNET | Detail |
Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induce... | DisGeNET | Detail |
SETDB1 positively stimulated activity of the WNT-β-catenin pathway and diminished P53 expression, re... | DisGeNET | Detail |
Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small... | DisGeNET | Detail |
Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic lethal in non-small c... | DisGeNET | Detail |
In non-small cell lung cancer (NSCLC), both USP7 expression and p53 gene status were reported to be ... | DisGeNET | Detail |
USP22 promotes NSCLC tumorigenesis via MDMX up-regulation and subsequent p53 inhibition. | DisGeNET | Detail |
Association of p53 and mdm2 in the development and progression of non-small cell lung cancer. | DisGeNET | Detail |
VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Ant... | DisGeNET | Detail |
Further experiments demonstrated that PANDAR expression was induced by p53, and chromatin immunoprec... | DisGeNET | Detail |
We analyzed human non-small cell lung cancer (NSCLC) cell lines either wild type (wt) or mutated in ... | DisGeNET | Detail |
Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overc... | DisGeNET | Detail |
NA | DisGeNET | Detail |
We observed a good overall stability between primary RCC and corresponding xenografted RCC at P1 and... | DisGeNET | Detail |
Here, we show that apoptosis-resistant RCC cells have a disconnect between activation of p53 and upr... | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs28934271 dbSNP
- Genome
- hg19
- Position
- chr17:7,565,097-7,590,864
- Variant Type
- snv
Genome browser